Diffusion MRI for characterising childhood brain tumours by Grech Sollars, M
  
 
Diffusion MRI for Characterising 
Childhood Brain Tumours 
 
 
 
 
Matthew Grech-Sollars BEng (Hons) MSc 
 
 
 
A thesis submitted to University College London  
in fulfilment of the requirements for the degree of  
 
Doctor of Philosophy in Medical Physics 
 
Imaging and Biophysics Unit 
UCL Institute of Child Health 
 
~ 2014 ~ 
 2 
DECLARATION  
 
I, Matthew Grech-Sollars, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
………………………………..……………. 
………………………………..……………. 
 
 3 
ABSTRACT 
Magnetic resonance imaging (MRI) is widely used both in the clinic and as a research 
tool in the management of brain tumours. While most studies focus on adult tumours, 
which have a higher incidence than those in children, paediatric brain tumours differ 
widely in terms of biology and treatment management. Furthermore, as a non-invasive 
and non-ionising imaging tool, MRI is used in the diagnosis, prognosis and assessment 
of treatment response of such tumours. This work focuses on diffusion MRI to study 
childhood brain tumours. 
The thesis is divided into three main parts: a reproducibility study of diffusion MRI 
parameters in order to answer the question of whether clinical imaging may be used 
interchangeably across multiple-centres to combine data from different institutions; a 
study on a tumour border diffusion measure as a prognostic biomarker in children with 
embryonal brain tumours – the apparent transient coefficient in tumour (ATCT); and a 
study analysing the functional diffusion map (fDM) as a tool for assessing treatment 
response in paediatric brain tumours.  
Diffusion MRI has been shown to have a good reproducibility and thus data from 
multiple centres and scanners can be combined in order to analyse clinical data for 
patients treated at different institutions; particularly where data for specific tumour 
types would otherwise be limited. In addition, ATCT has been shown to be a useful 
prognostic biomarker in children with embryonal brain tumours. Finally, while the fDM 
may be beneficial in assessing treatment response, the underlying biology of both 
tumour and healthy tissue needs to be carefully considered, and in particular, areas of 
necrosis, tumour grade and change in tumour size need to be taken into account. 
In conclusion, diffusion MRI is a valuable tool in the management of childhood brain 
tumours, with multi-centre studies paving the way for further research and validation 
of biomarkers.  
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GLOSSARY 
Term Definition 
MRI Section 
acquisition matrix The number of independent data samples taken in the 
phase-encode and frequency-encode directions, 
determining the resolution of the image. 
anisotropy A physical property of having different values for 
measurements in different directions; high diffusion 
anisotropy implies diffusion occurs more in one of the 
directions. 
artefacts False features in an image, produced during image 
acquisition. 
bandwidth A range of frequencies. 
contrast-agent A substance administered to the patient in order to 
enhance the image intensity of a particular region, generally 
by altering relaxation times. 
coronal plane The plane which divides the body into a dorsal and ventral 
part. 
dephasing The loss of phase coherence between signals in the 
transverse plane. 
echo time (TE) The time (in ms) between applying the 90  RF pulse and the 
peak of the echo signal produced using a spin echo 
sequence. 
eddy current An electric current induced in a conductor by a time-varying 
magnetic field, which may cause artefacts in images. 
energy state One of a number of distinct energy levels for each spin in a 
magnetic field, determined by the spin quantum number. 
field of view (FOV) A rectangular region over which MRI data is acquired. 
Glossary 
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Term Definition 
Fourier transform A mathematical transform which converts a time signal into 
the frequency domain and vice versa. It is used in MRI to 
reconstruct spatial information from the raw data acquired. 
free induction decay The decay of the transverse magnetisation MR signal 
towards zero with a time constant   
 . 
frequency encoding The encoding of MR signals along a direction by applying a 
magnetic field gradient along that direction during data 
acquisition, such that spatial information is encoded in a 
frequency gradient. 
ghosting artefact An image artefact associated with motion resulting in phase 
errors. 
gradient echo A signal echo produced by reversing the magnetic field 
gradient's direction. 
gyromagnetic ratio A constant for a given nucleus which represents the ratio of 
magnetic moment to angular momentum. 
ionising radiation Radiation which has enough energy to interact with an 
atom and remove one of its bound electrons, thus ionising 
the atom. 
k-space The space in which the Fourier transform of the image is 
represented, and in which MR data is acquired.  
Larmor frequency The frequency at which magnetic resonance in a nucleus 
can be excited. 
lattice The magnetic and thermal environment with which nuclei 
exchange energy in longitudinal (  ) relaxation. 
longitudinal 
magnetisation (  ) 
The component of magnetisation which is along the static 
magnetic field. 
magnetic field 
gradient 
A magnetic field gradient which changes in strength along a 
given direction. 
magnetic field 
inhomogeneity 
Deviation of the local magnetic field from the average 
value. 
Glossary 
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Term Definition 
magnetic resonance The absorption and/or emission of electromagnetic energy 
by a nucleus in a static magnetic field after an RF pulse is 
applied. 
matrix size The number of data points in each of the directions, which 
may be different from the acquisition matrix. 
noise The component of a reconstructed image relating to 
unwanted interference in the image. 
non-invasive A procedure that allows for the diagnosis or treatment of a 
disease without the need to enter into the body. 
NSA The number of signals averaged together to construct the 
image. 
nuclear spin An intrinsic property of a nucleus which gives an associated 
magnetic moment and angular momentum. 
parallel imaging A means of increasing acquisition speed by using multiple 
receiver coils to collect data from different areas 
simultaneously. 
partial volume effect The loss in contrast when one voxel covers more than one 
tissue type. 
phantom An object with known properties used for testing MRI 
systems. 
phase encoding The encoding of MR signals along a direction by applying a 
magnetic field gradient along that direction prior to data 
acquisition, such that spatial information is encoded in a 
phase difference. 
precession The motion of the axis of a spinning body such that the axis 
of rotation traces out the shape of a cone. 
radiofrequency An electromagnetic wave at a frequency in the same range 
as that used for radio transmission, in the MHz range. 
repetition time (TR) The time between the beginning of a pulse sequence and 
the subsequent pulse sequence. 
Glossary 
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Term Definition 
sagittal plane The plane which divides the body into left and right parts. 
slice selection A method for exciting a specific slice of tissue by applying a 
gradient magnetic field and a narrow-band RF pulse 
concurrently. 
SNR The signal-to-noise ratio describing the proportion of signal 
to random noise present in the image. 
spin echo A signal echo produced by first applying a 90  excitation RF 
pulse, followed by a 180  refocusing RF pulse. 
spin-lattice 
(longitudinal) 
relaxation time (  ) 
The time it takes spins to align themselves with the external 
magnetic field from a magnetisation in the z-direction of 0 
to 63% of its maximum value. 
spin-spin (transverse) 
relaxation time (  ) 
The time it takes for spins to lose phase coherence, and 
thus for the MR signal to lose 63% of its initial value. 
  -weighted An image where the majority of contrast stems from tissue 
differences in    values (fluid is dark, white matter is 
bright). 
  -weighted An image where the majority of contrast stems from tissue 
differences in    values (fluid is bright, white matter is 
dark). 
transverse 
magnetisation (   ) 
The component of magnetisation which is at right angles to 
the static magnetic field, and is responsible for the signal 
detected by MR. 
transverse plane The plane which divides the body into the superior and 
inferior parts. 
Cancer Section 
adjuvant In addition to the main treatment. 
anaplastic Lacking differentiation characteristics of the tissue of origin. 
angiogenesis The formation of new blood vessels. 
Glossary 
22 
Term Definition 
apoptosis Programmed cell-death. 
ataxia Loss of coordination of muscle movement. 
autophagy A cellular response to a lack of nutrients, causing the 
breakdown of organelles within the cell to provide energy. 
benign A growth which is confined to a specific area within a tissue 
with no evidence of invasion. 
calcification The deposit of calcium in a location. 
cancer A malignant condition in which abnormal cells grow and 
spread within the body. 
carcinogenic Able to contribute to or cause the formation of cancer. 
cell cycle The sequence of events a cell goes through from when it is 
created to when its DNA is doubled and the cell divides. 
centromere The region of the chromosome than holds the two 
chromatids together. 
chromosome A thread like structure found in nuclei and holding the 
genetic information in DNA. 
contralateral The opposite side. 
cystic Characterised by cysts, an abnormal sac containing liquid. 
cytosol The liquid component of the cytoplasm which contains all 
organelles. 
embolization The process of forming an embolus, a blood clot that can 
travel through the circulatory system and lodge somewhere 
in the body. 
eukaryotic Cells having a membrane-bound nucleus. 
extravasation The process of forcing (an embolus) out of the vascular 
system and into the surrounding tissue. 
Glossary 
23 
Term Definition 
gene The basic unit of heredity. 
genomic stability gene Genes which keep mutations to a minimum. 
genotype The genetic constitution of a person. 
growth factor A protein that is able to stimulate growth or cell 
proliferation. 
high-grade A tumour which has progressed and become malignant. 
histopathology The study of changes in tissue caused by disease. 
hypoxia The state of low oxygen levels reaching the tissue. 
immortality A trait of a cell to proliferate indefinitely. 
incidence The frequency of occurrence of a given disease. 
intravasation The process of forcing (a cancer cell) into the vascular 
system. 
invasion The process by which cancer cells move from a primary area 
to invade a secondary region. 
ipsilateral The same side. 
low-grade A tumour which has not progressed extensively and is 
relatively benign. 
lymphatic vessel A vessel which carries lymph, which is formed from the 
interstitial fluid between cells. 
malignant A growth which spreads into surrounding tissue or other 
parts of the body. 
metastasis A malignant growth which has spread to another region of 
the body. 
mitosis The process by which a single cell separates the 
chromosomes into two equal sets in preparation for cell 
division. 
Glossary 
24 
Term Definition 
morphology The shape and form of a cell. 
mortality The rate of cell death due to a specific disease or condition. 
motility The ability of individual cells to move from one location to 
another. 
mutation A change in the genotype, resulting in the creation of a new 
trait. 
necrosis The process of cell death which is not programmed. 
neoadjuvant Applied prior to the main treatment. 
oedema An abnormal retention of fluid. 
oncogene A cancer inducing cell. 
primary tumour The first mass of cancer cells at the place of origin, where 
the cancer began. 
prognosis A forecast of the likely course of a disease. 
progression The phase in tumour growth characterised by the ability of 
tumour cells to grow rapidly and invade other areas. 
resection Removal by surgery. 
secondary tumour Also metastases, a tumour which has spread to secondary 
regions different from the origin. 
stroma The space within a cell or tissue which supports the cell or 
tissue. 
telomere The structure at the end of the chromosomes, which 
protects the ends from degradation and from fusion with 
other chromosomes. 
transcription factor A protein involved in the transcription (copying of DNA 
sequences) of a gene. 
tumour A growth in one specific area. 
Glossary 
25 
Term Definition 
tumour suppressor 
gene 
A gene, which if inactivated leads to an increased chance of 
developing cancer. 
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Chapter 1 INTRODUCTION 
1.1 Background 
Cancer makes frequent appearance in the news. Its high prevalence means that it is a 
disease which touches the lives of a large proportion of the population, affecting not 
only patients, but also their families and friends. It is, however, rare in children and as 
a result fewer research studies have been carried out in this patient group. Brain 
tumours are the second most common tumour in children, after leukaemia, and are 
generally diagnosed using magnetic resonance imaging (MRI). This standard clinical 
imaging normally includes diffusion-weighted imaging, a technique which uses the 
diffusion of water molecules to determine the nature of the underlying microstructure. 
The main focus of this PhD thesis is to investigate the use of diffusion MRI in childhood 
brain tumours and to present work carried out in order to advance knowledge in the 
field. This was done with the view of improving patient treatment management 
through identifying prognostic imaging biomarkers, studying imaging tools used in 
treatment response and exploring the image variation expected in multi-centre 
studies.  
1.2 Objectives 
Research carried out in imaging of paediatric brain tumours is limited and sparse, 
which may be a reflection of the rarity of these tumours. As part of a multi-centre 
study, the objectives of this thesis include an analysis to determine whether data from 
multiple centres can be combined so as to conduct studies on a larger cohort of similar 
tumours, which would allow for more meaningful analyses of individual tumour types. 
Second, the thesis aims to study diffusion imaging as a prognostic tool in order to 
determine whether it can be used as a biomarker of survival so as to aid in the 
treatment planning and management of brain tumours. The third objective is to 
analyse diffusion imaging as a tool for identifying early treatment response by applying 
tools currently used in brain tumours in adults to those in children.  
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1.3 Thesis overview 
In Chapter 2 the basics of MRI and diffusion imaging are presented by describing the 
physics behind MRI and diffusion imaging. The chapter then describes the necessary 
data processing steps, from acquiring data on the scanner to performing the required 
statistical analyses, and concludes with the current uses of MRI in the clinic. 
Chapter 3 starts with a description of the basics of cancer by presenting cell biology 
and how a cancer cell may form, together with the hallmarks of cancer. It is followed 
by a description of brain anatomy, prior to presenting paediatric brain tumours in 
more detail.  
Chapter 4 presents the importance of reproducibility studies and current research 
carried out. It then focuses on the use of diffusion MRI in childhood cancer, particularly 
as a tool for diagnosis, prognosis and treatment response.  
The subsequent three chapters present the research component of this thesis. Chapter 
5 describes results for the reproducibility of diffusion MRI parameters from a multi-
centre study. Chapter 6 focuses on a prognostic imaging biomarker analysed in a 
specific paediatric brain tumour type. Chapter 7 then moves on to explore a diffusion 
MRI tool suggested for determining treatment response. 
Finally, a discussion is held on the advances provided by this work and in the field, and 
how this may be taken forward. 
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Chapter 2 MRI AND DIFFUSION IMAGING 
The main aim of this chapter is to provide a background of MRI physics, and in 
particular diffusion imaging. This is followed by an outline of how data is processed 
after images are acquired from the scanner and an overview of MRI safety, limitations 
and its uses in the clinic. 
2.1 Physics of MRI 
2.1.1 BACKGROUND 
 
Figure 2.1: The electromagnetic spectrum. Higher frequencies cause ionisation which raises safety 
issues. From the non-ionising set, visible light does not penetrate the skin, infrared is only able to enter 
the body superficially and microwaves cause heating and are thus not safe. MRI, which lies in the radio 
frequency range, is able to penetrate the body without causing harm. 
MRI is considered a safe and non-invasive imaging technique. The reason behind this 
can be explained in terms of the electromagnetic spectrum shown in Figure 2.1. To 
identify a suitable imaging technique, two elements need to be taken into 
consideration – transparency and safety. Visible light is not useful for body and brain 
imaging as it does not penetrate the skin. The higher frequencies on the 
electromagnetic spectrum tend to pose a safety issue: while X-ray, computed 
tomography (CT) and positron emission tomography (PET) are used in diagnostic 
medical imaging, they carry an element of risk in terms of radiation dose. The ionising 
radiation associated with these techniques may lead to DNA damage, caused by the 
free radicals formed as electrons are ejected from their molecules. In the lower 
wavelengths, infrared can be used, but it is only able to penetrate the skin superficially 
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and hence its applications are limited. That said, near infrared can be beneficial in the 
clinic, particularly in a neonatal setting to monitor tissue oxygenation1. Microwaves 
pose a safety issue due to thermal heating and hence the best frequency range for a 
safe and non-invasive imaging modality is that of radio waves, in which MRI 
frequencies lie. MRI therefore has the benefit of an imaging modality that is able to 
probe the whole body without causing harm. This section gives an account of the 
physics behind MRI and in particular diffusion imaging. 
2.1.2 A BRIEF HISTORY 
Magnetic resonance (MR) was first described by Rabi et al in 19382 as a method for 
determining nuclear magnetic moments. It was further explored following the Second 
World War by Purcell et al in 19453 and by Bloch in 19464. It can be explained by taking 
a quantum mechanics approach or a classical physics approach and a combination of 
both is taken in this chapter. In order to understand the basis for today’s MRI, we need 
to start with the behaviour of the most abundant chemical substance, hydrogen, the 
nucleus of which contains just one proton. 
2.1.3 SOME CHARACTERISTICS OF PROTONS 
 
Figure 2.2: Spin alignment in a magnetic field. Hydrogen nuclei, consisting of one proton, will possess a 
spin and in the absence of an external magnetic field (a) will orient themselves in a random direction. In 
the presence of a strong magnetic field (b), a very small majority of nuclei will orient themselves in the 
direction of the external magnetic field, while the other nuclei will orient themselves in the higher 
energy state which is against the external magnetic field,   . 
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Every nucleus with an odd atomic and/or mass number has what is known as spin and 
the associated property of angular momentum. Hydrogen, with an atomic number of 1 
consists of one proton and has a spin of ½. Due to the positive charge and this spin, 
each nucleus will also possess magnetic properties. In the absence of a strong external 
magnetic field, at thermal equilibrium, the spin of each hydrogen nucleus will have no 
preferred direction, and the overall magnetism of all the hydrogen atoms will be zero 
(Figure 2.2a). In the presence of a strong external magnetic field, a small majority of 
protons will orient themselves parallel to the direction of the magnetic field, and the 
remainder will take an anti-parallel direction (Figure 2.2b). The number of atoms which 
align with or against the direction of the magnetic field is given by Boltzmann’s 
equation in (2.1). 
   
  
   
    
   
 
(2.1) 
where    and    are the number of nuclei having a spin along and against the 
direction of the magnetic field    respectively,   is the gyromagnetic ratio of protons, 
  is the rationalised Planck’s constant,    is Boltzmann’s constant and   is the 
temperature of the material in Kelvin. 
 
Figure 2.3: Precession. A nucleus aligned with, or against, the external magnetic field will precess 
around the direction of the magnetic field at what is known as the Larmor frequency. 
The energy state of the nucleus depends on whether a nucleus will align parallel or 
against the direction of the magnetic field. A parallel direction requires less energy and 
at room temperature, there will be more nuclei aligned in this direction. Furthermore, 
the interaction of the nuclei with the magnetic field causes the nuclear magnets to 
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precess around the external magnetic field as shown in Figure 2.3. The precession 
frequency is given by the Larmor equation in (2.2). 
        (2.2) 
where   is the angular frequency of protons,   is the gyromagnetic ratio of protons 
and    is the magnetic field.  
In order for a nucleus to move from the lower parallel energy state to the higher anti-
parallel energy state, it must acquire energy through a radio-frequency (RF) pulse. The 
frequency at which this can happen is the Larmor frequency. When an RF pulse, at the 
Larmor frequency is applied, some of the nuclei will gain energy to move from the 
parallel direction to the anti-parallel direction. The nuclei can subsequently lose this 
energy by re-orienting in the parallel direction, a process known as relaxation. 
2.1.4 BEHAVIOUR OF A GROUP OF NUCLEI 
In MRI, we generally image a volume of tissue, or a voxel, and in each voxel a large 
number of hydrogen nuclei are present. By analysing voxels, we study the combined 
effect of the hydrogen nuclei in a specific area of tissue. Given there are more nuclei 
aligned parallel with the magnetic field, and the direction of precession is random at 
any given time point, the sum of all the spins will result in a net magnetisation,  , in 
the direction of the magnetic field as shown in Figure 2.4. As the number of spins 
aligning parallel to    is only marginally more than those aligning in the anti-parallel 
 
Figure 2.4: Net magnetisation. As there is a slight majority of nuclei aligned with the external magnetic 
field, there will be a small net magnetisation   in the same direction as the external magnetic field.  
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direction,   is very small and in the order of microtesla
5. Hence, it is difficult to 
measure at equilibrium while aligned with the main field   .  
When an RF pulse at the Larmor frequency is applied, some of the nuclei in the parallel 
direction will absorb the energy necessary to re-orient themselves into the higher 
energy state. It transpires that the net magnetisation will be flipped at an angle which 
is dependent on the strength and duration of the RF pulse as given by equation (2.3). 
         (2.3) 
where   is the flip angle,   is the gyromagnetic ratio,    is the magnetic field of the RF 
pulse and    is the duration of the RF pulse. 
Applying a 90  RF pulse, with    in the x-direction, forces the net magnetisation to flip 
into the transverse plane such that the longitudinal magnetisation (  ) is zero and the 
net magnetisation is equal to the transverse magnetisation (   ). This transverse 
magnetisation rotates at the Larmor frequency and can be measured through the 
voltage that it induces in a receiver coil. By Faraday’s law, the voltage generated is 
proportional to the transverse magnetisation, which can thus be measured.  
After flipping the net magnetisation into the transverse plane, the nuclear spins will 
fan out and become out of phase with each other. As the protons quickly dephase, the 
transverse magnetisation rapidly decreases towards zero. The resulting rapidly 
decreasing signal is known as free induction decay (FID). This dephasing of spins is an 
effect of both field inhomogeneity, inherent in every scanner, and interaction with the 
magnetism of neighbouring nuclei. Field inhomogeneity is a fixed effect, while the 
interactions with the neighbouring nuclei are a random effect. Overall, the rate at 
which the dephasing occurs, and hence at which the transverse magnetisation decays 
to its original value of zero, is given by Bloch equation (2.4) and is shown in Figure 2.5a.  
 
          
 
 
  
 
  
(2.4) 
where    is the transverse magnetisation,     is the net magnetisation in the 
transverse plane and is equivalent to the longitudinal magnetisation   before the 
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application of the RF pulse,   is the time allowed for recovery, and   
  is the   
  
relaxation time. 
 
Figure 2.5: Net magnetisation recovery. After the magnetisation is tipped into the transverse plane by 
application of the RF pulse, (a) the transverse magnetisation will decrease at a rate defined by   
  and (b) 
the longitudinal magnetisation will recover at a rate defined by   . 
While the decrease in    is rapid, the recovery of the longitudinal magnetisation is 
slower. When the RF pulse is switched off, the spins will start reverting back to the 
original direction, and as a result the longitudinal magnetisation will recover as given 
by Bloch equation (2.5) and shown in Figure 2.5b.  
 
         
 
 
    
(2.5) 
where    is the longitudinal magnetisation,    is the net magnetisation in the 
longitudinal plane,   is the time allowed for recovery, and    is the longitudinal 
relaxation time or spin-lattice relaxation time.  
After 1   the signal recovers to 63% of the original value, and after 5   the signal is in 
practice almost fully recovered. A longer value of    therefore implies a longer 
longitudinal recovery time. The longitudinal relaxation time is material-dependent. 
This is because longitudinal relaxation depends on local fluctuating magnetic fields, 
and in particular on fluctuations close to the Larmor frequency. Such fluctuations arise 
as a result of molecular motion, and so the degree of molecular mobility is an 
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important factor in determining    values. Hence, more liquid-like materials tend to 
have long    values – for example, cerebro-spinal fluid (CSF) has longer    values than 
grey and white matter. Additionally, the Larmor frequency is dependent on the value 
of   . Hence,    will also be affected by a change in   .  
2.1.5 FORMING THE SIGNAL  
As described, the signal we measure in MR, is the transverse magnetisation, and thus is 
dependent on the transverse magnetisation recovery time. The rapid decrease in 
magnetisation makes it difficult to acquire the MR signal, and the FID cannot be used. 
In practice, echoes – the gradient echo and the spin echo – are created, and the spin 
echo is here described.  
 
Figure 2.6: Spin echo phase diagram. (a) Spins are tipped into the transverse plane after application of a 
90  RF pulse. (b) Due to field inhomogeneity, spins will dephase at a different rate and the net 
magnetisation in the transverse plane will reduce rapidly at a rate defined by   
 . (c) After a 180  RF 
pulse is applied in the y-direction, the spins will flip along the axis and continue dephasing in the same 
direction and at the same rate as they previously were. (d) After a time TE, the spins will realign and the 
signal in the transverse plane reappears.  
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The main cause for the rapid dephasing in the transverse plane is the different 
magnetic fields each nucleus experiences. As this field inhomogeneity is a fixed effect, 
when we apply a 180  RF pulse on the y-axis, the spins will flip along the axis and 
continue dephasing at the same rate and in the same direction as shown in Figure 2.6. 
This implies that after a time TE, equal to twice the time from when the 90  pulse was 
switched off to the time the 180  pulse is applied, all spins will realign and the signal 
will reappear. However, it will do so at a lower strength than the original, and this is 
due to the energy loss from spin-spin interactions. The signal loss is described by Bloch 
equation (2.4), using a time constant   , described as the transverse relaxation time, 
or spin-spin relaxation time. While    describes the signal loss from spin-spin 
interactions, i.e. from the interactions with neighbouring molecules,   
  describes the 
faster signal loss from both spin-spin interactions and field inhomogeneity. The signal 
acquisition for a spin echo sequence, which reverses the losses associated with   
 , is 
shown in Figure 2.7. 
 
Figure 2.7: Spin echo signal acquisition. The signal acquired, the FID, is at a maximum after application 
of the 90  RF pulse and quickly decays at a rate defined by   
 . After applying the 180  RF pulse, the 
spins start to realign and the signal reappears at a time equal to twice the time between the two RF 
pulses, or TE. The signal reappears with a loss defined by the spin-spin relaxation time,   . 
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2.1.6 LOCATING THE SIGNAL 
The signal acquired, the FID, is an electromotive force induced by the rotating 
magnetic field in a coil. It is thus not dependent on a specific location but is obtained 
from the entire object. In order to localise the signal, the specific area being imaged 
needs to be excited separately. This is done by applying gradients.  
 
Figure 2.8 Applying a gradient. When a magnetic field gradient is applied in the x-direction, the 
magnetic field along the said direction will vary depending on position. As the Larmor frequency is 
dependent on magnetic field, only a specific area will be excited when applying a specific frequency.  
A gradient is a spatially linear variation applied onto the static magnetic field,   , in 
either of the x, y and z directions; as shown in Figure 2.8 for the gradient applied in the 
x direction,   . Following on from the Larmor equation (2.2), the precession frequency 
is dependent upon the magnetic field, and hence after applying the gradient, the 
precession frequency is dependent upon position. Applied gradients can be either 
positive, as in the case of Figure 2.8, or negative. A faster precession is experienced 
towards the end having a higher magnetic field, while a slower precession is 
experienced towards the end having a lower magnetic field. 
In order to image a 3D volume, gradients in the three orthogonal directions are used. 
First, the slice being imaged is selected. This is done by applying a gradient   , also 
known as the slice select gradient    , at the same time as applying an RF pulse tuned 
to the precession frequency of the specific slice being imaged,   . This RF pulse will 
include a narrow range of frequencies,   , which will only excite those nuclei 
precessing at that same frequency      . As shown in Figure 2.9, the location being 
imaged can be chosen by altering the frequency around which the RF pulse is centred, 
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while the slice thickness required is dependent on both the bandwidth of the RF pulse 
and the applied gradient. 
After the slice is selected, the x- and y- directions need to be encoded. When applying 
a gradient in the y-direction, a process of phase encoding is used, hence    is also 
known as the phase-encode gradient,    . In phase encoding, when a gradient is 
applied along the y-direction, the nuclei will start precessing slower or faster, 
depending on the location along the gradient. This implies that the spins will start 
getting out of phase and this phase difference increases with time. After     is turned 
off, the spins will return to precessing at the original frequency, but at the different 
phase angles acquired prior to the gradient being turned off as shown in Figure 2.10. 
This phase difference will last until either another gradient,    , is applied, or until the 
MR signal in the transverse plane decays due to   . The location in the y-direction is 
thus encoded in the signal phase. 
 
Figure 2.9: Slice selection. By applying a gradient in the z direction, a specific slice to image is selected 
by applying an RF pulse at the frequency corresponding to the slice of interest. The slice thickness is 
determined by the bandwidth   . 
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Figure 2.10: Phase encoding. In phase encoding, prior to applying a gradient, the spins along the y-axis 
(the phase encode direction) precess in the same direction. When a gradient is applied, the spins will 
have different energy and get out of phase from each other. Removing the gradient, brings the 
frequency of the spins back to the original value, however the phase difference is preserved. Location 
information is thus encoded in the phase of the spins. 
The gradient in the x-direction,   , is encoded in terms of frequency and hence is 
known as the frequency encode gradient,    . Frequency encoding works using the 
same principle shown in Figure 2.8. In this case, the gradient is kept on during signal 
collection. As long as the gradient is on, the nuclei experiencing different gradients will 
precess at different frequencies. Hence, location in the x-direction is encoded in terms 
of the frequency of the signal acquired. 
Hence, following slice selection using    , by combing the two gradients,     and    , 
we are able to acquire the signal for all voxels in the selected slice.  
2.1.7 OBTAINING THE IMAGE 
The signal obtained, the FID, consists of a number of sinusoids at different frequencies 
and phases, each representing a specific location. The location can thus be determined 
by using the Fourier transform to convert the signal. The Fourier transform is able to 
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transform any signal in terms of a sum of sinusoids with a specific frequency and phase 
for each. 
A one-dimensional signal in time can be represented in terms of a sum of sinusoids, 
which can be transformed from the time- to the frequency-domain using the Fourier 
transform. Similarly, a two-dimensional image in space can be represented in terms of 
a sum of sinusoidal basis images. The two-dimensional Fourier transform in this case 
can be used to move from the space domain to what is known as k-space. In a similar 
way to how the units of frequency are defined (   ), the units of k-space are given by 
   . Each point in k-space determines an individual sinusoidal basis image, the sum of 
which makes up the original image.  
Going back to the MR signal we obtain, the signal acquired is in k-space; with the signal 
in the phase encode (y) and frequency encode (x) directions being represented by     
and     respectively. The signal acquired has both a real and imaginary component, 
the magnitude of which is shown together with the Fourier transformation into the 
acquired image in Figure 2.11. 
 
Figure 2.11: Obtaining the image. The acquired signal is in k-space (left). Applying the Fourier transform 
to k-space will give the image (right). 
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2.1.8 DIFFERENT SEQUENCES HIGHLIGHT DIFFERENT THINGS 
Having explained how images are obtained, it is important to note that different 
sequences can be used to show different things. Thus, to obtain a specific type of 
image, a specific sequence is designed; consisting of RF pulses and the gradients in the 
x, y and z directions. Pulse sequence diagrams are drawn, defining the timing and the 
type of RF pulses applied and the gradients; also showing the repetition time (TR) and 
the echo time (TE).  
The signal we acquire is dependent on the values of   ,   ,   
  and the proton density, 
with each of these values being dependent on the material being imaged. For example, 
materials with a higher proton density will have a greater signal and thus appear 
brighter. Hence a difference in signal can be observed for different materials imaged 
depending on how the images are weighted.  
 
Figure 2.12:   - and   -weighted images.    and    weighted images vary in that areas of fluid appear 
dark in   -weighted images and bright in   -weighted images. White matter also appears brighter than 
grey matter in   -weighted images. 
  -weighted images have a contrast that is dependent on the recovery in longitudinal 
magnetisation,  . This can be measured in the transverse plane as   is related to 
   and    by equation (2.5); and if the RF pulse is applied before   has recovered, 
the amount of magnetisation available in the transverse plane,     is equal to  . 
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Hence,    is influenced by the    values of the tissue being imaged. In order to 
ensure   has not recovered, a short TR is required. As mentioned,    is also known as 
the spin-lattice relaxation, which describes the energy loss to the surrounding lattice. 
As neighbouring molecules in fluids (the lattice) vibrate faster than the Larmor 
frequency, energy cannot be easily lost from spin-lattice interactions and thus fluids 
have a longer   . This implies that when the signal is tipped to the transverse plane 
there will be less signal available, as less of   would have recovered, and hence fluids 
appear dark in   -weighted images, as shown in areas of CSF in Figure 2.12. 
On the other hand,   -weighted images are related to the spin-spin interactions and 
the energy loss between the surrounding spins. To ascertain that these images are not 
affected by values of   , a long TR is used such that   would have completely 
recovered to  , and a long TE is used such that the signal’s influence by    would be 
increased. In fluids, hydrogen nuclei are free to move around and thus spin-spin 
interactions are very limited, implying a longer time is taken to lose energy and thus 
fluids have a longer   . This implies that the signal in fluids is stronger and fluids 
appear bright in   -weighted images, as shown in areas of CSF in Figure 2.12. 
2.1.9 DIFFUSION WEIGHTED IMAGING 
In order to understand diffusion-weighted imaging (DWI), the concept of diffusion 
needs to be first explained. Diffusion of water molecules, also referred to as Brownian 
motion, describes how all water molecules move around in a random fashion, resulting 
from collision with other molecules. This in turn implies that, provided there is no 
barrier, water molecules will diffuse outwards according to a Gaussian distribution 
described by Einstein in equation (2.6).  
 〈  〉      (2.6) 
where 〈  〉 is the mean-squared displacement, D is the diffusion coefficient of the 
substance and   is the diffusion time. 
As the MR signal results from the hydrogen present in water molecules, diffusion can 
be imaged by using a specific sequence. A method for measuring the effect of diffusion 
was first proposed by Carr and Purcell in 19546, while Stejskal and Tanner introduced 
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the basic pulsed gradient spin-echo (PGSE) sequence, forming the basis for diffusion 
sequences today, in 19657.  
 
Figure 2.13: Diffusion-weighted imaging. After the RF pulse is applied the spins are tipped into the 
transverse plane. When a gradient is applied, the spins dephase with each area of tissue experiencing a 
different field getting out of phase from each other. During the time  , molecules will diffuse such that 
the spins move from one area to another. An equal and negative gradient is then applied such that the 
spins would realign. However, due to the diffusion which would have occurred, some spins will 
experience a different gradient to the original and will thus not rephase completely. This results in a 
signal loss. 
In order to apply diffusion-sensitization, a bipolar gradient is introduced after RF 
excitation and before signal acquisition. This can be done by either applying a positive 
gradient followed by an equal but negative gradient as shown in Figure 2.13, or by 
applying two equal positive gradients with a 180  RF pulse in between. When the first 
gradient is applied, spins will dephase according to the gradient applied. Following a 
time  , the molecules would have diffused such that some of the spins would have 
moved with respect to the gradient. When the negative gradient is then applied, 
rephasing will occur, however the diffused molecules will experience a different 
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gradient to the original and will thus not realign and the phase difference results in a 
signal loss. Diffusion is thus measured in terms of signal loss. 
The diffusion effect and thus the signal loss is dependent on four parameters: the time 
between the gradient pulses   – a longer time will imply more diffusion as given by 
equation (2.6) and hence less signal; the strength and duration of the gradient pulse G 
and   – a larger gradient or longer gradient length will imply increased spin dephasing 
and hence a larger signal loss when rephasing; and a diffusion constant D which is 
material dependent – a larger D implies water molecules can diffuse a larger distance 
per unit time as given by equation (2.6) and hence a larger signal loss. The relationship 
between these four parameters and the signal is shown in equations (2.7) and (2.8). 
 
  
 
  
     
(2.7) 
where   is the signal with diffusion weighting,    is the signal without diffusion 
weighting, D is the diffusion coefficient of the material and b is the diffusion weighting 
defined in equation (2.8). 
 
        (  
 
 
) 
(2.8) 
where b is the diffusion weighting,   is the gyromagnetic ratio of protons, G is the 
gradient amplitude, and (  
 
 
) is the diffusion time – with   being the gradient 
duration and   the gradient separation, as shown in Figure 2.13. 
Following from equation (2.7), the diffusion constant, D, can be measured by 
measuring the signal with no diffusion weighting (   ) and with diffusion weighting. 
The diffusion weighting, b, needs to thus be changed, in principle by altering G,   or  . 
In practice changing   alters the echo time, resulting in a signal which is both diffusion- 
and   - weighted; and increasing   is limited by the pulse sequence timing setup. 
Hence, when measuring the signal with multiple b-values, a change in the gradient 
strength is normally applied such that the variation in signal loss is only due to the 
diffusion effect. While using two points is enough to measure the diffusion coefficient, 
more b-values can be acquired and a least square fit applied so as to increase the 
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signal-to-noise ratio (SNR). That said, a more efficient way of improving SNR is to take 
multiple acquisitions at the optimal b-value, rather than using multiple b-values. SNR is 
also maximised by making G as large as possible and making   as small as possible to 
minimise the echo time. 
 As such, the diffusion coefficient measured is influenced by a number of factors, and 
hence the measured diffusion coefficient is called the apparent diffusion coefficient 
(ADC). The diffusion of water in tissue is more restricted than that in fluid areas and 
thus a smaller signal loss occurs at higher b-values in tissue as compared to fluid areas, 
where diffusion is high. As shown in Figure 2.14, the resultant ADC image shows areas 
of fluid, such as areas of CSF, as bright; while other more compact tissues appear dark. 
ADC is measured in      . 
 
Figure 2.14: Diffusion-weighted images. At b=0 there is no diffusion weighting, and the image is 
essentially a    weighted image. Diffusion weighting can be applied, with an increased diffusion 
weighting (b=1000) implying more signal loss and hence appearing darker, particularly in areas where 
diffusion is higher such as in areas of CSF. An ADC image is calculated from a b=0 image and at least one 
diffusion weighted image, commonly b=1000. 
When measuring ADC as described above, the diffusion gradient is applied along one 
direction. Thus ADC is only able to measure diffusion along one direction – which is not 
an issue if it is assumed that diffusion in any given direction is random. While ADC is a 
good measure for isotropic diffusion, it is unable to define anisotropic diffusion. An 
issue thus arises in imaging tissue which is anisotropic; and hence the concept of an 
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average ADC over three orthogonal directions was introduced, as shown in equation 
(2.9). For the purpose of this thesis, from here on ADC refers to the averaged measure 
of diffusion along three orthogonal directions. 
 
      
              
 
 
(2.9) 
where       is the averaged ADC over three orthogonal directions:      – the ADC 
measured in the x-direction,      – the ADC measured in the y-direction, and      – 
the ADC measured in the z-direction. 
2.1.10 INTRA-VOXEL INCOHERENT MOTION 
 
Figure 2.15: IVIM graph. While ADC images assume a linear fit for all points, it can be observed that at 
lower b-values a different fit exists. IVIM applies a biexponential to the data such that the gradient to 
the fit at higher b-values (shown in red) gives the slow diffusion coefficient, D; the intercept of the same 
fit is an approximation for the value of the perfusion fraction,  ; and the fit at the lower b-values gives 
the fast-diffusion coefficient,   .  
While in measuring the ADC, it is assumed that the diffusion coefficient is linear across 
all b-values and is thus modelled as a single exponential, in practice the signal has a 
non-linear behaviour, both at low b-values (          ) as shown in Figure 2.15 as 
well as at high b-values (           )8. Focusing on the signal at low b-values, 
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intra-voxel incoherent motion (IVIM) suggests applying a bi-exponential fit to data9. 
The model suggests that two components give rise to the diffusion effect; random 
Brownian motion of molecules in tissue (referred to as the slow diffusion component) 
and the flow of water in the randomly oriented micro-vascular network (referred to as 
the fast diffusion component). The IVIM model is given by equation (2.10).  
  
  
                   
   
(2.10) 
where   is the signal intensity at a given b-value,    is the signal intensity without 
diffusion-weighting,  is the slow diffusion coefficient of water molecules in tissue,    
is the fast pseudo-diffusion coefficient of water in blood capillaries, and   is the 
fraction of the total DWI signal which arises from the latter compartment.  
In the brain the fast diffusion coefficient,   is one order of magnitude higher than the 
slow diffusion coefficient   10. As shown in the model in Figure 2.15, the presence of 
the perfusion component at low b-values (          ) has an effect on the 
measured diffusion coefficient. In practice, the perfusion fraction,  , in the brain is 
small, and the value of  is lower than that of ADC – which measures the gradient as a 
linear fit to all b-values acquired. 
2.1.11 DIFFUSION TENSOR IMAGING 
While the averaged ADC deals with the issue of measuring diffusion in an anisotropic 
medium, it does not measure the anisotropy itself. The importance of measuring 
anisotropic diffusion lies in the fact that anisotropy is present in biological tissue, 
where water diffusion may have a preferred direction – such as along fibre tracts. 
Imaging the directionality of this diffusion may give an indication of the biological 
architecture and organisation of the tissue. Diffusion tensor imaging (DTI)11 aims to 
determine such directionality in order to attempt to build an image of the underlying 
structure. 
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Figure 2.16: Defining an ellipsoid. In order to define an ellipsoid six parameters are required. Three 
describe the lengths of the three axes and are known as the eigenvalues   ,    and   ; and three 
describe the orientation of the ellipsoid in space and are known as the eigenvectors   ,    and   . 
Isotropic diffusion in the shape of a sphere can be defined using one parameter – the 
radius. On the other hand, anisotropic diffusion in the shape of an ellipsoid requires six 
parameters – three determine the shape of the ellipsoid (the shortest, the longest and 
the middle axes) and three define the orientation in 3D space, as shown in Figure 2.16. 
The three parameters determining the shape of the ellipsoid are the eigenvalues   ,    
and   . The three parameters defining the orientation of the ellipsoid are the 
eigenvectors   ,    and   . In order to measure these six parameters, a minimum of 
six measurements along arbitrary axes are required. Using DTI, a minimum of six 
measurements are therefore required in addition to the b-zero signal and are defined 
in equation (2.11). 
 
 ̿  [
         
         
         
] 
(2.11) 
where ̿ is the diffusion tensor, with        ,        and       ;   ,     
and    are the diffusion measures along the three orthogonal axes; and the other 
diffusivities being described along correlations of two of the orthogonal axes. 
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As the diffusion tensor matrix is a symmetric matrix, the eigenvalues correspond to the 
diagonal of matrix ̿. In order to evaluate ̿, equation (2.7) cannot be used as it is only 
valid for isotropic diffusion. A different equation needs to be employed in anisotropic 
diffusion as shown in equation (2.12). 
  
  
     ̅
  ̿ ̅ 
(2.12) 
where   is the signal with diffusion weighting,    is the signal without diffusion 
weighting, b is the diffusion weighting defined in equation (2.8),  ̅ is a unit vector 
pointing in the direction of the diffusion gradient pulses, and  ̿ is the diffusion tensor. 
Once the diffusion tensor is constructed, the mean diffusivity (MD) is measured as the 
average of the sum of eigenvalues, which is also the mean of the trace of ̿ and is 
shown in equation (2.13). MD is in practice very similar to ADC in value, and has the 
same units. The basic difference is that while ADC is measured using DWI as an average 
of three directions, MD represents a diffusion measurement using DTI and thus a 
minimum of six directions would have been used to construct the diffusion tensor 
from which MD is extracted.  
 
   
        
 
 
           
 
 
(2.13) 
where MD is the mean diffusivity,   ,    and    are the eigenvalues with         , 
and   ,    and    are the diffusion coefficients in the x, y and z directions. 
The second important measurement in DTI is anisotropy, and the most commonly 
calculated parameter to represent anisotropy is the fractional anisotropy (FA), defined 
in equation (2.14). FA is defined such as to have values between 0 and 1, a value of 0 
representing isotropy and a value of 1 representing maximum anisotropy, where the 
ellipsoid is actually a line and hence has only one non-zero eigenvalue.  
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(2.14) 
where FA is the fractional anisotropy,   ,    and    are the eigenvalues, and MD is the 
mean diffusivity as defined in equation (2.13). 
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Figure 2.17: DTI parameters. The main DTI parameters calculated are the mean diffusivity (MD) and 
fractional anisotropy (FA). MD and ADC are similar and only differ in terms of the number of directions 
in which they are calculated. FA gives an indication of the anisotropy present in a given voxel. Using    , 
which shows the orientation for the principal eigenvalue, a colour map of the FA values can be built such 
that the orientation can be visualised. Red represents left to right, green represents anterior to 
posterior, and blue represents superior to inferior orientations. 
FA characterises the anisotropy for the diffusion in the voxel but does not give an 
indication of the direction of diffusion. This is provided by the eigenvector,   , which is 
related to the principal eigenvalue,   , such that a colour-coded map may be built on 
top of the FA showing the direction of diffusion. Conventionally, red represents 
diffusion between left and right, green represents diffusion anterior-posterior, and 
blue represents diffusion superior-inferior. By observing the direction of diffusion and 
the FA, DTI is able to reconstruct an image of the white matter fibres. Reconstruction 
of white matter pathways is done through tractography, a method which was first 
described in 199912–15 and is discussed in more detail in 16,17. Example DTI images are 
shown in Figure 2.17. 
2.1.12 IMAGE ARTEFACTS 
While all MR images may suffer from artefacts, diffusion imaging is particularly 
sensitive to motion due to the strong diffusion gradients. Motion can result in phase 
errors, which introduce ghosting artefacts. In order to mitigate this, the echo planar 
imaging (EPI) acquisition method is used. In this way, all of k-space is acquired in one 
scan such that a phase shift would affect the whole of k-space and should not have an 
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effect on the magnitude obtained after the Fourier transform is applied. This method, 
however, limits the image resolution and also introduces susceptibility errors. 
Susceptibility artefacts result from magnetic field inhomogeneity, particularly at tissue-
air interfaces, and become worse with increased field strength. 
Another artefact which is an issue in diffusion imaging involves the rapid switching of 
large magnetic field gradients, which induce eddy currents in the conductive parts of 
the scanner. The eddy currents produce additional unwanted magnetic fields, which 
alter the magnetic field at the sample from the value applied for a specific b-matrix. 
The eddy currents’ magnetic field also decays slowly during readout, causing 
geometrical distortions of diffusion images. 
Image artefacts, such as those caused by eddy currents, may be taken into account 
during data processing so as to minimise their effect. While the next section does not 
go into the detail of the data processing methods which can be employed to reduce 
such artefacts, it describes the process through which data obtained from the scanner 
is analysed in order to study the research question and draw meaningful conclusions. 
2.2 Data processing 
 
Figure 2.18: Data processing. Once data is obtained from the scanner, it needs to be converted into a 
format which can be easily processed. The parameters related to the data acquisition can then be 
calculated, followed by any necessary image processing and statistical analysis in order to test the 
experimental hypothesis. 
Once an image is acquired on an MR scanner as described in the previous section, the 
data is made available such that it can be viewed and analysed. Clinical data can be 
easily accessed using a picture archiving and communication system (PACS). However, 
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if any more information is required other than is available on the system, particularly 
in terms of answering a specific research hypothesis or clinical question, images may 
need to be processed further through additional tools. This section outlines the 
process of obtaining data from the scanner and describes tools available to analyse 
such data, according to the data processing steps shown in Figure 2.18.  
2.2.1 DATA TYPES AND DATA CONVERSION 
As imaging tools became an important component of patient management, and 
particularly as multiple images needed to be exchanged from one system to another, a 
need for standardising medical images across hospitals arose. In order to alleviate 
compatibility issues, the digital imaging and communications in medicine (DICOM) 
format was created. Although DICOM is the standard clinical image format, some 
manufacturers do use specifically developed formats, such as the Philips PAR/REC 
format, which would still however be compatible with the DICOM format. 
A DICOM image consists of two parts, the header – which contains patient and scan 
details, and the image data. While it has solved issues of compatibility in the clinic, the 
defined standard is broad and may be difficult to work with. Hence, more compact 
image formats tend to be applied in research. More specifically, most image processing 
software will use the ANALYZE or NIfTI18 formats, with NIfTI being the most commonly 
used format. 
Various software exist that convert data from DICOM to NIfTI. As well as being 
dependent on the computer platform and operating system in use, the choice of 
software may be affected by what scanner the images are coming from. Some 
software may work better with scanners from one manufacturer over another. Data 
conversion software available and explored in this work include MRIConvert19, dtoa20, 
dcm2nii21, TractoR22 and SPM23. 
2.2.2 PARAMETER ESTIMATION  
Diffusion imaging parameters may be output directly from the scanner, and hence 
available after data conversion. However, for the purpose of image analysis, it may be 
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important to estimate the parameters using a specific method and hence different 
software, such as MATLAB24, may be used.  
2.2.2.1 ADC  
ADC is generally calculated directly by the scanner. However, no standard way of 
calculating this parameter exists and the exact equation used is generally not 
published by the manufacturer25. Hence, in order to be able to reproduce the exact 
results across different scanners it may be important to calculate the ADC images using 
a specific script. ADC images from the b-value images output by the scanner can thus 
be produced by using the definition of ADC given in equation (2.7) and by averaging 
the measurement over the three orthogonal directions imaged by the scanner.  
2.2.2.2 D and f 
IVIM parameters are generally not estimated by the scanner directly but need to be 
calculated separately. Parameters given by the model in equation (2.10), can be 
calculated in different ways as mentioned in 26. 
2.2.2.3 MD and FA 
DTI parameters are normally calculated by the scanner, however, similar to ADC, the 
method employed is not standardised. In particular, one might want to correct for 
eddy currents or image registration issues. Therefore MD and FA can be calculated 
through own scripts or by using diffusion imaging processing software such as FSL27. 
2.2.3 IMAGE PROCESSING 
Once images are obtained from the scanner and the parameters calculated, images 
can be further processed through other image analysis software. The specific image 
processing carried out is dependent on the analysis required. Some analyses require 
registration and/or segmentation, described in the next sections. Analysis may also 
include other mathematical and statistical operations. Using MATLAB, images can be 
imported in a matrix format, which can be easily manipulated in order to conduct the 
necessary measurements. 
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2.2.3.1 Registration 
Image registration is an important image analysis tool. It allows for comparison of two 
images and reduces problems related to motion. Various techniques of image 
registration exist and include linear and non-linear methods, which have been 
implemented in software such as SPM23 and FSL27.  
2.2.3.2 Segmentation 
Image segmentation can be important in brain image analysis. In particular, SPM and 
FSL can be used to segment grey and white matter while other software such as 
FreeSurfer28 is able to carry out cortical and subcortical segmentation. Automated 
image segmentation is likely to introduce some errors and a degree of manual 
segmentation may help improve the results.  
2.2.4 STATISTICAL ANALYSIS 
After having estimated the diffusion parameters and processed the images so as to 
obtain the required measurements, statistical analysis is generally performed in order 
to infer possible conclusions from the analysis carried out. Various statistics software, 
such as R29, exist to perform these tasks. 
2.3 MRI in the Clinic  
In the beginning of this chapter we mentioned why MRI is considered to be a very 
useful imaging tool – in that it is both safe and non-invasive. In this section we explore 
the safety concerns and limitations of MRI, and mention the basic clinical protocols 
available together with an outline of the uses of diffusion imaging in the clinic. 
2.3.1 MRI SAFETY 
The main concern for MRI safety is related to the high magnetic field and radio 
frequency exposure, and a number of safety practices have been issued as guidance in 
order to mitigate risks30. While the presence of a large static magnetic field has not 
been shown to post a health concern in itself, its presence implies a number of safety 
issues. Very few fatalities have resulted from MRI. The main cause of such accidents 
was the effect of the static magnetic field on implants such as cardiac pacemakers, and 
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ferromagnetic objects which can act as a projectile. Furthermore, the effect of large 
field strengths has still not been studied thoroughly and current recommendations 
include applying a maximum field strength of 4T on foetuses and infants, while 
suggesting caution in experimental setups with field strengths higher than 8T31. 
RF radiation may generate heat due to the increased energy deposited in the 
molecules. The increase in temperature is small (  0.5 C) and can be controlled by 
altering the specific absorption ratio, a measure which needs to take into account both 
field strength and patient weight.  
Another safety issue, which needs to be considered in the clinic, is that the time 
varying magnetic fields introduced by the gradients may cause peripheral nerve 
stimulation. Apart from this, the noise generated by these gradients can exceed safety 
limits, and ear plugs are generally used by the patient and anyone else in the scanner 
room during scanning. 
While the above concerns need to be taken into account in the clinic, and caution is 
important, the safety of MRI is much greater than that of other imaging modalities 
such as PET, X-ray or CT, which all use ionising-radiation. 
2.3.2 LIMITATIONS OF MRI 
The main limitation of MRI is the low sensitivity. As described in the above sections, 
MRI requires a large number of nuclei to image what is known as a voxel. The size of 
the voxel therefore offers the limit which can be imaged – implying voxels may include 
in them more than one type of tissue, and particularly at boundaries MRI is susceptible 
to partial volume effects. This means that fine structures cannot be resolved using 
MRI. While voxel size can be reduced to increase resolution and decrease partial 
volume effects, the reduction in voxel size is limited by scan time and SNR. Another 
limitation for MRI in the clinic is its cost. MRI is more costly than X-ray, CT and 
ultrasound, both in financial terms and in terms of scanning time. In addition, in order 
to obtain good quality images it is important for the patient to cooperate and lie still in 
the scanner. This may be a challenge, particularly when imaging young children, and 
sedation or anaesthesia may be necessary. 
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2.3.3 BASIC CLINICAL BRAIN IMAGES 
In the brain, basic clinical imaging will include    and   -weighted images in the 
coronal, sagittal and axial planes. Post-contrast imaging, generally gadolinium, is also a 
common technique used in order to detect pathologies affecting the blood-brain 
barrier. Gadolinium affects the MRI signal by shortening    values and thus makes the 
areas it reaches appear brighter. DWI is also a common clinical imaging sequence, 
normally carried out in the axial plane. 
2.3.4 DIFFUSION IMAGING 
As stated, diffusion imaging is widely used both as a research tool and in the clinic. In 
particular it is beneficial in acute and chronic stroke, in assessing brain development, 
multiple sclerosis, epilepsy, neurodegenerative disorders, psychiatric disorders and 
brain tumours. Clinically, it is used both in the assessment of diseases and for 
neurosurgical planning. As this thesis focuses on diffusion imaging in brain tumours, 
the next chapter provides a background to cancer and in particular paediatric brain 
tumours prior to exploring current research work carried out in diffusion imaging in 
brain tumours. 
  
56 
Chapter 3 CANCER AND PAEDIATRIC BRAIN TUMOURS 
The main aim of this chapter is to provide a background of cancer biology, followed by 
an overview of brain anatomy. This chapter then focuses on paediatric brain tumour 
classification and treatment, concluding with a summary of imaging modalities used in 
brain tumour imaging. 
3.1 Cancer 
3.1.1 BACKGROUND 
Cancer is the second leading cause of death after cardiovascular disease. It is said that 
more than one in three people will develop cancer in their lifetime and it is thus not 
surprising that cancer research charities are amongst the charities receiving most 
income in the UK. Funding is driven by the general public’s awareness of the 
importance of improving cancer treatment, implying a need for understanding how 
cancer develops, evolves and reacts to treatment; and highlights how public 
engagement can have a considerable impact on scientific research. 
3.1.2 A BRIEF HISTORY 
The word “cancer” is Latin for the ancient Greek word “karkinos”, meaning crab, and 
was first used to describe the disease by Hippocrates (460 BC – c. 370 BC). Although 
this is the earliest mention of the term, the disease itself was known from Egyptian 
times (1500 BC)32. Different theories on how cancer developed were proposed 
throughout the centuries, but the main advances in cancer research happened 
following the discovery of the double helix DNA structure in 1953. In order to 
understand how cancer forms and develops we need to first start with the basic unit of 
life, the cell. 
3.1.3 SOME CHARACTERISTICS OF CELLS 
Two types of cells exist, one with and one without a nucleus, and here we are 
interested in the cell type of multi-cellular organisms - eukaryotic cells, i.e. cells which 
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contain a nucleus. The nucleus is an organelle inside a cell which contains the genetic 
material stored in the deoxyribonucleic acid (DNA) molecule. The basic structure of a 
cell together with a description of some of the organelles is given in Figure 3.1. 
 
 
Figure 3.1: Structure of a cell. A eukaryotic cell consists of (1) a cell membrane that separates the 
intracellular space from the extracellular space, protecting the cell by controlling the movement of 
substances in and out of the cell; (2) the cytoplasm, the part of the cell held within the cell membrane 
and containing the cytosol (the intra-cellular fluid) and all organelles, excluding the nucleus; (3) the 
mitochondria, which generate most of the cell’s energy and are involved in controlling cell growth and 
the cell cycle; and (4) the nucleus, which contains most of the cell’s genetic material. The nucleus 
contains (5) the nucleolus, which is responsible for assembling ribosomes (organelles which synthesize 
proteins within the cell); and (6) the chromosomes, which are the organised structure of the DNA. 
Chromosomes include (7) the telomeres, which are repeated strands of DNA at the ends of the 
chromosome, responsible for protecting it; (8) the centromere, which joins together two identical copies 
of the chromatid to form the chromosome, and helps keep the chromosomes aligned during cell 
division; and (9) genes, which are segments of DNA that represent a specific trait. Note that the 
centromere is not normally in the centre of the chromosome and the short arm is referred to as the p 
region while the longer arm is referred to as the q region. 
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Figure 3.2: The cell cycle. Cells which are not in a replicative stage are said to be in quiescence in the    
stage. Once a cell moves back into the cell cycle, at the    stage, it starts to increase in size and the cell 
gets ready for DNA synthesis by preparing the necessary components. The cell then moves in the 
synthesis stage, the S-stage, and DNA synthesis occurs such that all chromosomes are replicated. In the 
mitotic phase, the M-stage, nuclear division occurs, following which the cell divides in two daughter 
cells. Checkpoints exist during each of the stages to ensure that replication occurs without errors. 
One of the basic requirements of a cell is the ability to replicate. The cell division cycle 
occurs in a number of stages, shown in Figure 3.2. A cell that is in a non-dividing stage 
is said to be in the    stage. Once a cell is dividing it will enter the    gap stage where 
cells grow while carrying out normal metabolism. The cell then moves to the S-phase 
or the DNA synthesis-phase where DNA replication occurs and chromosomes duplicate 
inside the nucleus. From the S-phase, the cell enters the    gap stage, where the cell 
continues to grow and prepares for its actual division. In the M-phase or mitosis-phase, 
the nucleus in the cell will separate the duplicated chromosomes into two nuclei. The 
cell can then divide into two daughter cells. 
The cell cycle is complex, and findings from a study in 197033 suggested that the cell 
cycle is regulated by certain factors. A number of mechanisms, defined as checkpoints, 
exist so as to ensure that a perfect copy of the cell results after cell division34. A 
checkpoint detects errors and makes sure the cell cycle is stopped if one is identified. 
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For example, in response to DNA damage or failure in DNA replication, protein kinases 
are activated which prevent the cell from going into the mitotic phase35. When these 
checkpoints fail due to genetic mutations, a cancer cell may form. 
3.1.4 FORMING A CANCER CELL 
Cancer is a genetic disease and a cancer cell forms after a number of genetic 
mutations. The genes which drive tumourigenesis, the formation of a tumour, can be 
divided into three categories: tumour suppressor genes, oncogenes and genomic 
stability genes. Tumour suppressor genes suppress the formation of tumour, 
oncogenes induce the loss of growth control, and genomic stability genes keep 
mutations to a minimum by identifying DNA damage and correcting errors made 
during normal DNA replication. While these three categories represent the genes that 
contribute to forming a cancerous cell, specific genes may belong to more than one of 
these categories, and an example of one such gene is the TP53 gene. 
The TP53 gene is primarily a tumour suppressor gene and has significant consequences 
once mutated. TP53 encodes the polypeptide p53 – a transcription factor which 
activates genes involved in the regulation of the cell cycle and apoptosis (programmed 
cell death). When TP53 is activated as a response to stress or senescence, it forces the 
cell to stop growing and can also force apoptosis. Secondly, the gene is activated by 
proteins responding to DNA damage, stopping replication in the case of severe 
damage. If the gene is not activated, a loss in genomic stability occurs, allowing for 
more mutations to occur. Thirdly, some mutations to the TP53 gene result in a gain of 
an oncogenic function. While this gene is the most frequently mutated gene in adult 
cancer, it is rare in childhood cancer.36 
Most cancer mutations are developed during one’s lifetime. However, some forms of 
cancer mutations are inherited, which makes it more likely for the person to develop 
the disease. The fact that certain types of cancer are prevalent in certain families 
implies that genetic mutations that induce cancer can be inherited, and the loss of 
tumour-suppressor genes is one such mutation. Inherited mutations are termed 
germline mutations and these mutations are present at the formation of the embryo. 
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Mutations which occur in the body are termed somatic mutations. Somatic mutations 
occur in specific tissue in the body and may result in cancer, however these mutations 
are not passed on to any offspring.37 Genetic mutations forming cancer cells may occur 
as a result of exposure to carcinogenic chemicals, ionizing radiation, as well as a variety 
of tumour-inducing viruses38. In most cancers, all cells arise from a single cell which 
then proceeds to replicate uncontrollably. While cancer cells vary widely they may 
share some of the features described in Hanahan and Weinberg’s “Hallmarks of 
Cancer”39,40 and summarised in the next section.  
3.1.5 HALLMARKS OF CANCER 
Figure 3.3: Hallmarks of cancer. Initially six hallmarks of cancer were suggested: sustaining proliferative 
signalling, evading growth suppressors, enabling replicative immortality, activating invasion and 
metastasis, inducing angiogenesis, and resisting cell death. These were expanded to include four new 
hallmarks: avoiding immune destruction, tumour-promoting inflammation, genome instability and 
mutation, and deregulating cellular energetics. (Adapted from Hanahan and Weinberg, 2011.
40
) 
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3.1.5.1 Sustaining proliferative signalling 
As mentioned, a cancer cell will replicate uncontrollably. This is in part due to the 
ability of cancer cells to sustain proliferative signalling. Whereas in healthy tissue the 
cell cycle is controlled by growth-promoting signals, in cancerous tissue cells gain the 
ability to take control of these signals, either by producing the required growth factors, 
or by stimulating normal cells around the tumour stroma to supply the required 
growth factors. In this way a positive feedback signalling loop is created such that 
tumour proliferation may continue. 
3.1.5.2 Evading growth suppressors 
Cells respond to both positive growth-inducing signals and signals which negatively 
regulate proliferation. These growth suppressors work by forcing a cell into the    
stage of the cell cycle, a quiescent stage in which the cell is no longer in the cell 
division cycle, yet is still able to enter the cycle at a later time point. The alternative is 
to induce cells into a state where they can no longer enter the cell division cycle. This 
negative regulation can be brought about by tumour suppressor genes which limit cell 
growth and proliferation. The evidence of these signals can be seen in tissue culture, 
where normal cells will proliferate to yield a single layer of cells only, and further 
growth is suppressed through a variety of mechanisms. Cancer cells will however 
continue to propagate and pile up in order to form clumps. Cancer cells thus need to 
evade the growth suppressor signals in order to thrive.  
3.1.5.3 Avoiding immune destruction 
The role that the immune system plays in fighting cancer, both in cancer formation and 
progression, is not well understood. Theory suggests that the immune system is 
constantly alert and as soon as a new tumour is detected it is destroyed. Tumours 
therefore need the ability to avoid destruction by the immune system. One possibility 
here is that cancer cells may use immune-suppressive factors to avoid the immune 
system.  
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3.1.5.4 Enabling replicative immortality 
Normal cells in the body are only able to go through a limited number of consecutive 
cell growth and division cycles. The limit is provided by senescence, i.e. when a cell 
enters into a non-replicative state, and apoptosis. The replication limit is provided by 
telomeres at the end of each chromosome which shorten with each cell division until 
the minimum length is achieved. Variants of cells which are able to multiply without 
limit are defined as immortal cells. Cancer cells acquire this unlimited replicative 
potential by expressing telomerase. This extends telomeric DNA such that it is able to 
counter the telomere erosion which would otherwise occur, avoiding the triggering of 
senescence and apoptosis – both mechanisms which act as an anticancer defence.  
3.1.5.5 Tumour-promoting inflammation 
Almost all tumours will contain some immune system cells. The immune system 
response has been seen to be an attempt to destroy the tumour. However, the 
inflammatory response of the immune system appears to aid the tumour by supplying 
biological molecules which may sustain proliferation, resist cell death, encourage 
angiogenesis as well as facilitate invasion and metastasis. Thus the inflammation 
caused by the immune system may be considered as a characteristic which enables the 
tumourigenic process. 
3.1.5.6 Activating invasion and metastasis  
Tumours can invade other tissues through local invasion or metastatic spread. In local 
invasion, a tumour may invade the tissue surrounding it. In metastatic spread, the 
tumour spreads to tissues which are farther away from the original tumour. This 
section focuses on invasion through metastatic spread. 
Tissue invasion is the ability of a tumour to move to a different site and the tumour 
which forms in this new location is called metastatic tumour, a major cause of cancer-
related deaths in humans. In these new areas, cancer cells have access to more 
nutrients and space. The process of cancer metastasis is termed the invasion-
metastatic cascade. After a cancer cell is transformed and grows into a local tumour, 
angiogenesis is induced. Cancer cells may detach from the rest of the tumour and 
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enter the blood and lymphatic vessels by motility and a process termed as 
intravasation. Once in the vessels, embolization occurs such that the vessel is 
obstructed and these emboli are carried within the vascular system to a capillary bed. 
Here extravasation occurs such that the tumour emboli exit the blood and lymphatic 
vessels and reach an organ parenchyma, where they are able to grow similarly to the 
primary tumour but with the adaptations required according to the microenvironment 
of the host tissue.41 The process by which the growth of the micro-metastatic lesion 
grows into a macroscopic tumour is termed colonization and requires the metastatic 
tumour to establish a microenvironment in which it can survive. The process of 
invasion and metastasis is thus likely to involve a number of complex cell-biological 
programs. That said, the dissemination of metastasis is considered to be the final step 
of primary tumour progression and carries much lower survival rates. 
3.1.5.7 Inducing angiogenesis 
All tissue in the body needs access to nutrients and oxygen, and must be able to 
remove any metabolic waste and carbon dioxide. This is generally done through blood. 
In tumours, new blood vessels are created through a process called angiogenesis. 
While in normal tissue angiogenesis occurs only for short periods of time, in tumours 
angiogenesis is almost always activated. It is governed by both angiogenic regulators 
which may either induce or inhibit angiogenesis. Whereas in normal tissue vasculature 
is organised, in tumour tissue it tends to be random and chaotic, and is characterised 
by increased leakiness and an abnormal level of endothelial cell proliferation and 
apoptosis. The way tumours induce neovascularisation varies and the expression of 
angiogenic regulators may be upregulated by oncogenes present in the cancer cell. 
One such angiogenic regulator is the vascular endothelial growth factor (VEGF) and 
anti-VEGF antibodies are one of the therapeutic mechanisms used in order to impair 
neovascularization.  
3.1.5.8 Genome instability and mutation 
Genome mutation and instability provides a basis for cancer cells to prosper. Gene 
mutations may provide advantages to specific cells such that tumours may outgrow 
the local tissue micro-environment. Cancer can be seen as a multi-step process of 
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genetic mutations42. Cancer cells thus have an increased sensitivity to mutagenic 
agents and are also able to debilitate the defence mechanism of cells which aim to 
either resolve DNA mutations or force mutant cells to go into senescence or apoptosis. 
Genome instability is able to hasten the speed by which cancer cells obtain 
advantageous mutations and hence is instrumental in enabling tumour progression. 
3.1.5.9 Resisting cell death 
For a tumour to expand it needs to both proliferate and resist cell death. Apoptosis 
may occur as a way of destroying cells which would have replicated incorrectly, thus 
helping to prevent cancer development. Cancer cells may however develop a 
resistance to apoptotic pathways. This can be done in a variety of ways and is most 
commonly done through the loss of the TP53 tumour suppressor gene, which acts as a 
sensor for DNA damage. Cell death may also be resisted by increasing the expression 
of anti-apoptotic regulators or by decreasing the expression of pro-apoptotic 
regulators.  
While apoptosis is a programmed cell death, cancer cells may also be at risk of dying 
due to resource starvation. The increased proliferation of cancer cells implies that in 
certain areas of a tumour, cells may experience nutrient starvation such as a lack of 
glucose and oxygen. In these cases, cancer cells may use autophagy, a process by 
which cells will break down less important organelles to produce the required energy 
so as to survive. Autophagy is also a process which is regulated by the cells. Cancer 
cells which undergo this process may enter a state of reversible dormancy, which may 
result in tumour regrowth following treatment. Thus while autophagy limits the cell’s 
replicative capabilities, it may contribute to tumour progression. 
Cells may also die through a necrotic process which represents a form of traumatic cell 
death. Through necrosis cells become bloated and explode, resulting in the contents of 
the cell becoming part of the tissue micro-environment. Necrosis may also be 
controlled through a genetic process, and it has been suggested that necrotic cells 
could recruit inflammatory cells which are responsible for removing the necrotic 
debris. These same cells may however stimulate growth by enabling angiogenesis and 
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further proliferation of cancer cells. Necrosis may thus also contribute to tumour 
progression. 
3.1.5.10 Deregulating cellular energetics 
Apart from being able to proliferate, cancer cells need to make adjustments to the 
energy metabolism of the cell in order to promote cell growth and division. Cells can 
produce energy in one of two ways, either by using aerobic respiration (with oxygen) 
or by using anaerobic respiration (without oxygen). In aerobic respiration, glucose is 
converted to pyruvate via glycolysis in the cytosol of the cell, and pyruvate is then 
transported to the mitochondria in the cell to be further broken down into carbon 
dioxide and water through oxidisation. In anaerobic respiration glycolysis still occurs, 
however pyruvate is not oxidised, and thus much less energy is produced. Cancer cells, 
which often suffer from hypoxic conditions, appear to be able to regulate the 
metabolism of glucose to use only glycolysis, even in the presence of oxygen. In order 
to produce more energy some cancer cells will regulate the glucose transport so as to 
bring more glucose into the cytoplasm. The reprogramming of the cellular energy 
metabolism may thus be an important factor to consider in understanding how 
tumours progress and how they react to treatment. 
3.1.6 HISTOPATHOLOGY AND GRADING 
A number of features define the histopathological features of cancer. First, the 
morphology, or shape, of cancer cells is different from that of normal cells. Second, the 
architecture of a tumour is less organised than the parent tissue, as can be seen in the 
vascular network which tends to be more chaotic and leaky. Third, cancer cells may 
have an increased nucleus to cytoplasm ratio and some cells may be multi-nucleated. 
That said, cancers can be heterogeneous and different cells can vary in size.43  
Histopathologically it is important to be able to differentiate between benign and 
malignant tumours. Benign tumours grow slowly in a confined space within a tissue 
and do not invade or metastasize. Malignant tumours, on the other hand, grow more 
rapidly and appear to be invasive and may also metastasize.  
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One of the important tumour classifications carried out histopathologically, is tumour 
grading. Tumour tissue is analysed in order to determine whether it is similar to the 
tissue of origin, and if it is similar it is defined as well differentiated. Tumour tissue 
which does not have the features of the tissue of origin and shows aggressive growth 
and high mitosis is defined as poorly differentiated. While grading can differ from one 
cancer type to another, a basic grading system will define a well differentiated tumour 
as grade 1 and is considered a low grade tumour, a moderately differentiated tumour 
is defined as grade 2, a poorly differentiated tumour is defined as grade 3 and an 
undifferentiated tumour is defined as grade 4 and is considered a high grade tumour. 
Tumour grading carries prognostic significance and it is expected that patients with 
higher grade tumours will have a lower survival rate than those with low grade 
tumours.  
Histopathological reports include, where possible, the tumour size, grade, architecture, 
rate of mitosis, margin involvement and invasion of the vascular network. While 
histopathological analysis is important in identifying tumour severity, other factors 
need to be taken into consideration when staging a tumour. In particular, the size of 
the primary tumour, the presence of nearby lymph nodes and the presence of distant 
metastases need to be considered through clinical examinations and radiological 
analysis. Finally, in addition to the above, the location of the tumour carries a large 
significance in the prognosis of a tumour.  
As this thesis focuses on paediatric brain tumours, a basic anatomy of the brain is 
presented prior to describing childhood brain tumours in more detail. 
3.2 The Brain  
3.2.1 BACKGROUND 
The brain and the spinal cord form the central nervous system (CNS), which, together 
with the peripheral nervous system detects changes in the internal and external 
environments and brings about the required responses from muscles, organs and 
glands.44  
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3.2.2 CELL TYPES 
The nervous system consists mainly of nerve cells, or neurones, and neuroglial cells, or 
glia. Neurones need to be able to gather information from sensory receptors or organs 
and transmit these to other neurones or organs. Generally, neurones consist of the cell 
body, dendrites and axons. Dendrites emerge from the cell body and are able to 
receive information. The cell is then able to code the information in terms of electrical 
energy and transmit it via axons.  
Glia outnumber neurones and their role is to ensure that neurones function normally. 
The main types of glial cells are the oligodendrocytes, which are responsible for 
forming myelin sheath around nerve cell axons, forming an insulating cover and 
increasing the efficiency of electrical energy transmission; the astrocytes, which are 
thought to support the formation of the blood-brain barrier; and the microglia, which 
act as part of the immune defence system in the CNS.  
The CNS is a heterogeneous structure, with areas most abundant in neuronal cell 
bodies known as grey matter, and areas most abundant in myelinated axons known as 
white matter.  
3.2.3 ANATOMY  
 
Figure 3.4: Anatomy of the brain. The brain can be divided into four main regions: the cerebral 
hemispheres (1), the diencephalon (2), the brain stem comprising the midbrain (3), pons (4) and medulla 
(5), and the cerebellum (6). The brain, together with the spinal cord (7) make up the CNS. 
3. Cancer and Paediatric Brain Tumours 
68 
The brain can be broadly divided into four sections – the cerebral hemispheres (left 
and right), the diencephalon, the cerebellum and the brain stem, as shown in Figure 
3.4. The two cerebral hemispheres are not completely separated and are linked to 
each other through the corpus callosum. In addition, the brain includes the ventricular 
system. 
The cerebral hemispheres are the largest sections of the brain and consist of an outer 
layer of grey matter, described as the cortex, and an inner area of white matter. Their 
function lies in conscious awareness, thought, memory and intellect. All sensory 
modalities and motor functions are represented consciously in the cerebral cortex. The 
cerebrum is divided into four lobes: the frontal lobe containing the primary motor 
cortex which controls movement; the parietal lobe containing the primary 
somatosensory cortex which controls touch, pressure, pain and temperature; the 
occipital lobe containing the visual cortex; and the temporal lobe containing the 
auditory cortex. The effect of lesions in the four lobes is dependent on the location in 
which they occur and may differ from person to person, as different areas may be used 
for a similar function. For example, language is normally dominant on the left side of 
the brain but this is not universal to everyone and thus lesions on the right side may 
also cause speech deficits. The left and right side of the brain connect through the 
corpus callosum and lesions in these areas may effect communication between two 
sides of the brain. Another important structure, lying deep within the subcortical white 
matter is the basal ganglia which functions to facilitate useful and purposeful 
movements, and inhibit unwanted movements. Lesions in this region thus lead to a 
loss of control of voluntary movement. 
The diencephalon includes the thalamic regions: the epithalamus includes the pineal 
gland; the thalamus has an important role in sensory, motor and cognitive functions; 
the subthalamus is related to the basal ganglia in function; and the hypothalamus is 
involved in the autonomic nervous system, the limbic system and the neuroendocrine 
system. A lesion in the thalamus leads to a loss of sensation in the face and limbs 
contralaterally – on the opposite side of the body as to where the lesion is. 
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The brain stem, comprising of the midbrain, pons and medulla, constitutes a small part 
of the brain but provides a vital function as it links the brain to the spinal cord, and also 
controls some vital functions such as respiration and the cardiovascular system. A 
lesion in the brain stem will cause cranial nerve dysfunction and incoordination 
ipsilaterally – on the same side of the body; and hemiparesis (weakness on one side of 
the body), hyperreflexia (an over-reactive reflex system) and hemisensory loss (loss of 
sensation on one side of the body) contralaterally. 
The cerebellum is linked to the medulla, pons and midbrain through nerve fibres. The 
outer part of the cerebellum consists of grey matter, which surrounds a white matter 
core. The main role of the cerebellum lies in the coordination of movement and 
operates at an unconscious level. The symptoms of a lesion in the cerebellum differ by 
the region in which the lesion is present. In the midline a lesion results in loss of 
postural control and thus an inability to sit or stand. Unilateral lesions cause symptoms 
ipsilaterally such that a lesion on the right of the cerebellum causes incoordination in 
the right arm and right leg. Eye coordination is also effected by lesions to the 
cerebellum. 
 
Figure 3.5: The ventricular system. The ventricular system consists of a series of connecting chambers 
filled with CSF. The lateral ventricles (1) are located on either side of the cerebral hemispheres. They are 
then linked to the third ventricle (2) which continues to become the cerebral aqueduct (3). The cerebral 
aqueduct extends through the midbrain to link the third and the fourth ventricle (4). The fourth ventricle 
is located between the brain stem and the cerebellum. 
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The ventricular system includes the lateral ventricles, the third ventricle, the cerebral 
aqueduct and the fourth ventricle as shown in Figure 3.5. The ventricular system is 
filled by CSF which is produced by the choroid plexus, located in the lateral, third and 
fourth ventricles. The CSF acts so as to protect the brain from damage, remove waste 
products and provide some of the nutrients required. If the flow of CSF is obstructed, 
such as in the case of a brain tumour, an increase in fluid pressure occurs causing the 
ventricles to swell up. This is known as hydrocephalus and the main symptoms include 
headaches and unsteadiness. Hydrocephalus occurs when the rate of CSF production is 
higher than that of CSF absorption. Clinically, a shunt may be inserted in order to drain 
the excess CSF into another area of the body, normally the abdomen, and to the 
venous system through which it would have been absorbed under normal conditions. 
3.3 Paediatric Brain Tumours 
3.3.1 BACKGROUND 
Childhood cancer is the leading cause of disease related deaths in children aged 1-14.45 
Brain tumours are the second most common cancer in children, with leukaemia being 
the most common. Although brain tumours only account for between 20 and 25% of 
all cases, they are the main cause of cancer related deaths in children.36 Besides the 
higher mortality, due consideration needs to be given to the toxicity of treatment of 
brain tumours, with the aim in particular being to reduce late effects and diminish 
treatment side-effects.  
3.3.2 COMPARISON TO ADULT BRAIN TUMOURS 
When comparing adult tumours to those in childhood, it can be observed that 
childhood cancer is closely linked to tissue development, while in adults it is related to 
the interaction of cells with environmental carcinogens. In children, the primary event 
to initiate the tumour may occur during the development of the embryo, as in the case 
of embryonal tumours such as medulloblastoma.36  
The most common primary brain tumours in children are low grade gliomas and 
medulloblastoma, while the most common primary brain tumours in adults are 
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glioblastoma and meningioma46. Apart from tumour type, tumour location also varies 
between adults and children, with a much lower percentage of adults presenting with 
brain tumours involving the cerebellum than children. Children are also more sensitive 
to radiotherapy and chemotherapy and thus treatment has more potential side 
effects.47 
Unlike in the case of children, where most brain tumours are primary tumours, those 
in adults are tumours which would have metastasised from other parts of the body, 
such as lung cancer, breast cancer, melanoma and kidney cancer.48 Hence the biology 
of these tumours varies significantly from those in children. Only 2% of cancers are 
primary brain tumours in adults, compared to the 20-25% in children, and the vast 
majority of these are gliomas.49 Due to the differences in biology, location and 
sensitivity to treatment, childhood tumours need to be considered in a different light 
to adult tumours, and the rest of this chapter focuses on paediatric brain tumours. 
3.3.3 CLINICAL PRESENTATION 
The median symptom to diagnosis time interval varies by country – between 5 and 14 
weeks.36 Longer time intervals are generally related to slow growing tumours with 
vague symptoms. Brain tumour symptoms are non-specific and neuroimaging is 
required to confirm diagnosis. Clinical presentation may show signs of increased 
intracranial pressure. Symptoms vary widely and include headaches, nausea, vomiting, 
visual disturbance, behavioural issues and epilepsy, and are dependent on the site and 
type of the tumour.  
3.3.4 TUMOUR CLASSIFICATION 
Tumours are defined according to the location and cell type from which they are 
derived and the ICD-O classification for CNS tumours36 is shown in Table 3.1. A brief 
description of some of the tumour types is given in this section. 
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Table 3.1: Central nervous system tumour classification (ICD-O 9380–9539) 
 
Neuroepithelial 
(brain tumours, 
spinal tumours) 
Glioma 
Astrocyte 
Astrocytoma (Pilocytic astrocytoma, 
Pleomorphic xanthoastrocytoma, 
Fibrillary (also diffuse or low grade) 
astrocytoma, Anaplastic astrocytoma, 
Glioblastoma multiforme) 
Oligodendrocyte Oligodendroglioma 
Ependyma 
Ependymoma 
 Subependymoma 
Choroid plexus 
Choroid plexus tumour (Choroid 
plexus papilloma, Choroid plexus 
carcinoma) 
Multiple/ 
unknown 
Diffuse intrinsic pontine glioma 
Oligoastrocytoma 
Gliomatosis cerebri 
Gliosarcoma 
Mature 
neuron 
Ganglioneuroma: Ganglioglioma, Retinoblastoma, 
Neurocytoma, Dysembryoplastic neuroepithelial tumour, 
Lhermitte-Duclos disease 
PNET 
Neuroblastoma (Esthesioneuroblastoma, 
Ganglioneuroblastoma), Medulloblastoma, Atypical 
teratoid/rhabdoid tumour 
Primitive Medulloepithelioma 
Meningiomas 
(meninges) 
Meningioma Meningioma 
Hematopoietic Primary central nervous system lymphoma 
Adapted from 36 
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3.3.4.1 Low-grade Gliomas 
 
Figure 3.6: Juvenile pilocytic astrocytoma in a 9 year old female patient. A coronal FLAIR image (left) 
and an axial ADC image (right) are shown for a patient with JPA. Bright areas in ADC are representative 
of fluid areas and in this case gliomatous areas can be observed. These appear as cystic on the ADC 
image as they are more fluid than normal brain parenchyma. However, they are less fluid than areas of 
CSF and are not suppressed in the FLAIR image. The patient was treated via surgery, with two surgical 
resections taking place, followed by a watch and wait protocol. The patient was well at last follow-up, 
five years after diagnosis, age 14. 
Juvenile pilocytic astrocytoma: The majority of low grade astrocytomas are pilocytic 
astrocytomas – also termed juvenile pilocytic astrocytomas (JPA) due to their 
prevalence in children and adolescents. These tumours occur mostly in the cerebellum, 
are well circumscribed, have a low cellularity and do not infiltrate the surrounding 
brain. Many JPAs are associated with neurofibromatosis type 1 (NF1) – a gene 
responsible for activating the protein neurofibromin. Mutations to this gene can arise 
sporadically or can be passed on through germline transmission of an already 
established mutation. On MRI, JPAs may show cystic changes and show minimal or no 
contrast enhancement. These tumours are best visualised on a FLAIR (fluid attenuated 
inversion recovery) sequence. Following treatment, serial imaging is important due to 
the likelihood of recurrence. 
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Figure 3.7: Optic pathway glioma in a 1 year old female patient. A sagittal post-contrast T1 weighted 
image (left) and an axial ADC image (right) are shown, showing the tumour in the optic chiasm. A watch 
and wait protocol was first employed and this was followed with chemotherapy following progression. 
The patient received proton therapy at age 5 and was well at last follow-up, age 6. 
Optic pathway gliomas: These tumours represent 5% of paediatric CNS tumours and 
are a subtype of JPA which arise within the visual pathways (the optic nerve, chiasm, 
tract and radiation). They are also a low grade tumour. However, in contrast with JPA, 
they infiltrate the brain and can extend into the posterior visual cortex and other 
structures such as the hypothalamus. Their border is not well defined and surgery is 
generally avoided. Clinical presentation of optic pathway gliomas (OPG) includes a 
visual deficit, which may be difficult to detect, particularly in infants. Tumours which 
involve the hypothalamus will affect the endocrine system of the patient and may 
result in precocious puberty. Tumours which involve the thalamus may result in motor 
deficits. Biopsies are not required in these tumours where the appearance on MRI is 
typical, and surgery is often only carried out in more advanced stages of the tumour, 
where there is no vision. These tumours are generally treated via radiotherapy; 
however chemotherapy is used in order to delay radiotherapy in young children under 
the age of three. Although the overall survival of OPG patients is high, these children 
tend to suffer from considerable visual deficits.  
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Figure 3.8: Subependymal giant cell astrocytoma in an 11 year old male patient. A sagittal post-
contrast T1-weighted image (left) and an axial ADC image (right) are shown. Ventricular enlargement 
can also be observed in the images. Surgery was attempted but failed due to haemorrhage. The patient 
was treated via chemotherapy, reducing the size of the tumour and allowing for complete surgical 
resection. The patient was doing well at last follow-up, age 16. 
Subependymal giant cell astrocytoma: This is a benign tumour which occurs mostly in 
patients with tuberous sclerosis – a rare genetic condition. Subependymal giant cell 
astrocytomas (SEGA) are treated via surgery. Where surgery is not possible, new 
chemotherapeutic techniques such as rapamycin, which is able to target the molecular 
pathways affected by the tuberous sclerosis gene mutation, may be employed. These 
agents are able to decrease the size of the tumour in order to improve the likelihood of 
complete surgical resection. Although classified as an astrocytoma, tumour cells tend 
to be of both neuronal and glial origin.  
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3.3.4.2 High-grade gliomas  
 
Figure 3.9: Glioblastoma multiforme in a 7 year old male patient. Axial post-contrast T1-weighted 
(left), ADC (middle) and sagittal spinal (right) images are shown. The patient had disseminated disease in 
the spinal cord and also hydrocephalus. The patient was treated via chemotherapy and radiotherapy, 
and received palliative care as the solid component and metastases grew further. The patient died 8 
months after diagnosis. 
Glioblastoma multiforme: High-grade astrocytomas represent between 10 and 20% of 
paediatric CNS tumours and occur mostly in the supratentorial region (in the cerebral 
regions) and in the brain stem. Mostly these tumours include anaplastic astrocytoma 
and glioblastoma multiforme (GBM). Both tumours are diffusively infiltrative, making it 
difficult for the surgeon to identify tumour borders, and show high mitotic activity. 
GBM tumours tend to exhibit areas of necrosis, cystic regions, haemorrhagic areas and 
areas of high cellularity and thus the tumour itself is heterogeneous. While the clinical 
symptoms of high-grade tumours varies by site, age and biological aggressiveness, the 
time interval between onset of symptoms and diagnosis is much shorter in high-grade 
tumours than in low-grade tumours. Children with high grade tumours are generally 
treated first by surgery, requiring an aggressive resection while aiming to preserve 
neural function. Radiotherapy is generally a standard mode of treatment following 
surgical resection together with adjuvant chemotherapy. Survival of patients with high-
grade gliomas is still low, with less than 20% of patients surviving five years. 
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Figure 3.10: Gliomatosis cerebri in a 17 year old male patient. Post-contrast T1-weighted (left) and ADC 
(right) images show the tumour to have spread in different regions. The patient was diagnosed age 16 
and following the shown imaging was given palliative care. The patient died 1 year and 2 months after 
diagnosis, age 17. 
Gliomatosis cerebri: This rare high grade-glioma is characterised by a diffuse pattern of 
spreading across the brain parenchyma and defined by the World Health Organization 
(WHO) to involve at least 2 critical lobes, but often extending to infratentorial 
structures50. Histological samples are consistent with those of GBM, but total surgical 
resection is in this case not possible due to the diffuse nature of the tumour. Whole 
brain radiotherapy is thus the offered treatment, together with chemotherapy. 
Prognosis of patients with gliomatosis cerebri (GC) is very poor. 
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3.3.4.3 Brainstem gliomas 
 
Figure 3.11: Diffuse intrinsic pontine glioma in a 9 year old male patient. Sagittal post contrast T1-
weighted (left) and axial ADC (right) images show the tumour in the brain stem. The patient was treated 
with chemotherapy and radiotherapy and died 7 months after diagnosis, age 10. 
Diffuse intrinsic pontine glioma: Brain stem gliomas constitute between 10 and 20% of 
paediatric CNS tumours and most tumours arise in the pons but may extend into the 
medulla and midbrain. The vast majority of these tumours (75-85%) are diffuse 
intrinsic pontine gliomas (DIPG) and carry a very poor prognosis. DIPG tumours are a 
heterogeneous group of tumours, mostly grade 2-3 astrocytoma, which are generally 
not biopsied or resected due to their location. Diagnosis is normally carried out 
radiologically without histological analysis to determine the exact tumour type. DIPG 
tumours are treated with radiotherapy and chemotherapy, however, the survival 
outcome is dismal, with less than 10% of children surviving more than two years after 
diagnosis51. 
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3.3.4.4 Ependymoma 
 
Figure 3.12: Ependymoma in a 2 year old female patient. Post-contrast sagittal (left) and ADC (right) 
images show the tumour in the posterior fossa. Surgery and chemotherapy was given, with the tumour 
classified as a grade 2 tumour. The patient was alive at last follow-up, 7 years after diagnosis, age 9. 
Ependymomas are gliomas which arise from the ependymal cells lining the ventricular 
system. They constitute about 8% of all paediatric brain tumours and 25% of spinal 
cord tumours. In the brain, they occur mostly in the posterior fossa (infratentorial) and 
the most common sites are the fourth, third and lateral ventricles. Variants can be 
classified between grade 1 and 3. They are normally well delineated and may show 
areas of calcification, haemorrhage and cysts. Ependymomas are treated via surgery – 
aiming for gross total resection, with radiotherapy being a standard adjuvant therapy 
in older children and chemotherapy being used instead of radiotherapy in young 
children. Longer-term survival over 5 years is seen in over 50% of patients, and hence 
the effects of treatment need to be taken into consideration in order to reduce long-
term sequelae.  
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3.3.4.5 Choroid plexus tumours 
 
Figure 3.13: Choroid plexus papilloma (grade 1) in a one month old male patient. Post-contrast T1-
weighted (left) and ADC (right) images show a large mass in the ventricles, causing hydrocephalus. The 
patient was treated via surgery and was alive at last-follow-up, 7 years after diagnosis, age 7. 
Choroid plexus tumours account for between 1 and 5% of paediatric CNS tumours. The 
choroid plexus is responsible for producing CSF and hence these tumours tend to 
appear as a mass arising in the ventricles, secreting CSF and thus causing 
hydrocephalus. Choroid plexus tumours vary in grade between grade 1 and 3 and are 
removed via surgical resection, while also introducing a shunt in order to drain the 
ventricles and reduce the tension on the brain. Adjuvant radiotherapy and 
chemotherapy may also be provided depending on the age of the child and the extent 
of surgical resection. However, gross total resection and tumour grade are the most 
important prognostic factors. The long-term overall survival (>5years) is around 80% in 
children with choroid plexus papilloma (grade 1) and between 40 and 60% in children 
with choroid plexus carcinoma (grade 3). 
3.3.4.6 Embryonal tumours 
Embryonal tumours constitute a large proportion of paediatric brain tumours. 
Historically they have been grouped under the term primitive neuroectodermal 
tumours (PNET) and were characterised by a relatively homogeneous histological 
3. Cancer and Paediatric Brain Tumours 
81 
appearance which consisted of small round cells – undifferentiated neuroepithelial 
cells, exhibiting a high rate of mitosis. PNETs have been shown to be a heterogeneous 
group of tumours and embryonal tumours now include medulloblastoma, atypical 
teratoid/rhabdoid tumour (ATRT), supratentorial PNET (sPNET) and pineoblastoma. 
 
Figure 3.14: Medulloblastoma in a 7 year old female patient. Post-contrast T1-weighted (left) and ADC 
(right) images show a large mass in the cerebellum. The patient was treated with surgery, chemotherapy 
and radiotherapy and was doing well at last follow up, 6 years after diagnosis, age 13. 
Medulloblastoma: This tumour was originally referred to as an infratentorial PNET. 
However, advances have shown medulloblastoma to exhibit different biology and 
while histopathologically it is divided into four main WHO subgroups (classical 
medulloblastoma, anaplastic/large cell medulloblastoma, nodular desmoplastic 
medulloblastoma and medulloblastoma with extensive nodularity), it can also be 
subdivided into four main molecular subgroups (Wnt, Sonic Hedgehog or Shh, Group 3 
and Group 4)52. 
Overall, medulloblastoma is the most common malignant CNS tumour and constitutes 
around 20% of paediatric CNS tumours. It is thus the second most common paediatric 
brain tumour after JPA. All medulloblastoma types are classified as grade 4; however 
certain subgroups have a much better prognosis. Clinically, they present most often in 
the midline of the cerebellum close to the fourth ventricle and symptoms may include 
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behavioural changes and lower school performance, followed by headaches, vomiting 
and other neurologic signs such as ataxia. Tumours are removed via surgery in order to 
try and achieve gross total resection. Following resection, staging needs to be 
conducted in order to determine whether the tumour has disseminated. Prognosis is 
better in patients where there is no evidence of metastases, having had gross total 
resection, and who are over three years of age. Children less than three are unlikely to 
receive radiotherapy treatment and proceed with only adjuvant chemotherapy. When 
considering the molecular subgroups, those in the Wnt group have survival rates over 
90%52. Considering all subtypes, the overall 5 year survival stands at 60%. 
 
Figure 3.15: Atypical teratoid/rhabdoid tumour in a 2 year old male patient. Post-contrast T1 weighted 
(left) and ADC (right) images show a supratentorial tumour growing from the third ventricle. The ADC 
image also shows large areas of oedema surrounding the tumour. The patient was treated via surgery 
and chemotherapy and died 3 months after diagnosis, age 2. 
Atypical teratoid/rhabdoid tumour: ATRT is a rare tumour which constitutes between 1 
and 2% of paediatric CNS tumours and is more frequent in infants. It is a malignant 
grade 4 tumour and the majority occur in the posterior fossa. On MRI, ATRT has similar 
appearance to medulloblastoma and molecular diagnosis is required in order to 
determine whether a tumour is ATRT. Although these patients receive surgery and 
chemotherapy, prognosis is extremely poor, with the median survival being less than 
10 months and the majority of children dying within a year. Radiotherapy is only given 
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to children who are old enough to tolerate its effects, and hence older children have a 
better long-term survival. 
 
Figure 3.16: Supratentorial primitive neuroectodermal tumour in a 9 year old male patient. T2-FLAIR 
(left) and ADC (right) images show a supratentorial mass in the right temporal lobe. The patient was 
treated via surgery, chemotherapy and radiotherapy and died 1 year after diagnosis, age 10.  
Supratentorial primitive neuroectodermal tumour: sPNET tumours are located in the 
cerebrum and occur in around 2.5% of paediatric CNS tumours53. While sPNET tumours 
tend to share many similar features to medulloblastoma, they tend to have a much 
worse prognosis with a 3-year survival of 33%54. 
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Figure 3.17: Pineoblastoma in a 10 year old male patient. T2-FLAIR (left) and ADC (right) images show a 
mass in the pineal gland. The patient was treated with surgery, radiotherapy and chemotherapy and was 
doing well at last follow-up, 3.5years after diagnosis, age 14.  
Pineoblastoma: Tumours occurring around the pineal gland are rare and account for 
less than 3% of paediatric CNS tumours with pineoblastoma accounting for half of 
these tumours55. Pineoblastoma resembles medulloblastoma, is also classified as grade 
4 and can also metastasize. Children with pineoblastoma have a better survival than 
those with sPNET. 
3.3.5 A NOTE ABOUT OEDEMA AND NECROSIS 
Oedema is a common feature amongst many brain tumours. The term itself means 
swelling and this swelling may cause increased intracranial pressure. Oedema is 
currently classified into cytotoxic and vasogenic56. Cytotoxic oedema results as cells 
swell up and can occur in both grey and white matter. It therefore occurs on an 
intracellular level and leads to a slight decrease in extracellular fluid volume. Vasogenic 
oedema, on the other hand, results when the blood brain barrier becomes more 
permeable, allowing an extra net fluid flow into the extracellular space57. It therefore 
represents an increase in extracellular fluid volume, and can be found in areas of white 
matter. Brain tumour oedema is a result of more fluid moving into the brain than out 
of the brain and is likely to be vasogenic oedema56. 
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Necrosis is another common feature amongst brain tumours. It may occur as a result 
of hypoxia or ischaemia which comes about as the tumour outgrows its blood supply, 
resulting in a lack of oxygen and nutrients to cells. Apart from stress-induced necrosis, 
areas of necrosis may occur as a result of treatment, with chemotherapy targeting 
specific pathways inducing necrosis58. Of important note, radiotherapy may also 
induce necrosis and this radiation necrosis can sometimes act as a confound in imaging 
techniques as it may be difficult to differentiate between radiation necrosis, tumour 
recurrence and what is known as pseudoprogression – a possibly cytotoxic reaction to 
chemo or radiotherapy treatment which is associated with inflammation and 
oedema59. 
3.3.6 TREATMENT 
Treatment strategies generally involve a combination of radiotherapy, chemotherapy 
and surgery. Proton therapy is also considered in certain patients meeting the required 
criteria. As such treatment can be with curative intent or as a form of palliative care 
and the type of treatment given is thus dependent on the patient and disease stage. 
3.3.6.1 Radiotherapy 
Radiotherapy is used either as a curative method or as part of adjuvant treatment 
following surgery. An understanding of how radiotherapy works needs to start with an 
understanding of radiation biology. Radiation biology studies the effect of primarily 
ionising radiation on biological systems. Ionising radiation has enough energy such that 
when it interacts with an atom it forces the atom to become ionised by removing at 
least one electron.60 
Ionising radiation is reported in terms of the absorbed dose with the standard unit 
being the gray (Gy) and defined as       . It is able to produce damage to DNA and is 
most significant when damage causes breaks in both strands of the DNA and at 
multiple-points, making it difficult for the cell to repair. Ionising radiation forces cells 
to die through the loss of mitotic reproductive integrity or apoptotic pathways. The key 
features which affect a cell’s response to ionising radiation are radio-sensitivity, repair, 
redistribution, repopulation and reoxygenation. 
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Radio-sensitivity describes a tumour’s sensitivity to radiation therapy and thus 
determines the dose required to achieve control of the tumour. Different tumours will 
have a different radio-sensitivity, with tumours such as glioblastoma multiforme 
unlikely to be controlled with reasonable doses. Repair refers to the ability of the 
tissue to repair the damage incurred following the radiation dose given. Redistribution 
refers to the cells’ stage in the cell cycle at the time of radiation. As cells in the S-stage 
are most resistant to radiation and those in the   /M stage are the most sensitive, 
those in the latter stage are more likely to be killed. However the cells’ stages will 
redistribute in between radiation doses such that the radio-sensitivity of the cell 
population does not change with time. Repopulation refers to the tumour’s ability to 
proliferate and repopulate following radiotherapy. Finally, reoxygenation refers to the 
fact that the oxygenation status has a great effect on the radio-sensitivity of a tumour, 
with hypoxic regions being able to resist radiation damage much more effectively than 
oxygenated regions.  
The radiation dose given to a tumour is dependent on the location and the 
surrounding tissue’s radio-sensitivity. Different methods are employed in order to limit 
the damage done to healthy tissue while effectively treating the tumour. Fractionated 
radiotherapy involves spreading the dose given to a patient over a period of time in 
order to allow normal tissue to repair itself in between treatment fractions, and to 
allow for tumour cells which were hypoxic to reoxygenate, as well as for the cells to 
redistribute. Generally radiation is thus delivered once a day, five days a week for a 
number of weeks. Intensity modulated radiotherapy seeks to limit the dose to 
neighbouring healthy tissue. Limiting radiation damage to healthy tissue is important 
to reduce late effects associated with radiotherapy. In particular, younger children 
have a higher toxicity towards radiotherapy and it is not recommended in children 
under the age of three. 
3.3.6.2 Proton therapy 
Proton therapy is a form of radiotherapy which uses protons rather than photons. 
Protons have the advantage of being able to travel a finite distance and then deposit 
the majority of their energy at the end of the path. Therefore proton therapy is able to 
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direct most energy to the tumour while only delivering a moderate dose to the tissue 
in the path of the beam. Higher doses can thus be delivered to tumours in close 
proximity of radio-sensitive areas such as the brain stem. The main issue with proton 
therapy is the cost, which is much higher than for conventional radiotherapy, even 
more so due to the unavailability of facilities within the UK. 
3.3.6.3 Chemotherapy 
Chemotherapeutic agents work by targeting one of the hallmarks of cancer described 
in section 3.1.5. They can either interfere directly with the DNA replication and cell-
cycle, target specific intracellular biochemical pathways, or they can also work by 
targeting the requirements of a tumour such as anti-angiogenic agents which work by 
stopping the formation of new blood vessels.  
Drugs and their dose need to be chosen such that the anti-tumour effect is obtained 
with the minimum acceptable level of toxicity and is dependent on the tumour type. 
When administering chemotherapeutic drugs, the dose is measured taking into 
consideration the absorption, distribution, metabolism and elimination from the body 
of the specific drug. In principle, in order to be effective, chemotherapeutic agents for 
treating brain tumours need to be able to cross the blood-brain barrier. However, it 
can be observed that in some cases the blood brain barrier is disrupted around the 
tumour and thus the concentration of the drug may be seen to be higher in the tumour 
region than in the rest of the brain54.  
Chemotherapy in children has been shown to be successful when used in an adjuvant 
setting so as to control microscopic disease following surgery and/or radiotherapy. In 
these cases the aim is to reduce the risk of tumour recurrence. In other settings 
chemotherapy can be used as a neoadjuvant treatment, that is, it is administered prior 
to treatment via surgery. In this case the goal is to reduce the size of a tumour so as to 
make it operable or increase the likelihood of total resection. Chemotherapy can also 
be used in children under the age of three, and who do not tolerate radiotherapy 
treatment well in order to delay such treatment. 
3. Cancer and Paediatric Brain Tumours 
88 
As such, chemotherapy is part of the standard care paediatric brain tumour patients 
receive. However, it is not selective to cancer cells and thus carries a degree of toxicity 
and its effects, both short and long-term, need to be assessed. 
3.3.6.4 Surgery 
The extent of surgical resection is one of the most important predictors of survival in 
paediatric brain tumours.54 While this would call for an aggressive procedure, the 
extent of resection possible is dependent on the proximity of the tumour to important 
functional areas – such as areas of eloquent cortex that include motor and language 
pathways, the location of the tumour itself – particularly when the tumour involves the 
brain stem, and the presence of metastases at presentation. 
Improving surgery outcomes is possible by providing useful imaging methods. Neuro-
navigation can be provided by MRI which aids in planning the safest surgical route, 
avoiding important neural and vascular structures. Functional MRI (fMRI) and DTI can 
be used in order to build images of important areas and white matter pathways to be 
avoided so as to limit neurological deficits. Another imaging method which is 
employed in some centres is intra-operative MRI which allows for updated images 
throughout the surgical procedure and improves the extent of surgical resection. PET is 
another imaging method which can be used in operating brain tumours as a means of 
identifying eloquent cortex and in selecting areas to biopsy.  
3.3.6.5 Palliative care 
Depending on the stage of the tumour, treatment may either be with curative intent or 
terminal. In both cases palliative care can be provided. Palliative care involves dealing 
with the effects of the tumour, and therefore the symptoms, rather than treating the 
tumour itself. It may include the use of analgesics, chemotherapy and radiotherapy, 
and any specific symptoms should be taken care of as part of palliative care, whilst also 
offering psychological support. 
3.3.7 LATE EFFECTS 
The long-term morbidity in survivors of childhood cancer relates mostly to the 
treatment received, i.e. the effects of surgery, chemotherapy and radiotherapy, but 
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can also result due to the cancer itself. In childhood tumours, treatment aims to give 
the child a good quality of life rather than only long-term survival.61 The morbidity 
associated with late effects of treatment of brain tumours include effects on the 
endocrine system, neurological and cognitive effects, hearing and vision problems, and 
secondary tumours.62 
In particular, radiotherapy and chemotherapy can have severe effects on the 
endocrine system and can effect, amongst others, growth, puberty and fertility. 
Children who receive radiotherapy and chemotherapy are monitored by an 
endocrinologist and hormone replacements are administered to those children 
suffering from hormone deficiencies in order to mitigate these effects. 
Neurological and cognitive deficits are likely to occur in the treatment of brain tumours 
in children, but are specifically dependent on the location of the tumour and the 
aggressiveness by which they are treated. Nevertheless, the treatment of brain 
tumours in children is expected to impact on the cognitive and social abilities of the 
patient, and the psychological needs of these patients thus need to be addressed.  
Furthermore, tumours such as optic pathway gliomas will impact on vision and can 
result in blindness, while certain types of chemotherapy can result in hearing 
impairments, with 12% of CNS tumour survivors being reported to have suffered 
chronic hearing loss36. Finally, the formation of secondary brain tumours following 
previous successful treatment cannot be ruled out.  
In view of all the above late effects of treatment, patient follow-up needs to take place 
at a frequency which is patient and treatment dependent and in a setting which would 
ideally be multi-disciplinary in order to fit the needs of the patient.  
3.3.8 IMAGING 
Imaging is an important aspect of tumour diagnosis and management, and is generally 
carried out both before and after treatment. A number of imaging modalities exist 
with each having a specific purpose. Ultrasound can be useful for the diagnosis of 
abdominal and pelvic tumours, and plain x-rays can be useful for diagnosing bone 
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tumours36. However, when it comes to brain tumours, the major imaging modalities 
used are MRI, CT and PET.  
CT is utilised for assessing calcification in tumours and PET is effective in determining 
the metabolic activity of the tumour and can be helpful in distinguishing tumour from 
radiation necrosis. Both CT and PET however carry a safety risk in terms of radiation 
dose. MR is the most commonly used imaging modality to assess brain tumours and 
apart from standard   ,    and post-contrast imaging, a number of advanced MR 
techniques have been employed in assessing brain tumours. In particular MR 
spectroscopy, perfusion and diffusion have been found to be valuable. MR 
spectroscopy can be used as a non-invasive technique for determining metabolic 
information and can aid the radiologist in identifying tumour tissue, differentiating 
tumour type and to guide stereotaxic biopsies. MR perfusion is a modality used to 
image the perfusion dynamics by determining the cerebral blood volume, the cerebral 
blood flow and the mean transit time. It can be helpful in grading tumours and 
distinguishing radiation necrosis from tumour recurrence. MR diffusion has been 
shown to be useful in analysing tissue cellularity and visualising the involvement of 
white matter tracts for treatment planning. Diffusion imaging as a tool for the 
diagnosis and management of brain tumours is explored in the next chapter, with a 
particular focus on paediatric brain tumours. 
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Chapter 4 DIFFUSION IMAGING OF BRAIN TUMOURS 
The aim of this chapter is to bring together the imaging and cancer chapters and 
describe current research in diffusion imaging of brain tumours, with a particular 
emphasis on that which led to the research carried out as part of this thesis. The 
chapter starts by describing the need for reproducibility studies and covers some of 
the reproducibility work which has already been published. This is followed by a 
literature review of diffusion imaging as a diagnostic and prognostic tool, and as a tool 
for treatment response. As paediatric work is limited, studies carried out both in adults 
and children are explored, with a focus on childhood brain tumours where possible. 
4.1 Reproducibility Studies 
4.1.1 BACKGROUND 
Repeated measurements taken using a specific method should, ideally, yield identical 
results. However, variations exist which may be both equipment-dependent and 
operator-dependent. Reproducibility refers to the ability of a method to be repeated 
so as to give similar results, and measures the variability that exists between repeated 
measurements. It is an important feature of any imaging technique as it shows that the 
method can be employed so that the resultant images are directly comparable to each 
other. A reproducible imaging measure should thus be independent of scanner, centre 
and time-point. 
As mentioned, limited studies exist in childhood tumours and this may be a reflection 
of the difficulty of analysing tumours which are relatively rare and hence data is 
sparse. One way of reducing this limitation is to increase data available by combining 
data from multiple centres. Multi-centre studies are recognised to be essential not 
only in contributing to larger data sets but also in improving our understanding of how 
data can be used at different centres in order to aid clinicians with the diagnosis and 
management of brain tumours.  
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In order to be able to conduct any multi-centre imaging studies, we need to first 
ensure that data acquired at one centre is comparable to the data acquired at other 
centres. This can be done by carrying out multi-centre reproducibility studies. The 
importance of reproducibility studies can also be seen in terms of analysing data from 
different scanners, different centres, and multiple time points. Hence, in addition to 
multi-centre analyses, an analysis of reproducibility is important both in conducting 
single-centre longitudinal analyses and single-centre biomarker validation. 
4.1.2 PHANTOM STUDIES 
One way of analysing reproducibility of diffusion parameters is through the use of 
phantoms. Phantom studies benefit from the fact that the same phantom can be 
scanned on multiple scanners and patient motion is not an issue. However, these 
studies lack the realism of in-vivo clinical studies and a number of ways of overcoming 
specific limitations have been explored.  
 
Figure 4.1: Ice-water phantom. The ice-water phantom consists of five water tubes (W) and one sucrose 
tube (S). The T1 image (left) shows the six tubes surrounded by a mixture of ice and water. The ADC 
image (right) is able to show the contrast between the tubes filled with water and the one tube filled 
with sucrose. 
One of the limitations of scanning phantoms is that diffusion parameters are 
temperature dependent and while human temperature is relatively stable at 37oC, 
phantom temperature may easily differ. In order to overcome this, an ice-water 
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phantom was proposed, which ensures that the phantom is scanned at a fixed 
temperature of 0oC. The use of the ice water phantom has been shown by Chenevert 
et al63 and Malyarenko et al64. Both studies were performed by the same group, with 
the second paper being an update of the first. The second study was conducted on 
thirty five scanners, from three manufactures and including both 1.5 and 3T machines, 
across eighteen sites. A standard sequence was used, with scan parameters allowing a 
certain degree of variability, accounting for manufacturer requirements and 
limitations. The basis of the ice-water phantom, shown in Figure 4.1, is that water at a 
temperature of 0oC has a known ADC value. In order to ensure that the water being 
scanned is at this temperature, the phantom is filled with ice-water, which will force 
the water in the tubes present in the phantom to stay at a temperature of 0oC until the 
ice is dissolved. Using this phantom, the authors of the study found ADC values 
between sites to vary by less than 3% at the iso-centre. 
While the ice-water phantom has been shown to be useful in analysing ADC 
measurements, phantoms which are able to reproduce the white matter structures of 
the brain, and which would thus be ideal for analysing the reproducibility of FA, 
provide a bigger challenge. One study by Teipel et al65 assessed the reproducibility of 
FA in a phantom consisting of a ring of fibres with constant anisotropy. The phantom 
was imaged on sixteen scanners, with only half of these having good enough quality to 
be used. The mean CV was in this case found to be 6.9%. New phantoms are able to 
create FA variations in phantoms66 and their use could benefit the scientific 
community in measuring the reproducibility of FA parameters.  
Phantom studies provide information about the inherent reproducibility of in-vivo 
clinical measurements and these studies are important in order to test reproducibility 
factors related to the scanner itself and the environment it is in, in a more feasible 
way. However, in-vivo studies provide a more realistic view of the reproducibility of 
imaging parameters in the clinic. Various in-vivo studies have been conducted, both on 
single-scanners and multiple-scanners, as discussed in the next sections. 
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4.1.3 SINGLE-SCANNER STUDIES 
Single-scanner studies give an understanding of the reproducibility of diffusion 
parameters from the same scanner. Knowledge of the intra-scanner reproducibility is 
important in conducting analysis which test the said parameters as biomarkers on a 
number of patients, or when a longitudinal study is carried out – with patients being 
scanned on the same scanner at two different time-points.  
Very few reproducibility studies have been carried out in children. Bonekamp et al67 
analysed the ADC and FA in forty children aged 5.5 to 19.1 years on a single 1.5T 
scanner. In this case an identical protocol was used on all patients and a reproducibility 
analysis was carried out on ten of these with repeat scans taking place within 6 weeks 
from the initial scan. The reproducibility study compared ADC and FA values in six 
white matter fibre bundles. A coefficient of variation (CV) of between 0.8 and 3.4% 
was found for the ADC and between 2.6 and 5% for the FA. 
Another DTI study was carried out on twenty two healthy adult volunteers by Veenith 
et al68. Each volunteer was scanned twice on a single 3T scanner with a maximum of 6 
months between scans. Reproducibility was in this case analysed in twenty-three 
regions as defined by the Harvard Oxford subcortical atlas. In this case the mean ADC 
varied by 7.3% and the mean FA varied by 7.9%. 
Both studies refer to the reproducibility of ADC as part of a DTI sequence and this ADC 
could thus also be referred to as the MD. A large difference in reproducibility can be 
seen between the two studies and this is likely to be due to the method applied to 
determine the regions of interest used (ROIs). While in the first study the region of 
interest (ROI) was defined by an observer working on a colour-coded FA map with grey 
matter signal suppression, in the second study the ROIs were defined in standard MNI 
space and though these were checked by a clinical investigator, errors due to 
registration are more likely. In observing the reproducibility of a given parameter, the 
method employed needs to be thus carefully considered.  
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4.1.4 MULTI-CENTRE DWI STUDIES 
A few studies have been carried out on ADC parameters, as measured using a DWI 
protocol. One study by Sasaki et al69 reports the reproducibility of ADC in twelve 
healthy volunteers imaged at seven institutions, on eight 1.5T scanners and two 3T 
scanners, and from four manufacturers. Similar but not identical protocols were used 
across all scanners. ADC measurements were made in grey and white matter and the 
reproducibility assessed. Excluding one of the manufacturers, the data from which 
showed a large difference with the rest of the scanners, the variability between 
manufacturers was found to be 7% at 1.5T. The variability between scanners was 
reported to be 8%. The relatively low reproducibility found in this study may be due to 
the method used to identify grey and white matter. These were determined by one of 
the authors, drawing an ROI around the bilateral frontal white matter and the 
thalamus. This provides a limited number of voxels to analyse and results are thus 
more prone to partial volume effect errors. 
4.1.5 MULTI-CENTRE DTI STUDIES 
A number of studies have been carried out on the reproducibility of DTI 
parameters65,70–73. The image protocol parameters were matched as closely as possible 
in all but one study where the standard manufacturer protocol was used. In that study, 
by Magnotta et al72, five healthy controls were imaged on eight 3T scanners from two 
manufacturers. MD and FA were measured in six regions of the brain. The intra-subject 
CV was <1% and the variability between manufacturers was found to be between 1 
and 3%. While this study showed good reproducibility, other studies showed a lower 
FA reproducibility with a variability of 14% when using tract based spatial statistics65 
and variations of 10-15% in grey matter regions73. 
The method employed can thus be seen to have a considerable impact on the 
reproducibility of FA parameters. In particular, FA in grey matter is low and it is 
expected to have poorer reproducibility than that of FA in white matter. Similarly to 
reproducibility in single-centre studies, careful consideration for the method employed 
needs to be taken into account when assessing reproducibility values. 
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4.1.6 CURRENT NEEDS 
While various studies have analysed reproducibility of diffusion parameters, most 
studies tend to use a carefully selected diffusion protocol. Further work carried out in 
the context of this thesis, and explored in Chapter 5, asks the question of whether 
diffusion imaging parameters are reproducible across multiple centres using standard 
clinical protocols. 
4.2 Diffusion imaging as a diagnostic and prognostic tool 
4.2.1 BACKGROUND  
Diffusion imaging has been used both to aid in the diagnosis of brain tumours and as a 
prognostic tool. Such tools are beneficial in assessing the tumour’s aggressiveness, 
which can be in turn used in order to determine what treatment to apply. Firstly, the 
ADC has been shown to correlate with cell density. Secondly, diffusion imaging has 
been used in grading tumours and determining tumour types. Finally, diffusion 
biomarkers for determining the prognosis associated with a given tumour type has also 
been explored in the literature. This section gives an overview of research which has 
been carried out in these three areas. 
4.2.2 CELL DENSITY 
The idea that ADC can be correlated with cellularity was first studied in gliomas by 
Sugahara et al74. Since then many studies have looked at the correlation between ADC 
and cellularity in different tumour types75–77. The basic principle is that the ADC is 
affected by the diffusion path tortuosity as shown in Figure 4.2. The relationship 
between ADC and cellularity was studied in more detail in vitro78 and in the paediatric 
population79. It has been shown that the correlation is both related to the diffusion 
occurring in the extracellular space and also the diffusion taking place in the 
intracellular space78. Therefore it is not only cell count which affects the ADC, but also 
the nucleus-to-cytoplasm ratio79. 
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Figure 4.2: ADC and tumour cellularity. ADC is affected by the diffusion path tortuosity. In voxels with 
less cellular areas, the diffusion path is unrestricted and the ADC will be higher (left). Conversely, in 
voxels with highly cellular areas, the diffusion path is more tortuous and this restricted diffusion will 
result in a lower ADC. 
 
Figure 4.3: Comparison between ADC and histology. Tumours with lower cellularity appear brighter on 
ADC as can be seen in the low grade pilocytic astrocytoma (left). More cellular tumours appear darker 
on ADC as can be seen in ATRT (right). (Histology images obtained from 
80,81
). 
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The correlation between cellularity and ADC is an important concept in diffusion 
imaging of brain tumours and a comparison between histology and ADC is shown in 
Figure 4.3. This correlation has also been studied in paediatric cerebellar tumours, 
suggesting that while a negative correlation was found between cellularity and ADC, 
tumour cellularity is unlikely to be the only cause for the difference in ADC82. In fact, 
while low grade tumours can indeed be more cellular than healthy brain tissue, the 
ADC in Figure 4.3 can still be seen to be higher in the low grade tumour as compared to 
the surrounding normal appearing brain tissue. This could be explained by the 
presence of microcystic areas in low grade tumours, driving the ADC to be higher than 
the less cellular healthy tissue. 
While most studies have focused on ADC, the correlation between DTI measures and 
cell density has also been studied. As MD is very similar to ADC, a similar correlation is 
expected. However, while the ADC studies mentioned found a negative correlation, a 
positive but weak correlation has been found in one study83. In addition to this, the 
same study found a negative correlation between FA and cell density, while other 
studies found a positive correlation84,85. A link between FA and proliferation activity, as 
well as between FA and tumour infiltration has also been suggested in these same 
studies. 
In conclusion, the majority of studies agree on the existence of a negative correlation 
between ADC and tumour cellularity and this forms the basis of other studies carried 
out in diffusion imaging on brain tumours, relating to both tumour grading and 
treatment management. 
4.2.3 TUMOUR CLASSIFICATION AND GRADING 
A number of studies have used diffusion imaging for paediatric brain tumour 
classification and grading and a plot showing the mean ADC in children with different 
tumours is shown in Figure 4.4. The basis for such studies is that it would provide a 
non-invasive way of determining the tumour type and grade. 
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Figure 4.4: Mean ADC by tumour type in a paediatric cohort. The plot compares mean ADC in children 
with juvenile pilocytic astrocytoma (JPA), choroid plexus papilloma (CPP), dysembryoplastic 
neuroepithelial tumour (DNET), ependymoma, primitive neuroectodermal tumour including 
medulloblastoma (PNET), medulloblatstoma (PNET-MB) and atypical teratoid rhabdoid tumour (ATRT). 
Using mean ADC, patients with JPA appear to be easily distinguishable from patients with PNET and 
ATRT, but not from patients with CPP and DNET. (Adapted from Bull et al, 2012
86
) 
In one study by Bull et al86 histogram analysis was performed on fifty-four paediatric 
brain tumour patients with JPA, choroid plexus papilloma, dysembryoplastic 
neuroepithelial tumour, ependymoma, PNET (excluding ATRT), and ATRT. The authors 
conducted a histogram analysis of ADC measures in the tumour, including the peak 
height, the mean, mode and the 10th, 25th, 50th, 75th and 90th percentile points. The 
overall success rate for discriminating between tumour types stood at 74.1%. The 
authors were able to differentiate between ATRT and other PNET tumours in all cases 
when these were studied separately from the rest of the tumours.  
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Another study on forty children with posterior fossa tumours (medulloblastoma, JPA 
and ependymoma) also showed the ability to discriminate between tumours using ADC 
histogram features87. Moreover, this study showed the ability to discriminate classic 
medulloblastoma from the other types using ADC texture features in 89.4% of the 
cases. The differentiation of the same tumour types using ADC88 and using a 
combination of ADC and MR spectroscopy89 were also previously shown. That said, an 
overlap in ADC between the different tumour types does exist and one study showed 
two out of the ten medulloblastoma tumours analysed did not exhibit restricted 
diffusion90. 
Apart from differentiating between tumour types, other studies have also looked at 
whether ADC can be used to determine tumour grade. One study on twenty-four 
children with cerebellar tumours confirmed that ADC values were higher in low grade 
tumours (grades 1 and 2) than in high grade tumours (grades 3 and 4), and the study 
also suggests carefully excluding necrotic and oedematous areas before conducting the 
analysis91. In another study on supratentorial tumours in children less than one year 
old, the authors were able to differentiate between high and low grade tumours using 
the minimum ADC value in the tumour92. DTI measures have also been shown to 
differentiate between tumour grade in children with supratentorial tumours93. 
While diffusion imaging is unlikely to be an alternative to a histological analysis, it may 
prove to be useful in the clinical diagnosis by giving an indication of the tumour type 
and aiding the surgeons to determine the best area to biopsy, particularly in 
heterogeneous tumours. Diffusion imaging for classification of tumour types and 
grading may also be a valuable tool in diagnosing tumours which cannot be biopsied 
due to the tumour’s location. Most studies carried out in paediatric brain tumours 
indicate diffusion imaging to be a good biomarker to help determine the tumour type. 
The use of diffusion imaging significantly improves diagnosis of paediatric cerebellar 
tumours94, with the accuracy of such diagnosis being increased when used in 
conjunction with other imaging techniques and modalities. 
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4.2.4 PROGNOSTIC BIOMARKERS 
Very few pre-treatment diffusion imaging biomarkers have been studied, with the 
majority of studies being conducted in adults. In one study a correlation was found 
between DTI metrics and progression free survival in patients with glioblastoma 
multiforme95. Another study showed a link between low ADC values and survival in 
malignant astrocytoma96. In other work, tumour border measures were studied as 
biomarkers of survival. 
 
Figure 4.5: Tumour border biomarkers. The tumour border biomarker, as studied by Aghi et al, looked 
at the change in T2 values at the tumour border (left). Jenkinson et al applied this to ADC images. In 
both cases the biomarker consists of the gradient slope measured from four voxels, starting just outside 
the tumour border and entering towards the tumour core. (Adapted from Aghi et al, 2005
97
 and 
Jenkinson et al, 2007
76
.) 
Tumour border measures were studied as shown in Figure 4.5. Aghi et al97 proposed a 
tumour border biomarker based on the T2 border sharpness coefficient but their work 
did not include diffusion imaging. A later study by Jenkinson et al76 studied the tumour 
border measure in ADC images and termed it the apparent transient coefficient (ATC). 
In this study, oligodendroglial tumour genotypes were identified using variations in 
ADC and ATC. A third study analysed the ATC over the oedema and tumour boundaries 
in patients with glioblastoma multiforme and found a correlation between the tumour 
border measure and survival but not the oedema border measure98. 
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While various work has been carried out on tumour cellularity, classification and 
grading in paediatric tumours, little has been done in terms of prognostic biomarkers. 
Work carried out as part of this thesis has explored one such prognostic biomarker in 
children with embryonal brain tumours99 and is presented in Chapter 6. 
4.3 Diffusion imaging in treatment management 
4.3.1 BACKGROUND  
Imaging biomarkers which can be used in treatment management may have a 
significant impact on the outcome. First, imaging is required for treatment planning, 
particularly in surgical resection and identifying areas to biopsy, as well as in 
identifying the gross tumour volume to be targeted using radiotherapy. Second, 
advanced imaging techniques may provide to be useful in differentiating between 
confounds such as tumour recurrence and radiation necrosis, and in identifying cases 
of pseudoprogression. Finally, early identification of successful or unsuccessful 
treatment response could have a considerable impact on the management of brain 
tumour patients.  
4.3.2 TREATMENT PLANNING 
The main role of diffusion imaging in treatment planning lies in planning the resection 
itself. When considering surgery, the goal is to achieve a complete tumour resection, 
with the minimal neurologic deficit possible. This implies that for treatment planning, 
delineation of the tumour margins as well as locating the important structures and 
white matter pathways is of high importance. Using tractography, DTI is able to 
construct white matter pathways which can be visualised by the surgeon prior to 
surgery, and DTI findings can suggest how white matter is involved with the tumour. 
Studies have been carried out evaluating the use of DTI in pre-operative surgical 
planning both in adults100 and in children101. The use of intra-operative DTI has also 
been explored in treating brain tumours, and a greater surgical precision with less 
associated morbidity has been observed in those cases102,103.  
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4.3.3 DIFFERENTIATING IMAGING CONFOUNDS 
Another important use for an imaging tool would be the ability to differentiate 
between confounds seen in standard imaging techniques post therapy; more 
specifically, the ability to differentiate between tumour recurrence and radiation 
necrosis, as well as the ability to differentiate between tumour progression and 
pseudoprogression. 
Radiation necrosis may appear the same as tumour recurrence, both radiologically and 
clinically. It is a reaction to radiotherapy, occurring anytime from a few months to 
many years after treatment, and which results in the disruption of the blood brain 
barrier, oedema and mass effect59. Differentiation between tumour recurrence and 
radiation induced injury using diffusion imaging has been widely explored in the 
literature. ADC has been shown to contribute to making the right diagnosis, with lower 
ADC values seen in the recurrent tumour group104,105. Other case reports have looked 
at a few cases using FA and determined that FA may also be useful in differentiating 
between the two groups106. Furthermore, other imaging modalities such as PET, or 
combining advanced MRI techniques such as perfusion and diffusion imaging could aid 
in making a reliable diagnosis between radiation necrosis and tumour107. 
Another confound which may exist is that of pseudoprogression. It is a reaction to 
chemotherapy and radiotherapy, normally occurring two to three months after 
treatment, and which results in inflammation, oedema and increased vessel 
permeability59. Similarly to the differentiation between radiation induced necrosis and 
tumour recurrence, many studies have been carried out on the use of diffusion 
imaging for differentiation of pseudoprogression from true progression. These studies 
have determined the ADC to be a valuable biomarker in distinguishing between the 
two108–110. 
While numerous studies have been done on both confounders in adults, very limited 
work has been carried out in paediatric brain tumours. In one case report of 
pseudoprogression in a 6 year old patient, diffusion imaging provided to be useful in 
carrying out the correct diagnosis111. 
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4.3.4 TREATMENT RESPONSE  
One of the major uses of diffusion imaging in the management of brain tumour 
treatment has been in the area of treatment response. Currently change in tumour 
size, generally a few weeks after treatment, is the main method used clinically to 
determine treatment response. Post-treatment imaging is compared to the pre-
treatment image in order to determine whether the tumour decreased in size and thus 
responded to treatment. This method of assessing treatment response implies that 
follow-up imaging is carried out too late for clinicians to be able to alter the treatment 
given in cases with unresponsive tumours. Identifying good biomarkers of early 
treatment response is important in order to allow for a change in the tumour 
treatment protocol when necessary and possible, and also in order to validate new 
therapeutic drugs being studied. A large number of studies have been carried out on 
changes in diffusion imaging measures after treatment. 
One of the areas where the effects of treatment response on diffusion imaging have 
been explored is that of assessing response to steroidal treatment. Steroids are 
commonly used to treat symptoms of brain tumours and although their mechanism of 
action is not well understood, it is hypothesized that they act so as to reduce the 
volume of water inside oedematous regions112. It is thus expected that the diffusion 
coefficient is lower post-steroid treatment. Studies have in fact reported a decrease in 
the diffusion coefficient both within the tumour112,113 and peri-tumoural oedema113,114. 
While another study did not find a significant change in the diffusion coefficient when 
low-dose steroids were used115.  
Diffusion imaging has also been explored as a tool for identifying response to 
radiotherapy and chemotherapy. As such the two main uses of diffusion imaging in 
identifying tumour response to treatment are the use of ADC histograms116,117 and the 
functional diffusion map (fDM)118–121. In histogram analysis, ADC values are seen to 
shift upwards at treatment response, such that the mean of the histogram post-
treatment is higher than that pre-treatment, and the post-treatment histogram would 
have a lower kurtosis and thus a wider spread. The analysis however is carried out over 
the whole tumour area, and thus lacks spatial information in heterogeneous tumours. 
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The fDM attempts to capture the spatial information by analysing treatment response 
in individual voxels. 
The fDM, also known as the parametric response map, was first described by Moffat et 
al118 and is shown in Figure 4.6 and Figure 4.7. The technique involves a voxel-by-voxel 
comparison of pre-treatment and, either mid- or post-treatment data, for patients 
with tumours using ADC images. It works on the basic principle that ADC will increase 
with effective treatment – which would imply a decrease in tumour cellularity, and 
decrease with unsuccessful treatment – which would imply an increase in tumour 
cellularity. The fDM was proposed as a biomarker of early treatment response with 
studies showing good prediction of survival as early as 3 weeks after start of 
treatment122. A histological and receiver operating characteristic analysis has been 
carried out in order to validate the fDM and determine what thresholds are best to use 
in building the fDM121. 
 
Figure 4.6: The functional diffusion map. The fDM was proposed as a biomarker of early treatment 
response. The difference between pre- and mid-treatment images is computed and an increase in ADC is 
labelled in red, a decrease in ADC in blue and no change in ADC in green. A scatter plot of overall 
changes can then be drawn (left pane). The scatter plots B, D and F correspond to the tumours in A, C 
and E: patient A showed progressive disease, patient C stable disease and patient E treatment response 
(right pane). In the study no change in ADC was said to imply that the tumour did not respond to 
therapy and thus represented progressive disease. (Adapted from Moffat et al, 2005.
118
) 
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Figure 4.7: Biology of the fDM. The biological processes affecting the fDM where first described as 
shown in the left pane. Cells which respond to treatment can undergo a transient cell swelling, implying 
a decrease in ADC, before becoming necrotic and increasing in ADC; cells may also die through cell 
shrinkage and apoptosis (A). Necrotic areas may also reorganise such that cells move into the area and 
in this case a decrease in ADC is observed (B). Cells which did not respond to therapy were said to 
remain unchanged in ADC. However, other studies, as shown on the right, described the biology of the 
fDM to be related to a change in cellularity, postulating that an increase in ADC is related to a decrease 
in cellularity and a decrease in ADC is related to an increase in cellularity. (Adapted from Moffat et al, 
2005
118
 (left) and Ellingson et al, 2010
121
 (right)) 
Work on the functional diffusion map has mostly concentrated on adult brain tumours. 
One study has however analysed the fDM in high grade paediatric brain tumours and 
found a good correlation between the changes in ADC and response to treatment123. A 
study on the challenges posed to the functional diffusion map in a range of paediatric 
brain tumours was carried out as part of this thesis124 and is presented in Chapter 7. 
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Chapter 5 REPRODUCIBILITY OF DIFFUSION IMAGING 
PARAMETERS 
This chapter presents research carried out on the reproducibility of diffusion imaging 
parameters. The content of this chapter has been adapted from a paper prepared to 
be submitted for publication, the abstract of which has been accepted for a conference 
presentation125.  
5.1 Background  
Diffusion imaging is widely used both in research and in the clinic. In areas where 
clinical data is sparse, such as paediatric oncology or other rare diseases, it may be 
necessary to include data from multiple centres in order to conduct a sufficiently 
powered analysis. While the availability of multi-centre data may be beneficial in terms 
of increasing the amount of data available for a given study, it introduces the question 
of whether such data, obtained using standard clinical sequences and on different 
scanners with different field strengths, is comparable. This question may also arise in 
carrying out longitudinal studies, where the same patient may be scanned on the same 
or a different scanner to that used in the previous imaging session. The aim was thus 
to validate clinical diffusion imaging measurements across multiple centres and on 
different scanners. 
The basis of this study was to determine the reproducibility of diffusion measures, 
commonly used in multisite clinical research studies, on both a phantom and a group 
of volunteers, each being scanned at multiple sites and on different scanners. In this 
study, diffusion weighted imaging (DWI)7 and diffusion tensor imaging (DTI)11 
parameters were analysed. More specifically the reproducibility of the mono-
exponential fit to DWI – the apparent diffusion coefficient (ADC); the bi-exponential fit 
to DWI as applied through intra-voxel incoherent motion (IVIM)9; and the mean 
diffusivity (MD) and fractional anisotropy (FA) obtained from DTI datasets were 
investigated. 
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While previous studies have been carried out examining the reproducibility of these 
parameters at a single centre26,68 and at multiple centres69,72,73, most studies aimed to 
match the imaging sequence used across all scanners. Only one of these studies was 
carried out on a mixture of 1.5T and 3T scanners and this study analysed the 
reproducibility of ADC only69. The aim of this study was to quantify the reproducibility 
of DWI and DTI parameters acquired with sequences in routine clinical use locally (and 
therefore not specifically optimised or matched for multi-site comparison). This was 
conducted on scanners from two manufacturers and two field strengths in order to 
assess the reproducibility of the quantified diffusion parameters. 
5.2 Materials and Methods 
5.2.1 VOLUNTEERS  
Nine healthy volunteers (7 male, 2 female; aged 25 to 34 years at first scan; mean 29 
years) were enrolled in this multi-centre study. Ethical approval was given by the 
research ethics committee and informed consent was obtained at all centres. All data 
was anonymised in accordance with the Data Protection Act, UK.  
5.2.2 SCANNERS 
Eight scanners (three Siemens Avanto 1.5T, one Siemens Symphony 1.5T and four 
Philips Achieva 3T) across five centres were used in this study. Between four and eight 
volunteers were scanned on each scanner, with repeat scans performed on a different 
date to the first scan on one or two volunteers on each scanner. All scans were 
performed over a period of 18 months and in total 65 imaging sessions took place 
across the five centres. 
5.2.3 PHANTOM 
An ice water phantom64 was scanned on all scanners. Different fluids will have a 
varying ADC value which also varies according to temperature, with ADC in water 
measured between 1.756 x 10-3mm2s-1 at 15oC and 2.616 x 10-3mm2s-1 at 30oC126. The 
advantage of using ice-water is that the temperature is fixed, and is not affected by the 
temperature inside the scanner room. Ice-water is expected to have an ADC of 1.099 x 
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10-3mm2s-1.127 The ice-water phantom used consisted of five tubes filled with distilled 
water and one tube filled with sucrose. The phantom was filled with ice and water in 
order to bring the temperature of the fluid-filled tubes down to 0oC. Measurements 
were taken in the water-filled tubes. 
5.2.4 IMAGING PROTOCOL 
Tables 5.1 and 5.2 show the clinical protocols used at the different centres and 
scanners for DWI and DTI. These protocols were applied in the study, with the addition 
that in all centres b-values of 0, 50, 100, 300, 500, 600 and 1000 were acquired for the 
DWI protocol. DWI data was acquired on all eight scanners, while DTI data was 
acquired on seven scanners. In addition, a high resolution T1 weighted image was 
acquired at each centre. 
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Table 5.1: DWI protocol. 
Centre 
Great Ormond Street 
Hospital for Children 
NHS Trust 
St 
George's 
Hospital 
The Royal Marsden NHS 
Foundation Trust 
Nottingham 
University 
Hospital NHS 
Trust 
Birmingham 
Children's Hospital 
Scanner A B C D E F G H 
Manufacturer Siemens Siemens Philips Siemens Philips Philips Siemens Philips 
Model Avanto Symphony Achieva Avanto Achieva Achieva Avanto Achieva 
field strength 
(T) 1.5 1.5 3 1.5 3 3 1.5 3 
head coil 
channels 12 8 32 12 8 8  2 32 
TR (ms) 2700 3500 3800 3800 3800 3280 4400 3800 
TE (ms) 96 109 74 73 73 73 89 74 
b values 
0, 500, 
1000 
0, 500,1000 0, 1000 
0, 50, 
100, 300, 
600, 
1000 
0, 50, 100, 
300, 600, 
1000 
0, 1000 0, 1000 0, 1000 
FOV (mm) 
230 x 
230 230 x 230 230 x 230 230 x 230 230 x 230 224 x 224 
230 x 
230 
230 x 
230 
no. of slices 19 19 22 22 22 32 28 22 
slice thickness 
(mm) 5 5 5 5 5 4 5 5 
acquired 
matrix 
128 x 
128 128 x 128 128 x 128 128 x 128 128 x 128 112 x 112 
192 x 
192 
128 x 
128 
interpolated 
matrix 
128 x 
128 256 x 256 256 x 256 256 x 256 256 x 256 224 x 224 
192 x 
192 
256 x 
256 
orientation axial axial axial axial axial axial axial axial 
Bandwidth 
(Hz/px) 1502 1500 2308 1860 1860 2441 1240 2307 
Parallel 
imaging 2 none 2 2 2 2 2  2 
NSA 3 2 3 3 3 2 1 3 
voxel size 
(mm) 
1.8 x 1.8 
x 5 0.9 x 0.9 x 5 
0.9 x 0.9 x 
5 
0.9 x 0.9 
x 5 
0.9 x 0.9 x 
5 1 x 1 x 4 
1.2 x 1.2 
x 5 
0.9 x 0.9 
x 5 
SNR* 15 6.6 - 12.9 - - 4.4 - 
 
*SNR measured as per equation (5.1). SNR was not measured in Philips scanners as SENSE parallel imaging 
suppresses background noise and does not give a signal outside of the head. 
 
5. Reproducibility of Diffusion Imaging Parameters 
111 
Table 5.2: DTI protocol. 
Centre 
Great 
Ormond 
Street 
Hospital for 
Children 
NHS Trust 
St George's 
Hospital 
The Royal Marsden NHS 
Foundation Trust 
Nottingham 
University 
Hospital 
NHS Trust 
Birmingham Children's 
Hospital 
Scanner A C D E F G H 
Manufacturer Siemens Philips Siemens Philips Philips Siemens Philips 
Model Avanto Achieva Avanto Achieva Achieva Avanto Achieva 
field strength(T) 1.5 3 1.5 3 3 1.5 3 
head coil 
channels 12 32 12 8 8 2 32 
TR (ms) 7300 6000 7300 7767 6268 6510 6000 
TE (ms) 81 70 81 70 53 86 70 
b values 0, 1000 0, 1000 0, 1000 0, 1000 0, 1000 0, 1000 0, 1000 
FOV (mm) 240 x 240 240 x 240 240 x 240 240 x 240 240 x 240 240 x 231 240 x 240 
no. of slices 60 48 60 70 56 51 48 
slice thickness 
(mm) 2.5 2.5 2.5 2 2.5 2.5 2.5 
matrix 96 x 96 96 x 96 96 x 96 128 x 128 96 x 96 108 x 104 96x96 
Bandwidth 
(Hz/px) 1447 3324.3 1447 1783 3321 1493 3324 
parallel imaging 2 2 2 2 2 2 2 
NSA 1 1 1 2 1 2 1 
gradient 
directions 60 32 30 32 15 20 32 
b-zeros 3 1 5 1 1 1 1 
voxel size (mm) 
2.5 x 2.5 x 
2.5 
2.5 x 2.5 x 
2.5 
2.5 x 2.5 x 
2.5 
1.875 x 1.875 
x 2 
2.5 x 2.5 x 
2.5 
2.2 x 2.2 x 
2.5 
2.5 x 2.5 
x 2.5 
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5.2.5 DATA ANALYSIS 
5.2.5.1 Signal-to-noise Ratio 
The signal-to-noise ratio (SNR) was measured according to equation (5.1), suggested in 
128 and also used previously in measuring SNR in diffusion imaging129. The reported 
SNR was calculated on the unweighted (b0) DWI image, as the average SNR measured 
in two volunteers who were scanned across all scanners. 
 
    
       
         
        
(5.1) 
where     is the signal-to-noise ratio,        is the average signal in a region of 
interest of the image – chosen to include whole brain grey and white matter volumes, 
          is the standard deviation in a region of interest of the image consisting of 
noise – chosen to include the first ten rows of the image across all slices, and 0.6551 is 
a correction factor included to adjust for the Rician distribution of noise in a magnitude 
image, which is equivalent to a Rayleigh distribution for image regions with no 
signal130,131. 
5.2.5.2 Segmentation 
In volunteers, DWI and DTI parameters were measured in grey and white matter. For 
DWI parameters, the masks for grey and white matter were created by segmenting the 
b0 image using SPM
23 and a probability threshold of 0.95. For the DTI parameters, the 
masks were created by segmenting the S0 image – the estimated b0 image output by 
FSL27.  
DWI and DTI parameters were also measured in eight brain regions which could be 
particularly affected by neurological diseases and conditions seen in the clinic, with a 
particular emphasis on regions affected by paediatric brain tumours. The regions 
studied included the cerebellar white matter, cerebellar grey matter, brain stem, 
cerebral white matter, basal ganglia, thalamus, choroid plexus, and optic chiasm 
(shown in Figure 5.1). The masks for these areas were created by segmenting high-
resolution T1-weighted images using FreeSurfer28,132–134. High-resolution T1-weighted 
images were not available for all volunteers on scanner D and one volunteer on 
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scanner G and hence these were excluded from the analysis. Furthermore, the 
segmentation failed on one volunteer on scanner H. Thus the analysis was conducted 
on 56 imaging sessions for DWI and on 47 imaging sessions for DTI. The mean value for 
the DWI parameters in these regions were calculated by registering the b0 image to the 
high-resolution T1-weighted image, then subsequently applying the same 
transformation to ADC, D and f. Similarly, the mean value for the DTI parameters in 
these regions were calculated by registering the S0 image to the high-resolution T1-
weighted image and subsequently applying the same transformation to MD and FA. In 
order to avoid partial volumes, an image erosion process of one voxel was used on the 
masks output by FreeSurfer prior to applying these to the registered DWI and DTI 
parameters. All registration was performed using an affine 12-parameter model with 
tri-linear interpolation in FLIRT, the linear image registration tool provided by FSL135. 
 
Figure 5.1: Segmentation of T1-weighted images. Using FreeSurfer. T1-weighted images were 
segmented in order to create masks defining: cerebellar cortex (1), cerebellar white matter (2), brain 
stem (3), cerebral white matter (4), basal ganglia (including the caudate nucleus, the putamen and the 
globus pallidus) (5), thalamus (6) and choroid plexus (7). A mask for the optic chiasm (not shown) was 
also defined using FreeSurfer. 
5.2.5.3 Apparent diffusion coefficient 
The ADC was calculated through custom written MATLAB scripts using equation (5.2) 
to calculate the linear fit to the clinical b-values shown in Table 5.1.  
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        (
  
  
)  ⁄  (5.2) 
where    is the signal at the specific  -value, and    is the signal at   . 
In the phantom the ADC was calculated in the ice-water tubes by manually drawing a 
region of interest (ROI) over the tubes, avoiding boundary regions in order to include 
only areas of water, and calculating the mean ADC over the area. In volunteers, the 
segmented images were used as masks to calculate the mean ADC in grey matter, 
white matter, and in the eight regions mentioned.  
5.2.5.4 Intra-voxel incoherent motion 
DWI data were processed using the IVIM model9, which assumes that two diffusing 
species give rise to the observed signal during in vivo DWI. These are the incoherent 
flow of blood-water in the randomly orientated micro-vascular network (referred to as 
fast, micro-circulation driven pseudo-diffusion), and the molecular, thermally driven 
diffusion of water molecules in the extra-vascular space. Using this model, the 
observed signal intensity (S) at a given level of diffusion weighting (b) is given by 
equation (5.3). 
     
  
                   
   
(5.3) 
where    is signal intensity without diffusion-weighting,  is the diffusion coefficient of 
water molecules in the tissue,    is the fast pseudo-diffusion coefficient, and   is the 
fraction of the total DWI signal which arises from the latter compartment.  
The fitted parameters (f, D, and D*) were obtained in a stepwise-sequential manner, 
due to limitations in the precision of fitting equation (5.3) directly to DWI data136. 
Firstly, linear regression of ln(S/S0) vs b was used to obtain D, using only data acquired 
with b≥300 s/mm2, at which the fast diffusing component (D*) is negligible due to the 
dephasing caused by the diffusion gradients. Raw data from all b-values were then 
used to fit f and D* (with D fixed), using an iterative Nelder-Mead nonlinear least 
squares algorithm. The mean values of D and f for both phantom and volunteers were 
derived through the same masks used for measuring the mean ADC. 
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5.2.5.5 Diffusion tensor imaging 
 
Figure 5.2: Measuring FA in white matter areas. The segmented white matter mask (yellow) is shown 
overlaid on a high-resolution T1 weighted image registered to standard MNI space. The ICBM-DTI-81 
atlas (coloured areas) was used in order to measure the FA in areas defined as white matter according 
to the segmented mask in specific tracts: genu of the corpus callosum (1), body of the corpus callosum 
(2), splenium of the corpus callosum (3), superior longitudinal fasciculus (4), cerebral peduncle (5), 
sagittal stratum (6), cingulum (7), uncinate fasciculus (8). 
Mean diffusivity (MD) and fractional anisotropy (FA) were calculated through dtoa 
software20 which uses FSL27 to compute the DTI parameters following eddy current 
correction. In the phantom the MD and FA in the ice-water tubes were calculated by 
manually drawing an ROI over the tubes, excluding boundary areas, and calculating the 
mean MD and FA in these areas. In the volunteers, similarly to ADC, segmented images 
were used to calculate the mean MD and FA in grey matter, white matter, and in the 
eight brain regions described. In addition, for the FA analysis, the ICBM-DTI-81 atlas137 
available in FSL was used to measure the mean FA in specific white matter ROIs shown 
in Figure 5.2. This was done by first registering the S0 image to standard MNI space, 
then performing the same registration to the derived FA map, and then segmenting 
the S0 image to obtain a mask for the white matter. The mean FA in the ROIs was 
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determined by overlaying the white matter mask and the atlas to the registered FA 
map, shown in Figure 5.2. 
5.2.6 STATISTICAL ANALYSIS 
Statistical analysis on the phantom data consisted of measuring the coefficient of 
variation (CV), as defined by equation (5.4), using the group mean and standard 
deviation of each measured mean ADC value in ice-water, across all scanners. 
      ⁄       (5.4) 
where   is the standard deviation and   is the mean 
Statistical analysis for the volunteer data was conducted using R software29 and the 
lme4 package therein138. In order to calculate the reproducibility of the above 
mentioned parameters, a mixed effect model was used. The volunteer was considered 
as a random effect with the scanner considered as a fixed effect. The mixed effect 
model gives a mean and standard deviation for the fixed effects, together with the 
standard deviation expected for the random effect and an error-term which is 
considered to be the variation that can be expected in addition to both random and 
fixed effects. The CV was then calculated from the mean and standard deviation in 
order to measure the reproducibility of the given measures across different scanners 
(the inter-scanner CV), across different volunteers (inter-volunteer) and irrespective of 
volunteer or scanner (the intra-scanner CV). The model was also constructed 
separately for 1.5T and 3T scanners in order to study whether there is any major 
difference in reproducibility between the two field strengths.  
5.3 Results 
5.3.1 PHANTOM 
Results for the ice-water phantom are shown in Table 5.3, together with comparison 
images shown in Figure 5.3. Values for ADC, D and MD were comparable and very 
similar. The team imaging with scanner F confirmed that when the phantom was 
scanned, it was not given enough time to reach thermal equilibrium at 0oC and 
consequently produced higher values than in the other scanners. Hence, calculations 
5. Reproducibility of Diffusion Imaging Parameters 
117 
were also done excluding this scanner, which improved the CV for ADC, D and MD to 
0.7, 1.4 and 0.9% respectively. FA and f had a low reproducibility in the phantom. It 
was noted that f, at a value of 0.0591, was much higher for scanner G, compared to all 
other scanners. Excluding scanner G and scanner F, the mean estimated value of f in 
the phantom was 0.0120, with a standard deviation of 0.0033 and a CV of 27.3%. 
Table 5.3: Reproducibility of the ice-water phantom. The table shows the mean ADC, D, f, MD and 
FA for the ice-water phantom together with the associated standard deviation. The CV was computed 
and shown for each of these parameters. 
ice-
water 
phantom 
DWI IVIM DTI 
ADC mean ± std D mean ± std f mean ± std MD mean ± std FA mean ± std 
x10
-3
mm
2
s
-1
  x10
-3
mm
2
s
-1
    x10
-3
mm
2
s
-1
    
Sc
an
n
er
 
A 1.1103 0.0214 1.1041 0.0275 0.0114 0.0097 1.1030 0.0177 0.0226 0.0177 
B 1.1116 0.0218 1.1148 0.0258 0.0115 0.0102 - - - - 
C 1.1064 0.1070 1.1010 0.0274 0.0181 0.0137 1.0966 0.0271 0.0392 0.0149 
D 1.0971 0.0173 1.1060 0.0211 0.0081 0.0087 1.0921 0.0176 0.0240 0.0177 
E 1.1106 0.0191 1.1218 0.0169 0.0120 0.0141 1.1191 0.0315 0.0473 0.0234 
F 1.1525 0.0991 1.2059 0.0930 0.0229 0.0189 1.1884 0.0344 0.0488 0.0247 
G 1.1092 0.0914 1.1428 0.1147 0.0591 0.0451 1.0989 0.0240 0.0370 0.0145 
H 1.1223 0.0325 1.1346 0.0316 0.0110 0.0096 1.1116 0.0206 0.0405 0.0180 
overall 1.1150 0.0167 1.1289 0.0345 0.0193 0.0168 1.1157 0.0334 0.0371 0.0103 
CV 1.5% 3.1% 87.1% 3.0% 27.8% 
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Figure 5.3: Comparison of the ice-water phantom ADC images across scanners. Images of the phantom 
from each of the scanners using the same contrast range are shown. The tube filled with sucrose 
appears darker while the five tubes filled with distilled water are evenly spaced away from each other 
and can be seen to be surrounded by iced-water. The protocol for scanning the phantom was not 
adhered to for scanner F, with the image showing that iced-water was not surrounding all of the tubes 
at acquisition. 
5.3.2 VOLUNTEERS 
Box plots showing the range of values observed in all volunteers across all scanners are 
shown for grey matter in Figure 5.4 and for white matter in Figure 5.5. Results for 
reproducibility of ADC, D, f, MD and FA in grey matter, white matter and the eight 
brain regions for volunteer scans are shown in Tables 5.4 to 5.8 respectively. The 
tables show the mean, standard deviation and CV results from the mixed-effect model 
describing the variation expected if the same volunteer is scanned on a different 
scanner (inter-scanner reproducibility), if a different volunteer is scanned on the same 
scanner (inter-volunteer), and if the same volunteer is scanned on the same scanner 
(intra-scanner reproducibility).  
5. Reproducibility of Diffusion Imaging Parameters 
119 
Considering overall grey matter and white matter, ADC, D, MD and FA showed an 
intra-scanner and inter-scanner CV ranging between 1% (ADC in white matter) and 
7.4% (FA in grey matter), with a mean CV of 2.6%. The reproducibility of f was lower 
than for the other parameters with an average intra-scanner CV of 8.4% and inter-
scanner CV of 24.8%. Similarly to the results in the phantom, it was noted that the 
value of f in scanner G was much higher than in the other scanners, as also seen in the 
boxplots in Figure 5.4 and Figure 5.5; excluding this scanner reduced the inter-scanner 
reproducibility to 6.9%. 
The mean ADC, D and MD were 0.84, 0.75 and 0.85 x10-3mm2s-1 in grey matter and 0.7, 
0.65 and 0.7 x10-3mm2s-1 in white matter, respectively. The mean value of f was 0.1 in 
grey matter and 0.08 in white matter. Excluding scanner G, the mean value of f was 
0.093 in grey matter and 0.072 in white matter. The mean FA was 0.17 in grey matter 
and 0.42 in white matter.  
The reproducibility of ADC, D, MD and FA was lower in the specific brain regions 
analysed as compared to overall grey and white matter, and the highest CV was found 
in the choroid plexus and the optic chiasm. The reproducibility of FA in specific white 
matter areas is shown in Table 5.9. The mean intra- and inter-scanner CV was 4.2% and 
4.4% respectively, with a mean FA ranging from 0.43 to 0.65 depending on the areas 
analysed. 
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Figure 5.4: Box plots for DWI and DTI parameters across all scanners in grey matter (GM). ADC, D and 
MD are shown with the same range on the y-axis for direct comparison. A-H represent each scanner 
involved in the study, and the red data points represent individual subjects. ADC and MD had very 
similar values, while D had comparable but lower values. The boxplots confirm the higher values of f in 
scanner G. 
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Figure 5.5: Box plots for DWI and DTI parameters across all scanners in white matter (WM). ADC, D 
and MD are shown with the same range on the y-axis for direct comparison. A-H represent each scanner 
involved in the study, and the red data points represent individual subjects. ADC and MD had very 
similar values, while D had comparable but lower values. The boxplots confirm the higher values of f in 
scanner G. 
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Table 5.4: Reproducibility in volunteers for ADC. The table shows the mean and standard deviation 
values for the measured ADC together with the associated CV in grey matter (GM) and white matter 
(WM) in all scans, and in eight separate regions in fifty-six of the scans. The first column gives the 
mean – across all scanners and volunteers as measured by the model. The second column shows the 
inter-scanner reproducibility – the variation expected if the same volunteer is scanned on a different 
scanner. The third column shows the inter-volunteer reproducibility – the variation expected if a 
different volunteer is scanned on the same scanner. The fourth column shows the intra-scanner 
reproducibility – the variation expected if the same volunteer is scanned on the same scanner. Values 
which are not estimated (NE) imply that the level of variation was not sufficiently large to warrant 
inclusion of the random effect in the analysis, as explained in the software manual in 
139
. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner) 
Intra-scanner 
(intra-volunteer) 
D
W
I 
- 
A
D
C
 
O
ve
ra
ll 
GM 
x10
-3
mm
2
s
-1
  0.8327  ± 0.0203  ± 0.0246  ± 0.0242 
CV   2.4% 3.0% 2.9% 
WM 
x10
-3
mm
2
s
-1
  0.7010  ± 0.0210  ± 0.0156  ± 0.0072 
CV   3.0% 2.2% 1.0% 
C
er
eb
el
lu
m
 
Cortex 
(GM) 
x10
-3
mm
2
s
-1
  0.8322  ± 0.0914  ± 0.0207  ± 0.0290 
CV   11.0% 2.5% 3.5% 
WM 
x10
-3
mm
2
s
-1
  0.7244  ± 0.099  ± 0.0137  ± 0.0429 
CV   13.7% 1.9% 5.9% 
B
ra
in
 S
te
m
 
All 
x10
-3
mm
2
s
-1
  0.8710  ± 0.1240 NE  ± 0.0679 
CV   14.2% NE 7.8% 
C
er
eb
ru
m
 
WM 
x10
-3
mm
2
s
-1
  0.7346  ± 0.0590  ± 0.0113  ± 0.0190 
CV   8.0% 1.5% 2.6% 
Basal 
Ganglia 
x10
-3
mm
2
s
-1
  0.7574  ± 0.0590  ± 0.0162  ± 0.0293 
CV   10.6% 2.1% 3.9% 
Thalamus 
x10
-3
mm
2
s
-1
  0.7894  ± 0.0809  ± 0.0200  ± 0.0236 
CV   10.2% 2.5% 3.0% 
Choroid 
Plexus 
x10
-3
mm
2
s
-1
  1.9049  ± 0.5502  ± 0.0920  ± 0.2103 
CV   28.9% 4.8% 11.0% 
Optic 
Chiasm 
x10
-3
mm
2
s
-1
  1.4399  ± 0.3212  ± 0.1618  ± 0.3930 
CV   22.3% 11.2% 27.3% 
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Table 5.5: Reproducibility in volunteers for D. The table shows the mean and standard deviation values 
for the measured D together with the associated CV in grey matter (GM) and white matter (WM) in all 
scans, and in eight separate regions in fifty-six of the scans. All terminology is the same as for Table 5.4. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner)  
Intra-scanner 
(intra-volunteer) 
D
W
I 
- 
IV
IM
 -
 D
 
O
ve
ra
ll 
GM 
x10
-3
mm
2
s
-1
  0.7495  ± 0.0207  ± 0.0186  ± 0.0159 
CV   2.8% 2.5% 2.1% 
WM 
x10
-3
mm
2
s
-1
  0.6506  ± 0.0249  ± 0.0115  ± 0.0108 
CV   3.8% 1.8% 1.7% 
C
er
eb
el
lu
m
 
Cortex 
(GM) 
x10
-3
mm
2
s
-1
  0.7283  ± 0.0577  ± 0.0139  ± 0.0272 
CV   7.9% 1.9% 3.7% 
WM 
x10
-3
mm
2
s
-1
  0.6491  ± 0.0501  ± 0.0083  ± 0.0381 
CV   7.7% 1.3% 5.9% 
B
ra
in
 S
te
m
 
All 
x10
-3
mm
2
s
-1
  0.6819  ± 0.0665 NE  ± 0.0505 
CV   9.8% NE 7.4% 
C
er
eb
ru
m
 
WM 
x10
-3
mm
2
s
-1
  0.7035  ± 0.0294  ± 0.0098  ± 0.0157 
CV   4.2% 1.4% 2.2% 
Basal 
Ganglia 
x10
-3
mm
2
s
-1
  0.7184  ± 0.0308  ± 0.0145  ± 0.0209 
CV   4.3% 2.0% 2.9% 
Thalamus 
x10
-3
mm
2
s
-1
  0.7367  ± 0.0040  ± 0.0178  ± 0.0213 
CV   5.4% 2.4% 2.9% 
Choroid 
Plexus 
x10
-3
mm
2
s
-1
  1.8489  ± 0.2281  ± 0.1443  ± 0.2077 
CV   12.3% 7.8% 11.2% 
Optic 
Chiasm 
x10
-3
mm
2
s
-1
  0.9730  ± 0.0755  ± 0.0962  ± 0.2815 
CV   7.8% 9.9% 28.9% 
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Table 5.6: Reproducibility in volunteers for f. The table shows the mean and standard deviation values 
for the measured f together with the associated CV in grey matter (GM) and white matter (WM) in all 
scans, and in eight separate regions in fifty-six of the scans. All terminology is the same as for Table 5.4. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner) 
Intra-scanner 
(intra-volunteer) 
D
W
I 
- 
IV
IM
 -
 f
 
O
ve
ra
ll 
GM 
x10
-3
mm
2
s
-1
  0.1005  ± 0.0204  ± 0.0026  ± 0.0111 
CV   20.3% 2.6% 11.1% 
WM 
x10
-3
mm
2
s
-1
  0.0799  ± 0.0234  ± 0.0020  ± 0.0047 
CV   29.2% 2.6% 5.8% 
C
er
eb
el
lu
m
 
Cortex 
(GM) 
x10
-3
mm
2
s
-1
  0.1441  ± 0.0244  ± 0.0080  ± 0.0121 
CV   16.9% 5.6% 8.4% 
WM 
x10
-3
mm
2
s
-1
  0.0966  ± 0.0136  ± 0.0046  ± 0.0112 
CV   14.1% 4.8% 11.6% 
B
ra
in
 S
te
m
 
All 
x10
-3
mm
2
s
-1
  0.1771  ± 0.0249  ± 0.0159  ± 0.0218 
CV   14.1% 9.0% 12.3% 
C
er
eb
ru
m
 
WM 
x10
-3
mm
2
s
-1
  0.0832  ± 0.0175  ± 0.0035  ± 0.0060 
CV   21.1% 4.2% 7.2% 
Basal 
Ganglia 
x10
-3
mm
2
s
-1
  0.0765  ± 0.0197  ± 0.0056  ± 0.0094 
CV   25.7% 7.3% 12.3% 
Thalamus 
x10
-3
mm
2
s
-1
  0.1079  ± 0.0316  ± 0.0041  ± 0.0115 
CV   29.3% 3.8% 10.7% 
Choroid 
Plexus 
x10
-3
mm
2
s
-1
  0.2949  ± 0.0349  ± 0.0370  ± 0.0546 
CV   11.8% 12.6% 18.5% 
Optic 
Chiasm 
x10
-3
mm
2
s
-1
  0.4163  ± 0.1124  ± 0.0660  ± 0.1316 
CV   27.0% 15.8% 31.6% 
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Table 5.7: Reproducibility in volunteers for MD. The table shows the mean and standard deviation 
values for the measured MD together with the associated CV in grey matter (GM) and white matter 
(WM) in all scans, and in eight separate regions in forty-seven of the scans. All terminology is the same 
as for Table 5.4. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner)  
Intra-scanner 
(intra-volunteer) 
D
TI
 -
 M
D
 
O
ve
ra
ll 
GM 
x10
-3
mm
2
s
-1
  0.8490  ± 0.0212  ± 0.0080  ± 0.0202 
CV   2.5% 0.9% 2.4% 
WM 
x10
-3
mm
2
s
-1
  0.6971  ± 0.0111  ± 0.0180  ± 0.0094 
CV   1.6% 2.6% 1.3% 
C
er
eb
el
lu
m
 
Cortex 
(GM) 
x10
-3
mm
2
s
-1
  0.8506  ± 0.0824  ± 0.0212  ± 0.0446 
CV   9.7% 2.5% 5.2% 
WM 
x10
-3
mm
2
s
-1
  0.7209  ± 0.0523  ± 0.0100  ± 0.0393 
CV   7.3% 1.4% 5.5% 
B
ra
in
 S
te
m
 
All 
x10
-3
mm
2
s
-1
  0.9316  ± 0.0773  ± 0.0293  ± 0.0791 
CV   8.3% 3.1% 8.5% 
C
er
eb
ru
m
 
WM 
x10
-3
mm
2
s
-1
  0.7851  ± 0.0328  ± 0.0142  ± 0.0236 
CV   4.2% 1.8% 3.0% 
Basal 
Ganglia 
x10
-3
mm
2
s
-1
  0.8012  ± 0.0199  ± 0.0150  ± 0.0292 
CV   2.5% 1.9% 3.6% 
Thalamus 
x10
-3
mm
2
s
-1
  0.8846  ± 0.0618  ± 0.0394  ± 0.0871 
CV   7.0% 4.5% 9.9% 
Choroid 
Plexus 
x10
-3
mm
2
s
-1
  2.2421  ± 0.3140  ± 0.1241  ± 0.2634 
CV   14.0% 5.5% 11.7% 
Optic 
Chiasm 
x10
-3
mm
2
s
-1
  1.5959  ± 0.2154  ± 0.2592  ± 0.3011 
CV   13.5% 16.2% 18.9% 
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Table 5.8: Reproducibility in volunteers for FA. The table shows the mean and standard deviation 
values for the measured FA together with the associated CV in grey matter (GM) and white matter 
(WM) in all scans, and in eight separate regions in forty-seven of the scans. All terminology is the same 
as for Table 5.4. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner)  
Intra-scanner 
(intra-volunteer) 
D
TI
 -
 F
A
 
O
ve
ra
ll 
GM 
x10
-3
mm
2
s
-1
  0.1726  ± 0.0047  ± 0.0097  ± 0.0128 
CV   2.7% 5.6% 7.4% 
WM 
x10
-3
mm
2
s
-1
  0.4187  ± .0083  ± 0.0157  ±0.0088 
CV   2.0% 3.8% 2.1% 
C
er
eb
el
lu
m
 
Cortex 
(GM) 
x10
-3
mm
2
s
-1
  0.1991  ± 0.0142  ± 0.0077  ± 0.0201 
CV   7.1% 3.9% 10.1% 
WM 
x10
-3
mm
2
s
-1
  0.3872  ± 0.0253  ± 0.0204  ± 0.0269 
CV   6.5% 5.3% 6.9% 
B
ra
in
 S
te
m
 
All 
x10
-3
mm
2
s
-1
  0.4139  ± 0.0224  ± 0.0157  ± 0.0243 
CV   5.4% 3.8% 5.9% 
C
er
eb
ru
m
 
WM 
x10
-3
mm
2
s
-1
  0.3275  ± 0.0529  ± 0.0102  ± 0.0254 
CV   16.1% 3.1% 7.8% 
Basal 
Ganglia 
x10
-3
mm
2
s
-1
  0.2351  ± 0.0373  ± 0.0159  ± 0.0247 
CV   15.8% 6.8% 10.5% 
Thalamus 
x10
-3
mm
2
s
-1
  0.2879  ± 0.0090  ± 0.0151  ± 0.0220 
CV   3.1% 5.2% 7.6% 
Choroid 
Plexus 
x10
-3
mm
2
s
-1
  0.1592  ± 0.0321 NE  ± 0.042 
CV   20.1% NE 26.4% 
Optic 
Chiasm 
x10
-3
mm
2
s
-1
  0.1781  ± 0.0377 NE  ± 0.0857 
CV   21.2% NE 48.1% 
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Table 5.9: Reproducibility of FA. The table shows the mean and standard deviation for FA as measured 
in each of the specified white matter areas. All terminology is the same as for Table 5.4. 
Volunteers Mean 
Inter-scanner 
(intra-volunteer) 
Inter-volunteer 
(intra-scanner) 
Intra-scanner 
(intra-volunteer) 
D
TI
 -
 F
A
 
Genu of corpus 
callosum 
  0.6257  ± 0.0195  ± 0.0226  ± 0.0154 
CV   3.1% 3.6% 2.5% 
Body of corpus 
callosum 
  0.5838  ± 0.0199  ± 0.0260  ± 0.0143 
CV   3.4% 4.4% 2.5% 
Splenium of corpus 
callosum 
  0.6523  ± 0.0168  ± 0.0493  ± 0.0165 
CV   2.6% 7.6% 2.5% 
Cerebral peduncle - 
right 
  0.5966  ± 0.0314  ± 0.0493  ± 0.0235 
CV   5.3% 8.3% 3.9% 
Cerebral peduncle - 
left 
  0.6059  ± 0.0378  ± 0.0407  ± 0.0255 
CV   6.2% 6.7% 4.2% 
Sagittal stratum - 
right 
  0.5091  ± 0.0241  ± 0.0359  ± 0.0168 
CV   4.7% 7.0% 3.3% 
Sagittal stratum - left 
  0.4975  ± 0.0158  ± 0.0379  ± 0.0150 
CV   3.2% 7.6% 3.0% 
Cingulum 
(hippocampus) - 
right 
  0.4289  ± 0.0266  ± 0.0292  ± 0.0397 
CV   6.2% 6.8% 9.2% 
Cingulum 
(hippocampus) - left 
  0.4514  ± 0.0200  ± 0.0439  ± 0.0399 
CV   4.4% 9.7% 8.8% 
Superior longitudinal 
fasciculus - right 
  0.4462  ± 0.0224  ± 0.0319  ± 0.0132 
CV   5.0% 7.1% 3.0% 
Superior longitudinal 
fasciculus - left 
  0.4400  ± 0.0185  ± 0.0158  ± 0.0136 
CV   4.2% 3.6% 3.1% 
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5.3.3 FIELD STRENGTH COMPARISON 
When fitting the mixed-effect model to the 1.5T and 3T scanners separately, no 
consistent pattern for differences between the two field strengths was observed. 
Results for the CV from the two scanner field strengths are shown separately and 
combined in Table 5.10.  
Table 5.10: Comparison of CV in 1.5, 3T and all scanners. The table shows the inter-scanner and the 
intra- scanner CV when 1.5 and 3T scanners are analysed separately for GM and WM regions, 
together with the reported CV when combining all scanners together. A larger difference in inter-
scanner CV can be seen for f when combining data from all scanners together. No large differences in 
CV can be seen otherwise. 
      Inter-scanner Intra-scanner 
Field Strength 1.5T 3T All 1.5 3 All 
ADC GM 
C
V
 (
%
) 
1.5 1.4 2.4 2.6 3.5 2.9 
  WM 1.5 1.6 3.0 1.3 0.7 1.0 
D GM 3.9 0.8 2.8 1.4 2.5 2.1 
  WM 1.3 0.5 3.8 0.8 1.0 1.7 
f GM 5.5 5.6 20.3 7.5 13.9 11.1 
  WM 4.1 8.0 29.2 2.3 5.4 5.8 
MD GM 1.9 3.0 2.5 1.9 2.5 2.4 
  WM 1.2 0.5 1.6 0.9 1.4 1.3 
FA GM 2.9 2.5 2.7 7.2 1.6 7.4 
  WM 0.9 2.6 2.0 1.6 2.0 2.1 
 
5.4 Discussion 
Multi-centre studies are becoming increasingly important with the discovery of new 
genetic biomarkers that characterise more specific and rare disease types. In such 
cases, patients with specific rare diseases can be grouped and studied together across 
centres, leading to larger sample sizes and more powerful data analyses. Furthermore, 
meaningful use of imaging biomarkers for treatment stratification and prognostication 
is dependent on robust interpretation of data from multiple centres. In order to 
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compare diffusion imaging across centres the reproducibility of both DWI and DTI 
parameters were studied. 
5.4.1 PHANTOM 
The diffusion coefficient of water, at 0oC, in the ice-phantom is expected to be 
1.099x10-3mm2s-1.127 In the phantom there was no perfusion and hence the perfusion 
fraction, f, is expected to be close to zero, and the result of noise or model fitting 
errors. The IVIM model is also therefore expected to have a slow diffusion coefficient, 
D, similar to the ADC. MD is expected to have a value comparable to the ADC (ADC was 
measured using DWI as an average of three directions; MD was measured from the 
diffusion tensor with data acquired over 15 to 60 directions). FA is expected to be close 
to zero due to free diffusion in the water-filled tubes and therefore its calculated value 
is dominated by the effects of noise and a high CV is consequently expected.  
In the phantom, ADC, D and MD gave very similar results close to the expected value of 
1.099 x10-3mm2s-1 in all scanners except for scanner F, where the ice-phantom was not 
given sufficient time to reach thermal equilibrium. Excluding the result from this 
scanner gave a very good reproducibility, with a CV of <1.5% for the three parameters. 
The low reproducibility of FA was expected. Magnitude images have a rectified noise 
floor140, which leads to non-zero calculation of FA even in an isotropic medium, and 
hence is system dependent. Similarly, the low reproducibility of f was expected as it is 
a representation of both noise and over-fitting a bi-exponential to data which is in fact 
mono-exponential. The mean value of f was 0.02 and that of FA was 0.04. While the 
use of an anisotropic phantom would have been more relevant for an assessment of 
anisotropy, such a phantom was not available for this study. However, progress has 
been made in developing anisotropic phantoms such as that described in 66 which 
could be used in future multi-centre analyses of FA. 
5.4.2 VOLUNTEERS 
5.4.2.1 ADC, D and MD 
In volunteers, ADC and MD are again expected to yield similar results, with D having a 
similar but lower value due to the IVIM calculation incorporating a perfusion 
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component. Furthermore, the diffusion coefficient of grey matter is expected to be 
higher than that of white matter141. Results confirmed this with ADC and MD giving 
similar results for a value of 0.84 x10-3mm2s-1 and 0.85 x10-3mm2s-1 in grey matter 
respectively, and 0.70 x10-3mm2s-1 for white matter in both cases. D showed lower 
mean values of 0.75 x10-3mm2s-1 and 0.65 x10-3mm2s-1 in grey and white matter 
respectively. ADC, D and MD all had a good reproducibility in both white matter and 
grey matter with a mean CV of 2.3%.  
5.4.2.2 The perfusion fraction, f 
In the case of f, it is expected that the grey matter signal will have a higher volume 
fraction related to perfusion than white matter due to an increased vascular density. 
Results showed the mean values to be 0.10 and 0.08 in grey and white matter 
respectively, which are concordant with values found in previous literature where f in 
grey and white matter were found to be 0.11 and 0.076 respectively142. However, due 
to factors such as partial volume fractions and differences in relaxation times between 
grey matter, white matter and blood26,143, these values are not a direct measure of 
cerebral blood volume fractions (approximately 5.2% and 2.7% in grey and white 
matter respectively144). The significantly higher value of f in both grey and white 
matter compared to the ice-water phantom demonstrates that perfusion effects have 
a significant effect on the bi-exponential component in raw DWI data acquired in vivo. 
While the reproducibility of f was found to be low overall, excluding scanner G 
improved the reproducibility to a CV of 5.3% in grey matter and 8.5% in white matter. 
Scanner G had consistently higher f for both the phantom and volunteers. It is likely 
that the higher estimation of f in scanner G could be driven by the higher acquisition 
resolution in this scanner, as compared to the other scanners, implying a lower signal 
to noise ratio and, as shown in previous work, an increase in f.142 In measuring SNR, 
scanner G, with a resolution of 192 x 192, was in fact found to have the lowest SNR at 
4.4 as compared to the SNR of 15 and 12.9 in the other two Siemens Avanto scanners, 
both with a resolution of 128 x 128. It is thus recommended that the acquisition 
resolution and SNR are checked before comparing the f value for different scans. 
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5.4.2.3 Fractional anisotropy, FA 
FA is highest in white matter, where the presence of structured fibres contributes to 
the anisotropy of the diffusion of water molecules. Measured FA was higher in white 
matter, as expected, with a mean value of 0.42 as compared to that found in grey 
matter of 0.17. This further supports the use of an FA threshold of 0.2 when using 
tractography, which aims at following pathways within white matter145. FA had a good 
reproducibility, with a CV of 2% when measured over all the white matter regions and 
a lower mean CV of 4.3% for specific white matter tracts.  
5.4.2.4 Overall reproducibility 
Overall, the inter-scanner reproducibility of ADC, D, MD and FA in grey and white 
matter was less than 4% in all scanners. As expected, in most cases the intra-scanner 
reproducibility was better than the inter-scanner reproducibility. Furthermore, 
analysing the two scanner field strengths separately yielded similar results between 
1.5T and 3T scanners, with the overall inter-scanner CV being comparable for all 
parameters except for f. This implies that the error associated with using data from the 
different scanners analysed, both 1.5T and 3T, would have a similar impact as using 
data from the same scanner, and hence supports the use of ADC, D, MD and FA data 
from across the different scanners. 
Similar results to ours were observed in 68 where the intra-scanner CV for MD and FA 
was reported to be less than 6%; in 72 where the inter-scanner CV was reported to be 
less than 3.2% in both MD and FA; and in 73 where the intra-scanner CV was reported 
to be less than 3% and the inter-scanner CV to be less than 4.1% for FA. The inter-
scanner reproducibility of ADC in 69 was calculated from the minimum and maximum 
mean differences and ADC was shown to vary between 3.8 to 8.8% across both grey 
and white matter. That study showed a poorer reproducibility than the one calculated 
in this study, and could be attributed to the method used – where in 69 grey matter 
was considered by drawing an ROI around the thalamus, and white matter was 
considered by drawing an ROI around the bilateral frontal white matter. When 
analysing the thalamus separately, this study showed an inter-scanner CV of 10.2%, a 
result more comparable to that found in 69. 
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5.4.2.5 Analysing specific brain regions 
When measuring the reproducibility of diffusion imaging parameters in specific brain 
regions, the reproducibility was lower than in overall grey and white matter areas. This 
may be due to the lower number of voxels being analysed and errors associated with 
the introduction of a registration step. The CV was particularly low in the choroid 
plexus and the optic chiasm, which may be a reflection of the small areas being 
studied; these areas are also surrounded by CSF, making them particularly susceptible 
to partial volume effect. They were included as they are known sites for paediatric 
brain tumours, although tumours are much larger than the structures from which they 
arise and may well provide more reproducible data. Partial volume is highlighted by 
the high value of f in these regions, as a mixed population of diffusing species increases 
the biexponential behaviour of the DWI signal. Excluding these regions, the maximum 
inter-scanner CV was 14.2%, 9.8%, 9.7% and 16.1% for ADC, D, MD and FA with a mean 
CV of 11.3%, 6.5%, 6.5% and 9% respectively for each of the said parameters. In 
addition, the lower reproducibility of FA when studied in specific regions of the brain 
may be due to the inherent errors which exist in using a standard brain mask and 
registration. Nonetheless, the CV in each of the areas studied was less than 10% with a 
mean CV of 4.3% for both intra- and inter-scanner differences. The lower 
reproducibility when analysing specific regions highlights the care which needs to be 
taken when involving more image processing steps such as registration, and when 
segmenting smaller regions. 
5.4.3 ADVANTAGES 
While the current study showed comparable reproducibility to previous studies, it has 
used standard clinical sequences that had not previously been specifically matched for 
multi-centre studies. This allows the inclusion of previously acquired historical data, 
i.e. retrospective multi-centre studies. It also does not require any centre to alter their 
sequence parameters, which would result in specialised protocols that are different to 
those in routine clinical use in that centre. This is a desirable factor allowing potentially 
more centres to contribute data for multi-centre analyses. Furthermore, the study 
encompassed a range of scanners; four 1.5T and four 3T scanners. The CV can thus be 
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used as a way of determining the minimum diffusion parameter changes required in 
order to be able to correlate changes in imaging with other clinically relevant 
measures, such as treatment response or prognosis of specific tumour subtypes. While 
a change in such neurological conditions as stroke and tumours may be large enough 
to be analysed using different clinical sequences, other neurological disorders may 
show more subtle variations that may require more stringent conditions in terms of 
scanner and acquisition protocol variability. Thus the importance of having matching 
imaging parameters is also pathology dependent.  
5.4.4 STUDY LIMITATIONS 
The main limitation in this reproducibility study lies in the method for segmenting 
white matter, grey matter, and each of the different regions, which may be prone to 
partial volume effects, and in registration errors. In order to try and limit this as much 
as possible only those voxels with a probability higher than 0.95 were accepted for use 
as grey and white matter and segmented areas were eroded by one voxel. Also of 
note, previous studies have shown the maximum b-value to have an impact on the 
measured ADC146, however all sequences employed in this study had b-values between 
0 and 1000 and hence the impact of using a different upper range of b-values was not 
studied here. Finally, due to practical and ethical considerations the current 
reproducibility study was carried out in healthy volunteers; a study in patients would 
ideally be conducted in order to measure the effect of the specific pathology on the 
imaging reproducibility. 
5.4.5 CONCLUSION 
Diffusion MRI measures, in particular ADC, D, MD and FA have good reproducibility 
across both 1.5T and 3T scanners. Quantitative research studies can benefit from 
incorporating multi-centre data using standard clinical sequences and protocols 
without any significant loss of reproducibility compared to that which would be 
achieved from a single scanner at a single site. 
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Chapter 6 DIFFUSION IMAGING AS A PROGNOSTIC 
BIOMARKER 
Having studied the reproducibility of diffusion imaging parameters, we can proceed to 
use data from across different scanners. This chapter presents research work carried 
out as part of this thesis on diffusion imaging as a prognostic biomarker, and uses 
clinical data taken from two scanners. It is an expanded and adapted version of a 
paper published during the course of the research and is thus a more detailed version 
of the paper “Survival analysis for apparent diffusion coefficient measures in children 
with embryonal brain tumours” published in the journal “Neuro-Oncology” in 201299.  
6.1 Background 
As mentioned in Chapter 3, embryonal brain tumours constitute a large and important 
subgroup of paediatric central nervous system (CNS) tumours. They are a group of 
malignant tumours characterised by small round cells and high cellularity and are 
classified into three main groups: medulloblastoma, supratentorial primitive 
neuroectodermal tumours (sPNET) (also known as CNS-PNET), and atypical 
teratoid/rhabdoid tumours (ATRT).147–150 Given their common cellular features, they 
share similar characteristics when analysed using diffusion-weighted imaging (DWI), a 
sub-modality of magnetic resonance imaging (MRI). 
DWI, and more specifically, the apparent diffusion coefficient (ADC), is increasingly 
used in the diagnosis and treatment of various tumour types, as discussed in Chapter 
4. ADC, a measure of the diffusion of water, has been found to be a good biomarker 
for inferring tumour cellularity.74,75,121,151 Regions of increased cellularity provide 
barriers for diffusion, restricting water motion and thereby exhibiting a lower ADC. The 
ADC is also affected by intracellular space: a high nucleus to cytoplasm ratio limits the 
diffusion of water intracellularly and is therefore thought to contribute to a reduction 
in ADC.78,152 In areas where diffusion is not restricted, such as in cerebrospinal fluid 
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(CSF), brain oedema and necrotic regions of the tumour, the ADC will have a higher 
value.  
Non-invasive imaging biomarkers that aid in cancer treatment planning are of 
significant importance. Cancer imaging biomarkers based on DWI have been previously 
discussed from a clinical, neuroradiological and oncological perspective in order to 
review the current pathophysiological understanding of DWI.25 Furthermore, MRI 
biomarkers examining the gradient change over the tumour borders have also been 
studied.76,97,98 One such biomarker is the apparent transient coefficient (ATC) which 
measures the gradient change in ADC at tumour borders.76,98 Previous work examined 
the ATC from white matter into surrounding peri-tumoural oedema (ATCO), and from 
the peri-tumoural oedema into the tumour core (ATCT) and compared these to 
survival in adults with glioblastoma multiforme.98 A correlation was found between 
ATCT and survival in that patient group. 
The purpose of this research was to identify and analyse potential biomarkers that 
would predict survival outcome in children with embryonal brain tumours and aid in 
treatment planning and decision making. The work is based on the hypothesis that 
ATCT correlates with survival outcome in this important and highly malignant group of 
paediatric brain tumours. The tumours appear very dark on ADC images due to water 
restriction by both intra- and extracellular components.78,152 The study hypothesizes 
that a higher tumour cell density could be related to a lower survival and a range of 
ADC measures were examined for correlation with survival: minimum ADC, mean ADC, 
ATCT and ATCO. A lower survival rate is thus expected in patients with a lower 
minimum and mean ADC and a more negative value of ATCT.  As ATCO is hypothesized 
to be related to the presence of tumour cells in the surrounding oedema, it is expected 
that a lower value of ATCO would imply more tumour cells are present in the oedema 
and thus a lower survival.  
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6.2 Method 
6.2.1 PATIENTS 
61 patients with histologically proven embryonal brain tumours and who had DWI as 
part of their clinical imaging between 2004 and 2011 were enrolled in a retrospective 
study to correlate ADC measures with survival. Three children with pineoblastomas 
(PNET of the pineal gland) were excluded from the study as the lack of surrounding 
brain parenchyma and oedema precluded measurement of ATCT. Thus a total of 58 
patients (31 male, 27 female, aged 3 weeks to 14.6 years, mean 5.7 years) were 
analysed: 44 with infratentorial and 14 with supratentorial tumours; 40 were 
medulloblastoma, 9 were ATRT (5 supratentorial and 4 infratentorial) and 9 were 
sPNET tumours. Ethical approval was given by the local research ethics committee. 
Informed consent was not required as the data was obtained for clinical purposes. All 
data was anonymised in accordance with the data protection act. 
Forty patients > 3 years old underwent surgery (31 had gross total surgical resection 
and 9 had partial surgical resection) and this was followed by radiotherapy and 
chemotherapy in 39 children. Of the remaining 18 patients < 3 years at diagnosis, 14 
underwent surgery (6 had gross total surgical resection and 8 had partial surgical 
resection) followed by both radiotherapy and chemotherapy in 5 children and 
chemotherapy alone in 9 children. Palliative care was given to 1 patient > 3 years and 4 
patients < 3 years. 
6.2.2 IMAGING 
Imaging data from 43 of the 58 patients was acquired on a 1.5T Siemens Magnetom 
Symphony MRI scanner, with a maximum magnetic field gradient strength of 30mTm-1. 
The data from the remaining 15 patients was acquired on a 1.5T Siemens Avanto 
scanner, with a maximum magnetic field gradient strength of 40mTm-1. DWI data was 
obtained using a diffusion-sensitized single-shot echo planar imaging sequence (b = 0, 
500, 1000 s mm-2). Diffusion gradients were applied in 3 orthogonal directions, with an 
image matrix of 128 by 128 and field of view of 230 by 230 mm. On the Avanto 
scanner, 19 slices were acquired with a 5mm thickness, 1.5mm gap and a total 
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sequence time of 64 seconds, with TR = 2700ms and TE = 96ms. The Symphony 
protocol acquired 20 slices with a 5mm thickness, 2.5mm gap and a total sequence 
time of 56 seconds, with TR = 3600ms and TE = 107ms. 
6.2.3 MEASUREMENTS 
 
Figure 6.1: Measuring the ATCT. The white box in (A) indicates the area on the ADC map that is 
analysed. The oedema-tumour boundary is identified as marked by the white contour in (B), which also 
shows the white matter (WM), peri-tumoural oedema (O), and tumour core (T). The ATCT is measured 
at 4 different locations using a 2-voxel width as shown by the voxels highlighted in black. Therefore, 
ATCT is measured in a total of 8 locations. The calculation for the gradient change in ADC is shown in (C) 
and is performed by applying a linear fit to the circled ADC values for the vertical column of 4 pixels on 
the left, at the posterior side of the tumour. The gradient change in ADC is measured in all 8 locations, 
and the mean of these is the ATCT. In the image, voxels highlighted in white represent those voxels 
considered for measuring the ATCO. 
Diagnostic clinical MRI scans obtained before gross total resection and prior to any 
chemo- and radiotherapy treatment were used for data analysis. Minimum and mean 
ADC were considered in the analysis and were calculated by applying a manually 
segmented mask, drawn on the ADC images using high-resolution T1-weighted images 
where necessary. The masks were drawn over the whole tumour, excluding peri-
tumoural oedema but including necrotic regions of the tumour, to include the extent 
of necrosis in the analysis. The size of necrotic areas will influence the mean ADC as 
necrotic regions are expected to increase the mean ADC due to the higher ADC values 
in these areas.153,154 Calculations for the minimum and mean ADC were carried out 
using MATLAB (MathWorks, Natick, MA, USA). 
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The apparent transient coefficient (ATC) – the gradient change in ADC over a series of 
voxels at the tumour border, was measured in two regions; white matter into 
surrounding peri-tumoural oedema (ATCO), and peri-tumoural oedema into the 
tumour core (ATCT). Gradients were calculated from ADC images visualised using 
FSLView (FMRIB Image Analysis Group, Oxford, UK) on the slice that contained the 
largest tumour area. The white matter-oedema boundary and the oedema-tumour 
boundary were identified on the selected image. Four consecutive voxels were 
selected: for ATCO the first voxel selected in white matter and the next three voxels in 
oedema; for ATCT the first voxel selected in oedema and the next three voxels in the 
tumour core (Figure 6.1). A linear fit for these four points was applied in order to find 
the gradient change in ADC. Where possible, the gradient change in ADC was 
calculated at four different locations of the tumour, located by drawing a crosshair 
through the centre of the tumour. These were averaged to determine the ATCO and 
ATCT used in the survival analysis. A width of two voxels was used, such that the ATCO 
and ATCT were averaged over eight locations. It was expected that ATCO would be a 
positive gradient and ATCT would be a negative gradient, as ADC values in areas of 
oedema are higher than both white matter and tumour areas. The ATCT was not 
measured in necrotic regions of the tumour.  
6.2.4 SURVIVAL ANALYSIS 
6.2.4.1 Method description 
Survival analysis in this study consisted of a study on overall survival, and thus time to 
death. The major issue in conducting a survival analysis is that the event, in this case 
death, may not have happened by the time of last follow-up. Thus, the true survival is 
not known and the patient in question may have died one day later or may still be alive 
ten years later. In order to tackle this problem, the Kaplan-Meier survival method155 
was used to analyse the data and the process used to take this into consideration is 
known as censoring. Data points for patients who have not had the event happen at 
last follow-up are censored, which implies that the observation of the particular 
patient was cut off before the event happened.  
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Once the data has been obtained, survival probabilities can be constructed by 
considering time in small intervals156. In this way, all data can be used up until the day 
it is censored. The probability of surviving on day zero is equal to one and remains so 
up until the day at least one patient dies. The probability of surviving n days,      , is a 
conditional probability and is equal to the probability of surviving (n-1) days,        , 
multiplied by the probability of surviving the nth day,       as shown in equation (6.1). 
                   
        (  
  
  
) 
(6.1) 
where       is the survival probability for n days;         is the survival probability for 
n-1 days; and      is the probability of surviving on day n, which is equal to 1 – the 
probability of dying on day n, with    being the number of deaths on day n, and   
being the number of patients known to be alive just before the deaths occurred on day 
n – thus excluding censored data points occurring prior to day n. 
A survival curve can then be constructed from     , and this curve is known as the 
Kaplan-Meier survival curve157. The curve only changes at times when an event occurs 
and patients with censored data are included up until the last day the patient was 
known to be alive. Once the curve is constructed, the median survival can be extracted 
and is equal to the number of days 50% of the patients are expected to survive. Other 
measures such as the 25th percentile can also be extracted and this has been calculated 
in this analysis to give the number of days 75% of the patients are expected to survive.  
After constructing the survival curves, it may be important to conduct further 
statistical analysis to infer whether there is a significant difference in survival between 
groups. The most commonly used method and that employed in this analysis is the 
logrank test158. The method compares the observed number of events to the expected 
number of events in the scenario that there is no difference between groups and uses 
a    distribution to obtain a p-value.  
The Kaplan-Meier survival curves and the logrank test are both univariate analyses, 
and thus do not take into consideration other factors which may have influenced the 
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results. In this study, a multivariate survival analysis was also conducted, using the Cox 
proportional hazard model159. This model considers the hazard ratio, the ratio between 
groups for the probability that a patient under observation dies in a period centred on 
a given time. A hazard ratio above 1 implies that the covariate is related to a decreased 
survival160. 
6.2.4.2 Method employed 
A linear fit between survival and ATCO, ATCT, mean ADC and minimum ADC was 
applied to analyse whether there was any significant linear correlation. R and p values 
were calculated for this linear correlation.  
Kaplan-Meier survival curves157 were plotted for age at diagnosis (less than or greater 
than 3 years), extent of surgical resection (total or partial/none), tumour type (ATRT, 
medulloblastoma or sPNET), and whether the patient had metastasis at presentation. 
Parameters showing a significant difference from the Kaplan-Meier analysis and the 
linear fit were included in a multivariate survival analysis160, using a Cox proportional 
hazard regression model. The covariates considered were: the ATCT, whether patients 
were aged < 3 years at diagnosis, and the extent of surgery. In order to retain 
significant statistical power, a maximum of three covariates were included in the 
multivariate survival analysis, in compliance with suggestions outlined in 161. 
The ATCT was further analysed by subdividing it into four groups of increasing ATCT 
values in such a way that an equal number of patients were included in each group, 
and in accordance with the approach described in 162. Kaplan-Meier survival curves 
were constructed in order to visualise the difference in survival for the four ATCT 
groups. Statistical analysis was carried out using R software29 and the survival analysis 
package therein163. 
6.2.5 REPRODUCIBILITY STUDY 
An intra- and interobserver reproducibility study was conducted on the ATCT in a 
random selection of ten patients. Measurements were taken following familiarisation 
with the method, and intra-observer data was calculated from two measurements. 
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Inter-observer analysis was then carried out between a set of measurements made 
separately by two people. The coefficient of variation was determined in these ten 
patients for intra-observer and inter-observer agreement by using Bland-Altman 
analysis as proposed in 164,165. Calculations were made using equations (6.2) and (6.3), 
such that the coefficient of repeatability (CR) is defined as 1.96 times the standard 
deviation, and the coefficient of variance (COV) is given by CR divided by the mean of 
the observations and expressed as a percentage. The CR indicates the limits within 
which 95% of observations are expected to lie.  
 
       √
∑        
   
 
(6.2) 
where    is the coefficient of repeatability,    and    are first and second set of 
measurements taken respectively, and n is the number of observations. 
 
    
  
           
      
(6.3) 
where     is the coefficient of variance,    is the coefficient of repeatability, and    
and    are first and second set of measurements taken respectively. 
6.3 Results 
6.3.1 CORRELATING ADC MEASURES WITH SURVIVAL 
A plot of survival against ATCT (the gradient change in ADC from oedema into the 
tumour) showed that those patients who died (21/58) had more negative ATCT values 
than those who survived (Figure 6.2A). The linear correlation between survival and 
ATCT was tested and showed a statistically significant correlation (R = 0.49, p < 0.001). 
It is clear from the plot that there is a wide spread in survival, particularly as ATCT 
approaches zero; however, the data indicates a decreased chance of survival for highly 
negative values of ATCT. 
A linear correlation between survival and ATCO, mean ADC and minimum ADC was not 
found to be statistically significant (p = 0.17, 0.37 and 0.70 respectively) (Figure 6.2B, C, 
D).  
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Figure 6.2: Plot of survival against ATCT (A), ATCO (B), mean ADC (C) and minimum ADC (D) in 58 
patients. Patients who died are marked by a black box and can be seen to have a more negative ATCT 
value in (A). A statistically significant linear fit to the data was observed for ATCT (R = 0.49, p < 0.001). 
No significant correlation between survival and ATCO, mean ADC and minimum ADC was observed (p = 
0.17, 0.37 and 0.70 respectively). 
6.3.2 KAPLAN-MEIER CURVES 
Kaplan-Meier curves showed a statistically significant survival benefit in those children 
> 3 years at diagnosis compared to those < 3 years at diagnosis (p < 0.001) (Figure 
6.3A) and in those children who had total surgical resection (p = 0.04) (Figure 6.3B). 
There was a trend for a difference in survival between ATRT, sPNET and 
medulloblastoma (Figure 6.3C), with the poorest survival in ATRT, followed by sPNET 
and then medulloblastoma, but this did not reach statistical significance (p = 0.09). 
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Patients with metastasis at presentation appeared to have a poorer survival outcome, 
however this was not found to be statistically significant (p = 0.59) (Figure 6.3D). 
 
Figure 6.3: Kaplan-Meier survival curves for age at diagnosis (A), extent of surgery (B), tumour type 
(C), and metastasis at presentation (D). Children < 3 years are known to have a poorer prognosis as 
confirmed by the survival curves, and a statistically significant p-value of less than 0.001. Children having 
had total surgical resection have a statistically significant higher chance of survival (p = 0.04). Tumour 
type and metastasis at presentation were not found to be statistically significant (p = 0.09, p = 0.59 
respectively). 
6.3.3 MULTIVARIATE SURVIVAL ANALYSIS  
The Cox proportional hazard regression model indicated that the only statistically 
significant covariate was ATCT (p << 0.001). Age < 3 years at diagnosis and extent of 
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surgical resection were not found to be statistically significant covariates for the 
analysis (p = 0.17 and 0.62 respectively).  
6.3.4 ATCT KAPLAN-MEIER CURVES 
 
Figure 6.4: Kaplan-Meier survival curves for increasingly negative values of ATCT. The survival curves 
show a decreasing survival probability (p << 0.001). 
ATCT was the only covariate yielding high statistical significance, and survival analysis 
using Kaplan-Meier curves was conducted by dividing the patients into four groups of 
equal size and increasing values of ATCT. The result showed that more negative values 
of ATCT were related to a lower chance of survival (p << 0.001). Kaplan-Meier curves 
show how survival differs in children with embryonal brain tumours as the value in 
ATCT changes (Figure 6.4). Table 6.1 shows details of the survival outcome for the four 
different ATCT groups together with the median survival and the 25th centile. Lower 
values of median survival and 25th centile indicate a lower chance of survival and were 
identified in the groups with more negative ATCT values. Median survival and the 25th 
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centile could not be measured in the less negative ATCT groups as the survival 
probability was higher than 50% and 75% respectively, for the duration of the study. 
Table 6.1: Survival details for increasingly negative values of ATCT. The table shows an increased 
number of deaths for more negative values of ATCT. The median survival gives the probable number of 
days 50% of the patients would survive in each group. The 25th centile gives the probable number of 
days 75% of the patients would survive in each group. Median survival and the 25th centile could not 
be measured in the less negative ATCT groups as the survival probability was higher than 50% and 75% 
respectively, for the duration of the study. Likelihood of survival is higher in the patients having less 
negative ATCT values. 
ATCT range  
(x10
-3
mm
2
s
-1
vox
-1
) 
-(0 – 0.0615) 
-(0.0615 – 
0.08) 
-(0.08 – 
0.11) 
-(0.11 – 0.3) Overall 
 Least negative   Most negative  
no. of deaths/no. of patients 0/14 3/15 5/15 13/14 21/58 
median survival (days) N/A N/A N/A 226 N/A 
25
th
 centile (days) N/A 1006 342 104 299 
< 3 years (deaths/total) 0/3 1/1 4/7 7/7 12/18 
partial/no resection 
(deaths/total) 
0/4 2/4 2/6 7/7 11/21 
 
 
 
6.3.5 REPRODUCIBILITY STUDY 
Bland-Altman analysis gives an indication of the variability between two 
measurements by plotting the difference between two repeated measurements 
against the mean of those two measurements. The CR for the intra- and interobserver 
analysis was found to be 0.0289 and 0.0238 x 10-3mm2s-1vox-1 respectively, whilst the 
COV was found to be 30.1 and 28.4% respectively. In terms of the grouping in ATCT 
used in building the ATCT Kaplan-Meier survival curves, 7/10 patients and 8/10 
patients remained in the same group for the intra- and the interobserver analysis 
respectively. Of those patients changing group, 4 were to an adjacent group and 1 was 
a change of two groups, while both patients who died stayed within the two most 
negative groups and both surviving patients moved to the least negative group. 
Overall, all patients who died fell in the two most negative groups and the ones who 
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survived fell within the two least negative groups for both the intra- and the inter-
observer analysis. 
6.4 Discussion 
The main finding of this study is that a statistically significant difference was observed 
for survival data in children with embryonal brain tumours with respect to the change 
in ADC from peri-tumoural oedema into the tumour volume. Results show that more 
negative ATCT values are significantly associated with a poorer survival rate in children 
with embryonal brain tumours irrespective of tumour type, extent of resection, age 
under 3 years at diagnosis and metastasis at presentation. We hypothesized that an 
increased gradient change in ADC at tumour boundaries is related to a more malignant 
histological tumour type, hence explaining the lower survival outcome identified in this 
study. 
6.4.1 ATCT 
ADC has been shown to correlate with tumour cellularity in various tumour types. One 
study has shown a significant correlation between ADC values and tumour cellularity in 
medulloblastoma.77 ATCT, and thus the change in ADC over the oedema-tumour 
boundary, could be an indication of how rapidly the tumour cellularity is increasing 
(Figure 6.5A, D) and that a more rapid increase in tumour cellularity from the oedema-
tumour boundary into the tumour is an indication of a poorer prognosis and reduced 
survival. More negative ATCT values could also be due to higher ADC values in the 
oedema itself, indicating that cellularity might not be the only cause for poorer 
prognosis (Figure 6.5B, C). Previous studies focussed on tumour border MRI features 
and histology have shown that a sharper border on T1- and T2- weighted imaging could 
be indicative of an intact 1p/19q genotype which is related to reduced survival in 
oligodendroglial tumours.166,167 The results reported here support the hypothesis that 
tumour border biomarkers are useful indicators of survival in childhood embryonal 
brain tumours. 
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Figure 6.5: Visualising the ATCT. The image visualises the hypothetical difference between a highly 
negative value of ATCT (A, B) and a less negative value of ATCT (C, D). A highly negative value of ATCT 
means that there is an increased change in ADC from the first voxel on the oedema-tumour boundary 
towards the tumour core. This could be related to either a larger change in cellularity from the first 
voxel towards the tumour core (A) or due to increased oedema in the first voxel (B). The increasingly 
darker shades of grey represent the decreasing values of ADC as tumour cellularity inside the 
corresponding voxel increases. Conversely, the less negative value of ATCT could be due to less 
oedema being present (C) or due to a smaller change in cellularity from the first voxel towards the 
tumour core (D). 
6.4.2 ATCO, MEAN AND MINIMUM ADC 
The change in ADC from white matter into oedema (the ATCO) was not found to 
correlate with survival. This result is consistent with previous findings showing that 
ATCO was not a good biomarker for survival outcome in adults with the highly 
malignant tumour glioblastoma multiforme.98 Furthermore, in this cohort, mean ADC 
and minimum ADC values did not correlate with survival. 
6.4.3 TUMOUR TYPE  
Previous studies have shown that patients with sPNET have a poorer prognosis than 
patients with medulloblastoma168, and patients with ATRT have a poorer prognosis 
than patients with either medullublastoma or sPNET169. In this analysis these 
differences did not reach statistical significance, however, the observed trends in the 
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data (Figure 6.3C) are in line with current literature, showing patients with ATRT to 
have the poorest prognosis and patients with medulloblastoma to have the best 
prognosis. The lack of statistical significance is likely to be due to the small number of 
sPNET and ATRT patients in this cohort, reflecting the rarity of these tumour types. 
However, when comparing pairs of tumour types, medulloblastoma was found to have 
statistically significant better survival than ATRT (p = 0.04) in agreement with previous 
literature169, whilst the trend for sPNETs to fare worse than medulloblastoma did not 
reach statistical significance (p = 0.22). 
6.4.4 METASTASIS AT PRESENTATION 
Metastatic medulloblastoma170 and metastatic ATRT171 are well recognised to have 
reduced survival rates compared to their non-metastatic counterparts. Conflicting 
results have been obtained in patients with sPNET, with some studies finding no 
correlation between survival and metastasis at presentation.53 The results from this 
study did not show a statistically significant difference in survival for patients with 
metastasis at presentation across the three tumour types. However, a trend for a 
poorer prognosis for those patients with metastasis can be seen in Figure 6.3D. Again, 
the lack of statistical significance is likely to be due to the smaller sample size in this 
cohort when compared to the previous studies mentioned, which showed a difference 
in survival between patients with and without metastasis at presentation (119 patients 
in the study on medulloblastoma170 and 48 patients in the study on ATRT171).  
6.4.5 ATCT ACROSS EMBRYONAL BRAIN TUMOURS 
The sample of tumours in this cohort included medulloblastoma, sPNET and ATRT. It 
has been shown that parameters derived from ADC histogram measures can 
discriminate between ATRT and both sPNET and medulloblastoma.86 It is important to 
establish that the ATCT can be applied generally across different types of embryonal 
tumours, broadening it’s clinical utility. However, the correlation between ATCT and 
survival in the medulloblastoma group alone was examined and, similarly to the 
findings in the entire cohort, ATCT was found to strongly correlated with survival in this 
group (p << 0.001). The relatively small sample sizes in the sPNET and ATRT groups 
6. Diffusion Imaging as a Prognostic Biomarker 
149 
precluded a meaningful correlation of ATCT and survival in those groups if studied 
separately. 
When looking at the survival analysis for the three embryonal tumour types, findings, 
taken together, demonstrated that the ATCT is a more sensitive biomarker of survival 
than age less than 3 years at diagnosis, extent of surgery, tumour type and metastasis 
at presentation. The tumour types included in this sample reflect the typical 
presentation of embryonal tumours such that the ATCT can be generalised across 
these tumour types. 
6.4.6 STATISTICAL ANALYSIS 
In the method a description of how a maximum of three covariates could be included 
in the multivariate analysis in order to retain sufficient statistical power is given. All 
variables were initially tested in a univariate analysis. Three covariates were found to 
be significant in the univariate analysis and all of these were included in the 
multivariate analysis. Hence, there was no reason for including more covariates even if 
the method and numbers allowed us to do so. 
Furthermore, in conducting Kaplan-Meier survival analysis and in order to visualise the 
findings, ATCT was categorised into four groups. Having ATCT divided into four equal 
groups provided for an analysis with 3 different cut-off points and as can be seen in the 
Kaplan-Meier curves, there does not appear to be a single cut-off point which 
determines favourable or unfavourable survival outcome. Results show that the more 
negative the cut-off point used, the worse the survival probability. 
6.4.7 STUDY LIMITATIONS 
This study is limited by various factors. ATCT is a subjective measurement as oedema 
and tumour boundaries are identified by visual inspection, and a maximum of four 
locations on the tumour borders were used in the calculation of the ATCT. This 
limitation is reflected in the reproducibility of the method. Semi-automated methods 
for voxel selection for the ATCT may improve the robustness of the method and could 
be a fruitful avenue for future work. Given the data was collected over a period of 7 
years, some patients would have received different treatment regimes, with palliative 
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care being offered in five cases. These different treatment procedures might have also 
had an impact on the survival outcome in this cohort.  
Although the intra- and interobserver COV for the ATCT was found to be 30.1% and 
28.4% respectively, the changes had a negligible impact on the overall results. The 
tendency for patients who died to fall under the two most negative groups and for the 
surviving patients to fall under the two least negative groups was maintained in all 10 
cases analysed for both the intra- and the interobserver analysis.  
Medulloblastomas are classfied into four different histological subgroups 
(medulloblastoma with extensive nodularity, desmoplastic/nodular, anaplastic and 
large cell medulloblastoma)149 and recent advances in molecular genetics have 
indicated that medulloblastomas can be further classified into four different molecular 
subgroups (Wnt, Shh, group 3 and group 4)172. However, these histological and 
molecular classifications had only been collected very recently and were not available 
for the majority of the cohort. Nonetheless, future studies could examine the ATCT in 
these distinct histological and molecular tumour types to evaluate the value of the 
ATCT as a biomarker in comparison to the predictive value of these classifications on 
survival. 
As discussed in 173, the patient cohort in this group was a heterogeneous one. As a 
limitation, heterogeneity is expected to mask the effects of interest and hence, for 
example, the lower survival in medulloblastoma patients having metastases at 
presentation could have been masked by including other tumour types such as the 
supratentorial primitive neuroectodermal tumours, where conflicting evidence exists 
as to whether there is a relationship between metastasis at presentation and survival. 
In a similar way, it would be expected that the relationship between survival and ATCT 
would be masked by cohort heterogeneity, if it is dependent on tumour type. 
Therefore, the fact that ATCT was significant across embryonal tumour types makes a 
strong case for it to be considered as a measure of prognosis in addition to currently 
used variables. Although different tumour subtypes have different prognoses, ATCT 
can still be a useful indicator of longer survival across all of them. Since there was no 
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evidence in the data to suggest that patients with one or another tumour type did not 
fit the general pattern, the results may be said to broadly apply in all cases. By 
contrast, restricting the analysis to a very homogeneous sample would severely restrict 
the generalizability of the conclusions that can be drawn. Therefore, cohort 
heterogeneity reinforces the strength of ATCT as a biomarker of survival across a range 
of embryonal tumour types. Nonetheless, further analysis on larger patient groups of a 
more homogeneous nature would aid in identifying those groups in which it would be 
most beneficial to incorporate ATCT as part of clinical trials and as a biomarker of 
survival. 
6.5 Conclusion 
In conclusion, identifying non-invasive biomarkers of survival outcome is of utmost 
importance in managing and planning the treatment of children with brain tumours. 
Results showed that ATCT measured at diagnosis is a sensitive biomarker that 
correlates with survival in childhood embryonal brain tumours. While prognostic 
biomarkers are useful in the initial steps of treatment planning, treatment 
management needs to be consolidated through the use of biomarkers of treatment 
response.  
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Chapter 7 DIFFUSION IMAGING FOR TREATMENT RESPONSE 
Biomarkers of treatment response are an essential tool for managing the treatment 
plan of patients. This chapter presents research work carried out as part of this thesis 
on diffusion imaging for treatment response. It is an adapted version of a paper 
published during the course of the research and titled “Challenges for the functional 
diffusion map in pediatric brain tumors” in the journal “Neuro-Oncology” in 2014124.  
7.1 Background 
As has already been mentioned in Chapter 3, brain tumours are the most common 
solid tumour in children and differ in biology and development from adult brain 
tumours. However, few biological markers have been studied in paediatric brain 
tumours compared to those carried out in adults due to the relative rarity of childhood 
tumours. As a consequence limited literature is available and this includes low patient 
numbers, who receive diverse treatment regimens.174,175 Chapter 4 has introduced 
diffusion weighted imaging (DWI) as a tool for tumour diagnosis86 whilst Chapter 6 has 
shown its use as a biomarker of prognosis99 in childhood brain tumours. This chapter 
looks at DWI as a biomarker of treatment response. 
The concept of measuring the diffusion of water molecules in tissue, and quantifying 
this in terms of the apparent diffusion coefficient (ADC) has already been introduced. 
Through this, DWI is able to image cellularity as a consequence of water diffusion 
restriction in more densely packed tumours.74 The functional diffusion map (fDM), 
which is also known as the parametric response map, compares ADC changes over 
time and has been introduced in Chapter 4. In the fDM, a voxel-wise comparison of 
pre- and post-treatment ADC maps is carried out in the tumour areas, and the 
difference in ADC labelled in blue, green or red depending on whether a decrease, no 
change or an increase in ADC, respectively, was observed. In published studies, an 
increase in ADC is said to reflect a decrease in tumour cellularity and a good treatment 
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response. On the other hand, a decrease in ADC is said to reflect an increase in tumour 
cellularity and a poor treatment response. 
Currently tumour size is the conventional measure of tumour response to treatment. 
The fDM has been proposed as a tool to monitor early treatment response and 
efficacy, in an attempt to identify patients that will benefit from further adjuvant 
therapy prior to a change in tumour size.118,119,121 This study examines three factors 
identified as possible confounders for the fDM in childhood brain tumours; and 
hypothesizes that necrosis, tumour grade and change in tumour size need to be taken 
into consideration when interpreting fDM analysis in childhood brain tumours.  
Firstly, tumour necrosis can be seen following both tumour growth, as the tumour 
outgrows its blood supply, as well as a result of successful treatment. Limited literature 
is found that links areas of necrosis to survival. One study in osteosarcoma patients, 
showed no correlation between 90% necrosis and survival, and suggested that more 
data was necessary to determine a possible correlation between 70% necrosis and 
survival.176 In an earlier study carried out in children with brain stem gliomas treated 
with radiotherapy, no association was found between the absence or presence of 
necrosis post-radiation and outcome.177 Furthermore, the presence or absence of 
necrosis as a prognostic factor is dependent on the disease type in which it occurs. It is 
currently being debated whether the inflammation in necrotic areas carries a good 
prognosis or not178 as it is possible that a certain degree of necrosis may induce 
angiogenesis through the immune inflammatory cells which necrotic cell death 
promotes40. This study thus aimed to analyse whether the fDM in necrotic areas 
discriminated between the treatment outcomes.  
Secondly, tumour cellularity varies by tumour type and grade and the fDM technique 
was applied to tumours of varying grades to establish its utility throughout a range of 
childhood tumours.  
Thirdly, some tumours change considerably in size after treatment. Since this may 
cause problems of registration, the aim was to identify whether the fDM can be 
successfully applied in these cases. 
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7.2 Method 
Thirty-four childhood brain tumour patients (19 male, 15 female; aged 4 months to 
16.5 years; mean 7.8 years) who had DWI as part of their clinical imaging between 
2005 and 2012, were enrolled in a retrospective study. Ethical approval was given by 
the local ethics committee. Informed consent was not required for imaging data as this 
was obtained for clinical purposes. Informed consent was obtained in those cases were 
the histology of patients was used. All data was made anonymous in accordance with 
the Data Protection Act.  
Patients were selected so that fDM characteristics could be evaluated across a range of 
tumour types and grade. The cases that were chosen were those that had clinical DWI 
data available at two time-points, with a significant tumour volume at presentation 
and no surgery taking place in between the two time-points (which would obviate a 
meaningful assessment of the fDM). Of the thirty-four patients, 18 were diagnosed 
with diffuse intrinsic pontine glioma (DIPG), 6 with optic pathway glioma (OPG), 4 with 
tuberous sclerosis and sub-ependymal giant cell astrocytoma (SEGA), 3 with 
glioblastoma multiforme (GBM) and 3 with gliomatosis cerebri (GC). Histological 
diagnosis was confirmed in 4 SEGA patients, 3 GBM patients, 2 GC patients and 1 OPG 
patient. In the remainder, the diagnosis was made on neuroradiological grounds with 
imaging discussed in a multi-disciplinary team setting and accepted as a basis for 
treatment. The diagnostic histology was reviewed in two patients (one GBM and one 
OPG). This was then compared to that from a patient showing normal appearing white 
matter.  
7.2.1 IMAGE ACQUISITION 
Imaging data was acquired on a 1.5T Siemens Magnetom Symphony MRI scanner, with 
a maximum magnetic field gradient strength of 30mTm-1 and on a 1.5T Siemens 
Avanto scanner, with a maximum magnetic field gradient strength of 40mTm-1. DWI 
data was obtained using a diffusion-sensitized single-shot echo planar imaging 
sequence (b = 0, 500, 1000 s mm-2). The clinical ADC, using all three b-values was used 
in this analysis. Diffusion gradients were applied in 3 orthogonal directions, with an 
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image matrix of 128 by 128 and field of view of 230 by 230mm. On the Avanto scanner, 
19 slices were acquired with a 5mm thickness, 1.5mm gap and a total sequence time of 
64 seconds, with TR = 2700ms and TE = 96ms. The Symphony protocol acquired 20 
slices with a 5mm thickness, 2.5mm gap and a total sequence time of 56 seconds, with 
TR = 3600ms and TE = 107ms. 
7.2.2 FDM ANALYSIS 
 
Figure 7.1: Construction of the fDM. The fDM is built by using tumour images at two time points. After 
registration of the two images, a difference image is calculated. A decrease in ADC is labelled in blue, an 
increase in ADC labelled in red and no change in ADC labelled in green. 
Figure 7.1 shows how the fDM is constructed. Prior to building the fDM, ADC maps at 
the time-points analysed were co-registered to the patient’s T2- weighted image at 
diagnosis or post-surgery to exclude major changes in the tumour due to surgery. 
Where pre-treatment images were not available, as some patients would have arrived 
at our institution with these images already taken, two post-treatment images were 
used. MATLAB (MathWorks) and SPM823 were used for co-registration, applying the 
standard normalised mutual information and a trilinear interpolation algorithm. A 
visual inspection was carried out on all co-registered images to ensure successful 
registration.  
The fDM, implemented in MATLAB, was applied in tumour areas by specifying a region 
of interest (ROI) using FSLView (FMRIB). ROIs were defined across all tumour image 
slices by considering both ADC and T2-weighted images; including tumour regions and 
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areas of necrosis, but excluding peri-tumoural oedema where possible. The tumour 
boundary was identified using both ADC and T2 weighted images. Areas of bright ADC 
outside the defined tumour boundary were considered to be peri-tumoural oedema 
and thus were excluded. Infiltrative oedema was included in the analysis as it cannot 
be easily differentiated from tumour using ADC and T2 weighted imaging. 
A voxel-wise comparison was carried out, over the whole tumour, on the two time-
points being investigated. Specific thresholds were used to determine whether there 
was an increase, decrease or no change in ADC when comparing ADC images. This 
study employed the suggested threshold of 0.40 x 10-3mm2s-1, the threshold indicating 
the highest sensitivity and specificity in the receiver operating characteristic (ROC) 
analysis121. This means that a voxel with ADC increasing by more than this value is 
classified as increasing in ADC and displayed in red in the fDM. A voxel with ADC 
decreasing by more than this threshold is classified as decreasing in ADC and displayed 
in blue. Any voxels with an ADC change between these thresholds are classified as not 
changing in ADC, and are displayed in green. fDM findings are compared to clinical 
imaging reports in order to identify whether the fDM correctly identifies tumour 
response from tumour progression as reported by the clinical Radiologist. 
7.2.3 AREAS OF NECROSIS 
In the course of showing the biological processes involved in the fDM, Moffat et al. 
have briefly mentioned that necrotic or cystic regions can undergo a displacement of 
water which results in a reduction in ADC as tumour cells move into the area.118 
Moreover, in theory, areas of necrosis can increase or decrease in size irrespective of 
treatment outcome. Figure 7.2 shows a flow map for the different possible outcomes 
of treatment response in terms of necrotic areas within the tumour. 
The fDM was studied in areas of necrosis in patients with DIPG and with GC as these 
were the patients which showed most necrosis as compared to the other groups 
studied. Areas of necrosis were identified in each image as those voxels with an ADC 
value higher than 1.8x10-3mm2s-1 – a value observed to make up most of the necrotic 
regions on the ADC image whilst excluding both normal and tumour tissue, as well as 
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being the value for the mean ADC in areas of necrosis measured in other tumour 
types154,179. The ROI was selected such that only tumour areas visible on both pre- and 
post-treatment images were included in the analysis. A comparison was made 
between fDM tumour treatment response classification when including and excluding 
necrosis to test the hypothesis that necrotic areas act as a confounder in the fDM. 
 
Figure 7.2: Theoretical change in areas of necrosis by treatment. Necrotic areas of a tumour can 
increase in size as a result of (A) tumour growth (causing increased hypoxic regions and hence necrosis) 
and (B) successful treatment (as cells are killed, tumour regions are replaced by areas of necrosis). 
Conversely, a reduction in size of necrotic regions can be due to (C) tumour growth through 
angiogenesis (making the tumour more vascular and hence more cellular in areas which would have 
otherwise been necrotic), and (D) tumour size reduction due to successful treatment (as the tumour 
shrinks in size, areas of necrosis may be replaced by glial cells). 
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7.2.4 TUMOUR GRADE 
Most fDM studies have been carried out on adults in high grade tumours.122,180,181 
Given that high and low grade tumours differ in ADC86, the corresponding fDM may 
also differ in terms of treatment response classification. Figure 7.3 shows the 
theoretical changes that can occur to the ADC and the fDM when high and low grade 
tumours respond to treatment or show signs of progressive disease. The fDM in high-
grade (GBM – WHO grade IV), mid-grade (DIPG – WHO grade II and III) and low-grade 
(OPG – WHO grade I) tumours were analysed and findings compared with the outcome 
described in clinical reports obtained at the time of the follow-up (second) imaging 
session.  
 
Figure 7.3: Theoretical changes in the fDM in tumours of varying grade. (red represents an increase, 
blue a decrease and green no change in ADC). The upper half of the image shows the theoretical change 
in ADC in high grade tumours which appear dark with low ADC values. (A) Progressive high grade 
tumours will increase in cellularity and result in a lower, and darker, ADC value (blue in fDM). (B) 
Conversely, a high grade tumour responding well to therapy will decrease in cellularity and increase in 
ADC to values more similar to that of healthy tissue (red in fDM). The lower half of the image shows the 
theoretical change in ADC in low grade tumours which appear bright with high ADC values. (C) In 
progressive disease it is expected the tumour will either grow or become necrotic hence, excluding 
areas of necrosis, it is not expected to change in ADC (green in fDM) – which is also indicative of stable 
disease. (D) Low grade tumours which respond to therapy are likely to be replaced by lower ADC healthy 
tissue and hence responsive low grade tumours would decrease in ADC (blue in fDM). 
7. Diffusion Imaging for Treatment Response 
159 
7.2.5 CHANGE IN TUMOUR SIZE 
SEGA patients were found to respond well to rapamycin182 and the effect of a 
reduction in tumour size was addressed by analysing the fDM in this patient group as 
there was a positive response to treatment, with the tumour decreasing in size 
considerably in three of four patients. The images were analysed using first a pre-
treatment mask and then the overlap between the pre-treatment tumour areas and 
post-treatment tumour area. fDM findings were then compared to clinical imaging 
reports at the time of the follow-up (second) image. 
7.2.6 STATISTICAL ANALYSIS 
In order to analyse the fDM in areas of necrosis and in tumours of varying grade, 
contingency tables were constructed (Tables 7.1 and 7.2). Fisher’s exact test183 was 
applied to these tables using MATLAB and a pre-defined function184. Contingency 
tables show how categorical variables are related to each other by representing the 
frequency distribution of the variables analysed. Fisher’s exact test allows for the 
analysis of such tables, particularly when the sample size is small. 
7.3 Results  
Of the patients included in this study, none of the DIPG and OPG patients had partial or 
total resection of tumour. 2 GBM patients, 1 GC patient and all 4 SEGA patients had 
partial or total resection of tumour. The fDM was built in 11 patients pre- and post- 
treatment, in 20 patients using two post-treatment images, and in 3 patients using two 
pre-treatment images were a watch and wait or a palliative care protocol was 
employed. The time interval between the two images ranged from 2 weeks to 13 
months. 
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7.3.1 AREAS OF NECROSIS 
 
Figure 7.4: The fDM in areas of necrosis. The DIPG patient was treated with radiotherapy and 
chemotherapy and the fDM was constructed from one-post treatment image and a 3 months follow-up 
image. (A, B) The fDM in DIPG shows areas of increased ADC (red) (A) which are eliminated when 
excluding areas of necrosis (B). The GC patient was treated via surgery followed by chemotherapy and 
the fDM was constructed from one image taken 3 months after start of chemotherapy and a 1 year 
follow-up image. (C, D) The fDM in GC showed areas of increased ADC in necrotic regions (C) which were 
again eliminated when necrotic regions were excluded (D). Removal of the necrotic regions is 
concordant with no tumour response in two patients with no change in tumour size. 
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Table 7.1: The fDM in necrotic areas compared to clinical response and change in size in necrotic 
areas. 
The fDM in necrotic areas 
ADC  
Increase No Change Decrease P value 
Size of Necrotic Area 
Increase 6 
  
 
No Change 
 
3 
 
 
Decrease 
  
4 P < 0.001 
Clinical Response 
Response 3 1 1  
Stable 2    
Progression 1 2 3 P = 0.31 
 
 
 
In the DIPG patient group, the tumour area consisted of, on average, 11.2% necrosis 
while the GC patient group had on average 31.6% necrosis; measured by calculating 
the percentage of voxels with an ADC higher than 1.8x10-3mm2s-1 in the tumour ROI. 
10/18 patients with DIPG and all 3 patients with GC showed areas of necrosis > 5%. In 
all of these cases, an increase or decrease in ADC in areas of necrosis was related to an 
increase or decrease in size of necrotic regions respectively and was not related to the 
treatment response identified in clinical image reports. Table 7.1 shows a summary of 
the fDM in necrotic areas and how these related to the size of necrotic areas and 
clinical response. Fisher’s exact test on this data confirmed the fDM in areas of 
necrosis to be related to the change in size of necrotic areas (p<0.001) and was not 
related to clinical response (p=0.31). When classifying tumour response using the fDM, 
excluding areas of necrosis made a difference in four out of 21 patients studied. Figure 
7.1 shows two examples of the fDM showing an increase in ADC in areas of necrosis 
while clinical image reports identified stable disease in both cases. 
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7.3.2 TUMOUR GRADE 
 
Figure 7.5: The fDM in tumours of varying grade. A comparison of the fDM in GBM (A, D), DIPG (B,E), 
and OPG (C, F), in areas of progression (top row) and treatment response (bottom row) is shown. (A) In 
high grade tumours a decrease in ADC (blue) was indicative of an increase in cellularity and progression. 
(E,F) In mid- and low grade tumours a decrease in ADC was indicative of positive treatment response as 
high ADC tumour was replaced by healthy tissue. (D) Similarly an increase in ADC (red) was indicative of 
positive treatment response in high grade tumours, and in the above cases, (B,C) progression in mid- 
and low grade tumours (B, C). Tumour progression and treatment response was defined by a radiologist 
at the time of second imaging. 
The fDM in GBM (high-grade) showed areas of decreased ADC at progression, and 
areas of increased ADC with positive treatment response. Conversely, in DIPG (mid-
grade) and OPG (low-grade), the fDM showed areas of increased ADC at progression 
and areas of decreased ADC at tumour treatment response (Figure 7.5). In the lower 
grade tumours it was noted that an increase in ADC was mostly associated with an 
increase in necrotic/cystic components of the tumour. 
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Table 7.2: fDM changes by tumour grade and clinical response. 
The fDM by tumour grade  Tumour Grade  
  High- Mid- Low- P value 
fDM increase in ADC 
Clinical 
Response 
Response 1 
  
 
Stable 
   
 
Progression 
 
5 1 P < 0.001 
fDM no change in ADC 
Clinical 
Response 
Response  2   
Stable  3 6  
Progression 1 3  P = 0.04 
fDM decrease in ADC 
Clinical 
Response 
Response  5 4  
Stable     
Progression 2   P < 0.001 
 
 
Table 7.2 shows a summary of the changes in the fDM according to tumour grade and 
response. Fisher’s exact test showed that there was a significant difference between 
tumour grade and clinical response for the increase and decrease in ADC (p<0.001). 
The comparison between grade and clinical response when the tumour fDM did not 
change was only marginally significant (p=0.04).  
Of the 3 GBM patients, one showed small areas of increased ADC at response and large 
areas of decreased ADC at progression. A second patient showed small areas of 
decreased ADC at progression. In the third patient negligible changes in ADC were 
observed at progression. 
Of the 18 DIPG patients, 8 progressed at second imaging with 5 showing an increase in 
ADC and 3 showing minor to no changes in ADC; 7 responded to treatment with 5 
showing a decrease in ADC and 2 showing minor to no changes in ADC; 3 showed 
stable disease with minor changes in ADC. 
Of the 6 OPG patients, 4 showed areas of decreased ADC at treatment response and 
minor to no change at stable disease, with one of these patients progressing at a later 
time point and showing increased ADC; 2 patients showed minor to no changes in ADC 
with stable disease.  
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7.3.3 CHANGE IN TUMOUR SIZE  
 
Figure 7.6: Change in tumour size. A comparison of the fDM when using (A,C) a pre-treatment mask and 
(B, D) only the overlap between pre- and post-treatment images is shown in a SEGA patient. The top row 
shows T1-weighted post-contrast imaging. The bottom row shows the fDM in one patient, showing (C) a 
mixture of areas of increased ADC (red) and decreased ADC (blue) when considering the pre-treatment 
mask, and (D) mostly areas of increased ADC when considering the tumour overlap area. 
Of the 4 SEGA patients analysed, there was a large decrease in tumour size in 3 
patients. When using pre-treatment masks, the fDM showed a large area of decreased 
ADC in the three SEGA patients responding to treatment. These areas were excluded 
from the fDM when looking at only the overlap (Figure 7.6). Outside of the tumour 
overlap areas, a decrease in ADC was observed when tumour areas were replaced by 
healthy tissue, and an increase in ADC was observed when tumour areas were 
replaced by areas of cerebrospinal fluid (CSF). In selecting only tumour overlap areas, a 
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more accurate assessment of the fDM findings was therefore given, although results 
did not indicate the fDM to give any more information than standard clinical imaging 
reports. 
7.3.4 HISTOLOGY 
 
Figure 7.7: Histological comparison of low and high-grade tumours. A comparison of a low-grade OPG 
(B), with a histological diagnosis of pilocytic astrocytoma (WHO grade 1), and a high-grade GBM (C) are 
shown together with a comparative image from normal appearing white matter (WM) (A). The low-
grade tumour showed some areas with high cellularity (as compared to WM) as well as myxoid areas 
shown in B. The microcystic changes observed in the low-grade tumour, could explain the increased ADC 
observed in these tumours when compared to normal appearing white matter. The high-grade tumour 
(C) showed the highest cellularity, which restricts diffusion and explains why these tumours appear dark 
in ADC images. (All images are haematoxylin-eosin stained and at the same magnification.) 
A comparison of high-grade (GBM), low-grade (OPG) and normal appearing white 
matter is shown in Figure 7.7. The low-grade tumour had some areas of increased 
cellularity compared to normal appearing white matter and some myxoid areas with a 
loose microcystic stroma. This may help explain the increased ADC observed in low-
grade tumours. The high-grade tumour showed the highest cellularity and due to this 
restricted diffusion, these tumours appear dark in an ADC image.  
7.4 Discussion 
Determining treatment response early on in the treatment cycle is of vital importance 
as this allows the choice of personalised medicine with the ability to alter doses or 
change therapy in those cases where the current treatment is seen to be ineffective. 
The fDM was previously shown to be an effective biomarker for detecting treatment 
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response earlier than current standard techniques which consist of radiological 
assessment, in most cases at the end of therapy.122 However, in this analysis, a number 
of limitations have been identified and studied, and these indicated the need to 
exercise caution when interpreting fDM results.  
7.4.1 AREAS OF NECROSIS 
Necrotic areas of a tumour can increase in size both as a result of successful treatment 
(as cells are killed, tumour regions are replaced by areas of necrosis), as well as a result 
of tumour growth (causing increased hypoxic regions and hence necrosis). The results 
of this study indicate that the fDM does not give an accurate interpretation of 
treatment response in areas of necrosis. An increase/decrease in ADC in these areas 
was mostly related to an increase/decrease in necrotic areas rather than positive 
treatment response or progression. Eliminating areas of necrosis made a difference in 
treatment response classification in 20% of the patients studied, and given such areas 
may act as a potential confounder in the fDM, the study suggests excluding these areas 
from the fDM in order to accurately assess tumour response. 
7.4.2 TUMOUR GRADE 
Our results have identified tumour grade as a potential confounder in the fDM and the 
importance of taking this into consideration in analysing the fDM has been shown. 
Previous publications have shown an increase in ADC in the fDM to be indicative of 
positive treatment response118, and a decrease in ADC to be indicative of tumour 
progression181. This concept is underpinned by research which showed the ADC to be 
inversely correlated with cellularity.74 This was based on the assumption that the ADC 
is lower in tumour tissue than in surrounding healthy tissue, due to the increased 
cellularity of tumours. While this is valid in high grade tumours, in lower grade 
tumours, tumour tissue can include microcystic areas or areas of infiltrative oedema, 
driving the ADC up, even though the cellularity of the tumour itself may be higher than 
that of surrounding tissue.86 Unless there is tumour progression from low- to high-
grade, a decrease in ADC in low grade tumours is therefore likely to be a sign of 
treatment response, as the higher ADC tumour tissue is being replaced by healthy 
tissue, rather than the tumour progressing by becoming more cellular. Furthermore, 
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an increase in ADC in low grade tumours is more likely to be associated with an 
increase in necrotic regions and, as shown in this study, tumour response cannot be 
inferred from these areas.  
7.4.3 CHANGE IN TUMOUR SIZE 
Previous research has shown how image registration, particularly due to an increase in 
tumour size, may be a major limitation to the technique employed in the fDM, and 
methods of non-linear registration may be beneficial.185 In the cases investigated in 
this study, there was a considerable decrease in tumour size. In tumour regions 
replaced by healthy tissue, a decrease in ADC was observed in the areas where there 
was a reduction in size back to healthy tissue, and an increase in ADC where tumour 
areas were replaced by CSF. In the leftover tumour volume, areas of decreased ADC 
were limited and hence no inference could be made as regards to treatment success or 
progression. Given the limited number of patients in this group no definite conclusion 
can be drawn as to whether reduction in size is a confounder in the fDM when using 
linear registration – however a reduction in size is already an indicator of treatment 
success and the fDM did not appear to give any further information in the patients 
analysed. That said changes in tumour size need to be treated with caution, and 
careful visual inspection of registered images needs to be carried out in order to avoid 
problems of registration due to a change in tumour size. 
7.4.4 STUDY LIMITATIONS 
The main limitation of this study is that it was carried out on a group of childhood 
brain tumours, having small numbers of similar tumours. However, different tumour 
types were specifically selected so that the fDM could be evaluated in paediatric 
tumours of differing grade. Case ascertainment was limited by the rarity of childhood 
brain tumours and the fact that patients often arrive at our institution with pre-
treatment imaging that did not include comparable DWI to allow an fDM to be 
generated. In some cases surgery took place immediately, and hence the fDM could 
only be applied to two post-treatment images. However, fDM results were compared 
to clinical imaging reports at the time of follow-up (second) imaging rather than the 
final clinical outcome in order to minimise this limitation. Further analyses are 
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warranted on other tumour types and in larger numbers in order to evaluate more 
fully the effects of the confounders described here on the fDM.  
While the majority of patients were imaged on one scanner, the fDM in some patients 
was constructed from one image from each of the two scanners, and thus the 
reproducibility of ADC parameters needs to be considered and may affect the results. 
However, as discussed in Chapter 5, the inter-scanner variability of ADC was observed 
to be ± 0.02 x 10-3mm2s-1 in grey and white matter and ± 0.12 x 10-3mm2s-1 in the brain 
stem. These thresholds are much smaller than the fDM threshold used in this study to 
determine an increase or decrease in ADC (0.40 x 10-3mm2s-1) and hence it is expected 
that using data from the two different scanners would have a negligible impact on the 
results.  
7.5 Conclusion 
In conclusion, results from this chapter have shown that, while the fDM may be a 
useful tool for determining tumour treatment response, careful interpretation needs 
to be carried out, considering the underlying biology of both tumour and healthy 
tissue. Areas of necrosis, tumour grade and change in tumour size are all factors that 
need to be taken into account when carrying out fDM analyses.  
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Chapter 8 DISCUSSION 
This chapter intends to bring together the main points from the research work carried 
out as part of this thesis by describing the advances made and outlining how these 
advances may be used in future studies to expand our current knowledge of diffusion 
imaging in paediatric brain tumours and beyond.  
8.1 Advances made 
Three studies were performed as part of this thesis. The first, explored in Chapter 5, 
was a comprehensive analysis of the reproducibility of diffusion imaging parameters – 
ADC, D, f, MD and FA. In this study, nine volunteers and one phantom were scanned on 
four 1.5T scanners and four 3T scanners using sequences employed for routine clinical 
use locally. A mixed-effect model was constructed and ADC, D, MD and FA were found 
to have a good reproducibility and vary by less than 4% across all scanners. On the 
other hand, f was found to have a poor reproducibility and to be affected by scan 
acquisition resolution. The study showed that diffusion imaging parameters are robust 
across 1.5T and 3T scanners and are suitable for use in multi-centre clinical studies and 
trials. 
The second study, presented in Chapter 6, analysed the use of the gradient change in 
ADC across the tumour border, from oedema into the tumour core (ATCT), as a 
measure of survival in children with embryonal brain tumours. Identifying biomarkers 
of survival is important in managing and planning the treatment of childhood brain 
tumours. The survival analysis, on fifty-eight patients, confirmed being under the age 
of 3 years at diagnosis and partial surgical resection contribute to lower survival. 
Furthermore, it identified ATCT as a good biomarker of survival, with a more negative 
value correlating with reduced survival. This correlation was found to be irrespective of 
tumour type, extent of surgical resection, age less than 3 years at diagnosis and 
metastases at presentation. 
8. Discussion 
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The third study, described in Chapter 7, involved an analysis of the functional diffusion 
map in paediatric brain tumours. The fDM has been recommended as a tool for 
determining early treatment response. In the study three factors which may affect the 
fDM were examined: areas of necrosis, tumour grade, and change in tumour size. 
Thirty-four paediatric patients with a range of brain tumours were enrolled in the 
study and a qualitative analysis was carried out to determine how fDM findings may be 
affected by each of the confounds. This was done by comparing the fDM to clinical 
image reports. Results showed that the fDM in areas of necrosis did not discriminate 
between treatment response and progression. Furthermore, tumour grade appears to 
alter the behaviour of the fDM: while a decrease in ADC in a high grade tumour is a 
sign of tumour progression, a decrease in ADC in a low grade tumour may be a sign of 
response to treatment. Finally, results suggested that only the tumour overlap area 
should be considered when analysing tumours which change in size considerably. The 
study concluded that, while the fDM may be useful in determining treatment 
response, careful interpretation needs to take into account areas of necrosis, tumour 
grade and change in tumour size. 
8.2 Future studies  
The results from the reproducibility study pave the way for a host of analyses which 
could be performed by combining multi-centre data. As paediatric brain tumours are 
rare, combining multi-centre data may be necessary for significant and meaningful 
analyses. Furthermore, multi-centre analyses are essential in order to show how 
biomarkers of survival or treatment response can be used clinically across centres. 
Following on from the reproducibility study, the analysis on ATCT as a biomarker of 
survival in embryonal brain tumours could be expanded to encompass data from 
multiple-centres in order to determine whether the correlation found applies across 
centres, and to further determine the usefulness of the biomarker. The analysis could 
also be taken forward by conducting a histological comparison in order to understand 
better what the biomarker is representing in biological terms. 
8. Discussion 
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Finally the study on the fDM recommends caution in generalising the tool for 
determining treatment response across all tumours and that the underlying biology 
needs to be taken into account. A more specific fDM analysis on individual tumour 
types could be carried out by incorporating multi-centre data in order to analyse the 
utility of the technique in individual tumour types.  
8.3 Conclusion 
Diffusion MRI is a valuable tool in the management of childhood brain tumours. It has 
been explored in this thesis as a biomarker of survival and as a tool for determining 
early treatment response in paediatric brain tumours. A multi-centre study on 
diffusion imaging parameters showed a good reproducibility, and this result paves the 
way for further research and validation of biomarkers in the field. 
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